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Abstract
Home telemonitoring or structured telephone support 
programmes after recent discharge in patients with heart 
failure: systematic review and economic evaluation
A Pandor,* P Thokala, T Gomersall, H Baalbaki, JW Stevens, 
J Wang, R Wong, A Brennan and P Fitzgerald
School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK
*Corresponding author
Background: Remote monitoring (RM) strategies have the potential to deliver specialised care and 
management to patients with heart failure (HF).
Objective: To determine the clinical effectiveness and cost-effectiveness of home telemonitoring (TM) or 
structured telephone support (STS) strategies compared with usual care for adult patients who have been 
recently discharged (within 28 days) from acute care after a recent exacerbation of HF.
Data sources: Fourteen electronic databases (including MEDLINE, EMBASE, PsycINFO and The Cochrane 
Library) and research registers were searched to January 2012, supplemented by hand-searching relevant 
articles and contact with experts. The review included randomised controlled trials (RCTs) or observational 
cohort studies with a contemporaneous control group that included the following RM interventions: (1) 
TM (including cardiovascular implanted monitoring devices) with medical support provided during office 
hours or 24/7; (2) STS programmes delivered by human-to-human contact (HH) or human-to-machine 
interface (HM).
Review methods: A systematic review and network meta-analysis (where appropriate) of the clinical 
evidence was carried out using standard methods. A Markov model was developed to evaluate the cost-
effectiveness of different RM packages compared with usual care for recently discharged HF patients. TM 
24/7 or using cardiovascular monitoring devices was not considered in the economic model because of the 
lack of data and/or unsuitability for the UK setting. Given the heterogeneity in the components of usual 
care and RM interventions, the cost-effectiveness analysis was performed using a set of costing scenarios 
designed to reflect the different configurations of usual care and RM in the UK.
Results: The literature searches identified 3060 citations. Six RCTs met the inclusion criteria and were 
added to the 15 trials identified from the previous systematic reviews giving a total of 21 RCTs included in 
the systematic review. No trials of cardiovascular implanted monitoring devices or observational studies 
met the inclusion criteria. The methodological quality of the studies varied widely and reporting was 
generally poor. Compared with usual care, RM was beneficial in reducing all-cause mortality for STS HH 
[hazard ratio (HR) 0.77, 95% credible interval (CrI) 0.55 to 1.08], TM during office hours (HR 0.76, 95% CrI 
0.49 to 1.18) and TM 24/7 (HR 0.49, 95% CrI 0.20 to 1.18); however, these results were statistically 
inconclusive. The results for TM 24/7 should be treated with caution because of the poor methodological 
quality of the only included study in this network. No favourable effect on mortality was observed with STS 
HM. Similar reductions were observed in all-cause hospitalisations for TM interventions, whereas STS 
interventions had no major effect. A sensitivity analysis, in which a study was excluded because it provided 
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better-than-usual support to the control group, showed larger beneficial effects for most outcomes, 
particularly for TM during office hours. In the cost-effectiveness analyses, TM during office hours was the 
most cost-effective strategy with an estimated incremental cost-effectiveness ratio (ICER) of £11,873 per 
quality-adjusted life-year (QALY) compared with usual care, whereas STS HH had an ICER of £228,035 per 
QALY compared with TM during office hours. STS HM was dominated by usual care. Similar results were 
observed in scenario analyses performed using higher costs of usual care, higher costs of STS HH and 
lower costs of TM during office hours.
Limitations: The RM interventions included in the review were heterogeneous in terms of monitored 
parameters and HF selection criteria and lacked detail in the components of the RM care packages and 
usual care (e.g. communication protocols, routine staff visits and resources used). As a result, the 
economic model developed scenarios for different RM classifications and their costs were estimated using 
bottom-up costing methods. Although the users can decide which of these scenarios is most 
representative of their setting, uncertainties still remain about the assumptions made in the estimation of 
these costs. In addition, the model assumed that the effectiveness of the interventions was constant over 
time, irrespective of the duration of deployment, and that the intervention was equally effective in 
different age/severity groups.
Conclusion: Despite wide variation in usual care and RM strategies, cost-effectiveness analyses suggest 
that TM during office hours was an optimal strategy (in most costing scenarios). However, clarity was 
lacking among descriptions of the components of RM packages and usual care and there was a lack of 
robust estimation of costs. Further research is needed in these areas.
Study registration: PROSPERO registration no. CRD42011001368.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Glossary
Technical terms and abbreviations are used throughout this report. The meaning is usually clear from the context, but a glossary is provided for the non-specialist reader. In some cases, usage differs in the 
literature, but the term has a constant meaning throughout this review.
Base-case analysis In modelling, the base case is the primary analysis based on the best estimates of 
each model input (cf. sensitivity analysis).
Baseline risk The probability of an event (e.g. death) occurring in the comparator arm. This is a term 
used in modelling in which the baseline risk from one data source might be combined with a risk 
ratio from another source to estimate the probability of an event occurring for patients receiving a 
different intervention.
Conservative assumption When there is uncertainty, modellers may have a choice of which value to 
give to a model input. A conservative assumption is when the modeller chooses the parameter in such 
a way that it cannot bias in favour of the new treatment (and is likely to be biasing in favour of the 
standard treatment).
Cost-effectiveness acceptability curve A way of illustrating cost-effectiveness results by plotting the 
probability that the intervention is cost-effective (y-axis) against the maximum that society is willing to pay 
for an improvement in health (x-axis).
Cost-effectiveness plane A way of illustrating cost-effectiveness results by plotting the mean 
incremental cost and effectiveness on a four-quadrant graph. Interventions that are more costly and more 
effective fall in the north-east quadrant.
Incremental cost-effectiveness ratio The difference in costs between one intervention and an 
alternative divided by the difference in outcomes.
Length of stay The total number of days that a participant stays in hospital.
Meta-analysis A statistical technique for combining (pooling) the results of a number of studies that 
address the same question and report on the same outcomes to produce a summary result. The aim is 
to derive more precise and clear information from a large data pool. It is generally more reliably likely to 
confirm or refute a hypothesis than the individual trials.
Quality-adjusted life-year A measure of benefit of health care combining the impact of both expected 
length of life and quality of life.
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List of abbreviations
ACE angiotensin-converting enzyme
ARB angiotensin receptor blocker
BHF British Heart Foundation
CAD coronary artery disease
CEAC cost-effectiveness 
acceptability curve
CHARM Candesartan in Heart failure: 
Assessment of Reduction in 
Mortality and morbidity
CHF chronic heart failure
CI confidence interval
COPD chronic obstructive 
pulmonary disease
CrI credible interval
DRG diagnosis-related group
EQ-5D European Quality of 
Life-5 Dimensions
ESC European Society of Cardiology
EVPI expected value of 
perfect information
GPRD General Practice 
Research Database
HDS Health Distress Score
HF heart failure
HH human-to-human contact
HM human-to-machine interface
Home-HF Home Heart Failure Study
HR hazard ratio
HRQoL health-related quality of life
ICER incremental 
cost-effectiveness ratio
LVEF left ventricular ejection fraction
LVSD left ventricular 
systolic dysfunction
LYG life-years gained
MCMC Markov chain Monte Carlo
MLHFQ Minnesota Living with Heart 
Failure Questionnaire
NICE National Institute for Health and 
Care Excellence
NMA network meta-analysis
NMB net monetary benefit
NY&Y NHS North Yorkshire and York
NYHA New York Heart Association
PSA probabilistic sensitivity analysis
PSSRU Personal Social Services 
Research Unit
QALY quality-adjusted life-year
QoL quality of life
RCT randomised controlled trial
RM remote monitoring
RR risk ratio
ScHARR School of Health and 
Related Research
SF-12 Short Form 
questionnaire-12 items
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xii
SF-36 Short Form 
questionnaire-36 items
STS structured telephone support
TEN-HMS Trans-European Network – Home-
Care Management System
TIM-HF Telemedical Interventional 
Monitoring in Heart Failure
TM telemonitoring
WTP willingness to pay
WSD Whole System Demonstrator
All abbreviations that have been used in this report are listed here unless the abbreviation 
is well known (e.g. NHS), or it has been used only once, or it is a non-standard 
abbreviation used only in figures/tables/appendices, in which case the abbreviation is 
defined in the figure legend or in the notes at the end of the table.
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Scientific summary
Background
Heart failure (HF) is a complex clinical syndrome. It is associated with significant morbidity, mortality 
and reduced quality of life (QoL) and as such exerts a substantial burden on health-care systems, mainly 
because of repeated and lengthy admissions to hospital. The highest risk period for rehospitalisation is 
in the first few weeks after discharge from hospital, with 20–30% of patients being readmitted within a 
month, rising to 50% at 6 months. Early remote monitoring (RM) of patients (as a component of a care 
package) using structured telephone support (STS) or telemonitoring (TM) may be one way to meet the 
growing needs of HF patients.
Objectives
The aim was to determine the clinical effectiveness and cost-effectiveness of home TM or STS strategies 
compared with usual care for adult patients who have been recently discharged (within 28 days) from 
an acute care setting after a recent exacerbation of HF. Specifically, the objectives were to (1) update two 
existing systematic reviews (published between 2009 and 2010) of TM or STS programmes for patients 
with HF within the scope of the current review; (2) evaluate the effectiveness and cost-effectiveness of 
home TM and/or STS packages compared with usual post-discharge care; and (3) identify key areas for 
primary research.
Methods
Fourteen electronic databases (including MEDLINE, EMBASE, PsycINFO and The Cochrane Library) and 
research registers were searched to January 2012. Searches were supplemented by hand searching of 
relevant articles (including citation searching) and contacting experts in the field. The systematic review 
included randomised controlled trials (RCTs) or observational cohort studies with a contemporaneous 
control group that met the following criteria: remote home TM (using patient-initiated external electronic 
devices or cardiovascular implanted monitoring devices, with transfer of physiological data from patient 
to health-care provider using telecommunications technology) or STS programmes (including regular 
telephone contact between patients and health-care providers and reporting of symptoms and/or 
physiological data) in adults (≥ 18 years of age) with a HF diagnosis and discharged from acute care 
(within 28 days) to home. The methodological quality of each included study was assessed according to 
established criteria. Where sufficient data existed, a random-effects network meta-analysis (NMA) was 
conducted using Markov chain Monte Carlo (MCMC) simulation.
A Markov model was developed to evaluate the cost-effectiveness of RM packages compared with usual 
care for recently discharged HF patients. RM interventions included (1) STS delivered via human-to-
machine interface (HM), (2) STS delivered via human-to-human contact (HH) and (3) TM during office 
hours compared with (4) usual care. TM with medical support provided 24 hours a day, 7 days a week 
(24/7) or using cardiovascular monitoring devices was not considered in the economic model because of 
the lack of data and/or unsuitability for the UK setting. Given the heterogeneity among usual care and RM 
intervention components, cost-effectiveness analyses were performed using several costing scenarios. RM 
intervention costs included costs of the RM devices, monitoring costs in the RM centre and medical care 
costs to deal with alerts. Bottom-up costing methods were used to estimate the costs of these scenarios, 
designed to reflect usual care and different configurations of RM systems available in the UK. Base-case 
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costs and higher- and lower-cost scenarios were developed for each RM strategy whereas base-case and 
higher-cost scenarios were developed for usual care.
The costs and quality-adjusted life-years (QALYs) accrued by each strategy were estimated using monthly 
probabilities of death and of hospitalisations (HF-related complications or other causes), dependent on 
the type of RM intervention. Cost-effectiveness was assessed using both an incremental cost-effectiveness 
analysis and a net benefit approach at the £20,000 per QALY threshold. Probabilistic sensitivity analysis 
(PSA) and expected value of perfect information (EVPI) analysis were performed to capture uncertainty in 
the model parameters. A 30-year time horizon was taken and the economic perspective of the model was 
the NHS in England and Wales.
Results
The literature searches identified 3060 citations. Six RCTs met the inclusion criteria and were added 
to the 15 trials identified from the previous systematic reviews. No trials of cardiovascular implanted 
monitoring devices or observational studies met the inclusion criteria. The methodological quality of the 
21 included studies varied widely and reporting was generally poor on random sequence generation, 
allocation concealment, blinding of outcome assessment, definition and confirmation of HF diagnosis, and 
intention-to-treat analysis. Twenty studies contributed to the network comparing different pairs or triplets 
of treatment for TM or STS programmes with usual care, although not all studies provided information 
on each outcome. One study was excluded from the NMA because there were no events in either 
intervention group. For adults who have recently been discharged from an acute care setting after a recent 
HF exacerbation, the NMA found that, compared with usual care, RM was beneficial in reducing all-cause 
mortality by 23%, 24% and 51% for STS HH [hazard ratio (HR) 0.77, 95% credible interval (CrI) 0.55 to 
1.08], TM with medical support during office hours (HR 0.76, 95% CrI 0.49 to 1.18) and TM 24/7 (HR 
0.49, 95% CrI 0.20 to 1.18) respectively; however, the results for TM 24/7 should be treated with caution 
because of the poor methodological quality of the only study in this network. No beneficial effect on 
mortality was observed with STS HM. TM with medical support during office hours or 24/7 was associated 
with 25% (HR 0.75, 95% CrI 0.49 to 1.10) or 19% (HR 0.81, 95% CrI 0.33 to 2.00) reduction in all-cause 
hospitalisations, respectively, whereas there was no major effect of STS HM (HR 1.06, 95% CrI 0.44 to 
2.53) or STS HH (HR 0.97, 95% CrI 0.70 to 1.31). Although there were no major effects on HF-related 
hospitalisation for STS HM (HR 1.03, 95% CrI 0.66 to 1.54) and TM with medical support during office 
hours (HR 0.95, 95% CrI 0.70 to1.34), STS HH (HR 0.77, 95% CrI 0.62 to 0.96) was associated with a 23% 
reduction. The posterior predictive distributions for the HRs estimated from the NMA as predictive intervals 
(PrIs) also provided similar results as CrIs, albeit with more uncertainty. Whilst data were limited, care 
packages that included STS and TM generally improved QoL and were acceptable to HF patients.
A sensitivity analysis that excluded data from the Home Heart Failure Study (Home-HF) (as it provided 
better-than-usual support and optimal medical treatment to patients in the control group and appeared 
to be inconsistent with the data from the remaining studies, i.e. an outlier) found that TM with medical 
support during office hours was more effective than STS HH for all-cause mortality (HR 0.62, 95% CrI 
0.42 to 0.89 and HR 0.75, 95% CrI 0.59 to 0.96 respectively) and all-cause hospitalisation (HR 0.67, 95% 
CrI 0.42 to 0.97 and HR 0.96, 95% CrI 0.72 to 1.27 respectively) but not HF-related hospitalisation (HR 
0.86, 95% CrI 0.61 to 1.21 and HR 0.76, 95% CrI 0.61 to 0.94 respectively). By excluding this study from 
the NMA, larger reductions in effects were observed for all-cause mortality, all-cause hospitalisation and 
HF-related hospitalisation for TM during office hours.
In the cost-effectiveness analyses, base-case monthly costs per patient were estimated using bottom-up 
costing methods: £27 for usual care, £119 for STS HM, £179 for STS HH and £175 for TM during office 
hours. Five cost scenarios were also developed to calculate lower and higher estimates of costs of STS 
HH (£175 and £192 per month respectively) and TM during office hours (£133.50 and £215 per month 
respectively) along with a higher estimate of usual care costs (£92 per month).
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The full incremental cost-effectiveness analysis using the base-case costs found that TM during office hours 
was likely to be the most cost-effective strategy at a £20,000 per QALY threshold. TM during office hours 
had an estimated incremental cost-effectiveness ratio (ICER) of £11,873 per QALY compared with usual 
care, whereas STS HH had an ICER of £228,035 per QALY compared with TM during office hours. STS 
HM was dominated by usual care. PSA showed substantial uncertainty in the most probable cost-effective 
strategy. TM during office hours was the most cost-effective strategy in 40% of the PSA runs whereas STS 
HH was most cost-effective in 35% of the PSA runs. STS HM and usual care were the most cost-effective in 
19% and 6% of the runs respectively. Cost-effectiveness analysis performed using the HRs from the NMA 
that excluded the data from the Home-HF trial showed an improvement in the cost-effectiveness of TM 
during office hours. STS HM and STS HH were dominated and extendedly dominated, respectively, with 
the ICER of TM during office hours against usual care estimated as £6942 per QALY. The results from the 
uncertainty analyses suggest that TM during office hours was cost-effective in 73% of the runs, whereas 
STS HH and STS HM were cost-effective in 19% and 7% of the runs respectively.
Scenario analysis using higher costs of TM during office hours (£215 per month) increased uncertainty. 
TM during office hours and STS HH were both cost-effective in 37% of PSA runs, but TM during office 
hours was dominated by STS HH. The same scenario analysis (i.e. higher cost of TM during office hours 
of £215 per month) performed using the HRs from the NMA that excluded the data from the Home-HF 
trial suggested that TM during office hours would still be the most cost-effective strategy with an ICER of 
£8223 per QALY compared with usual care (STS HH is extendedly dominated by a combination of usual 
care and TM during office hours). Threshold analysis performed excluding the data from the Home-HF trial 
suggested that the monthly cost of TM during office hours has to be > £390 to have an ICER > £20,000 per 
QALY compared with STS HH. The ICER of TM during office hours compared with usual care, at a monthly 
cost of £390, is £13,357 per QALY. Scenario analyses performed using higher costs of usual care, higher 
costs of STS HH and lower costs of TM during office hours do not substantially change the conclusions. 
TM during office hours was estimated to be the most cost-effective strategy in all of these scenarios.
Discussion
Although an extensive literature search was conducted, it is possible that some relevant studies may 
have been missed. However, such omissions are likely to have been minimal as the search included all 
identifiable publications in the grey literature (including contact with clinical experts in the field).
Data were analysed exactly by assuming a binomial likelihood function for the sample data. The statistical 
model acknowledged the fact that events accumulate over time by adjusting for the varying durations of 
each study using a complementary log-log link function. Parameter estimates, including between-study 
standard deviation, were estimated using MCMC simulation, which allows for uncertainty in estimates of 
between-study standard deviation; it also allowed estimation of the predictive distribution of the effect of 
each intervention in a new study.
The clinical effectiveness findings had several limitations. RM interventions were heterogeneous in 
terms of monitored parameters and HF selection criteria. Some trials were underpowered to detect the 
primary clinical outcome and did not report outcome assessor blinding. Furthermore, few trials reported 
results in such a way as to enable an assessment of intervention effect modifiers (i.e. meta-regression). 
Consequently, uncertainties remain around determinants of patient responsiveness, suitability of different 
systems and ‘active ingredients’ of RM interventions. A limitation of the statistical model (because of 
having only one observation from each study) was that hazards and relative intervention effects were 
assumed to be constant over time; nevertheless, this is better than assuming that duration of study has 
no impact on the data. Similarly, in the cost-effectiveness model, these constant effectiveness parameters 
were applied to the time-dependent baseline mortality hazard (which is greatest in the early period after 
discharge and subsequently declines over time) and constant risk of hospitalisation. If the studies reported 
observations at different time points, time-dependent effectiveness parameters can be estimated and used 
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in the cost-effectiveness model. Furthermore, optimal duration for each of the RM interventions can also 
be identified.
None of the reviewed studies provided estimates for patient utility and whether or not there was a 
difference between the RM and usual care groups; thus, in the economic model, similar utility values 
were used for HF patients undergoing both RM strategies and usual care. However, the validity of 
this assumption is unclear. Furthermore, the lack of detail provided in research studies concerning the 
components of RM packages and usual care (e.g. communication protocols, routine staff visits and 
resources used) made it difficult to estimate costs. Costing scenarios for different RM classifications were 
developed and costs were estimated using microcosting methods. Although users can decide which of 
these analyses is most representative of their setting, uncertainties remain about the assumptions made 
in the costing estimation. This uncertainty in costing was a limitation, especially given the small difference 
in QALYs between STS HH and TM during office hours. Hence, a small change in the difference between 
costs of TM during office hours and STS HH can lead to a marked change in the ICER. A further limitation 
was that the effectiveness remained the same for the different cost scenarios whereas in reality there might 
be some correlation between the costs and effectiveness of different RM strategies.
Hazard ratios of mortality and hospitalisation were the key drivers in the cost-effectiveness model, as 
mortality reductions lead to a gain in QALYs whereas reductions in hospitalisations lead to fewer costs and 
more QALYs. The intervention costs were only a small part of the overall costs (hospitalisation costs being 
the main contributor); thus, RM is likely to be cost-effective if it can save lives and reduce hospitalisations 
to a sufficient extent. However, some uncertainty persisted in the effectiveness parameters as suggested in 
the EVPI analysis.
Conclusions
In general, although the effectiveness of the interventions varied widely according to the type of RM 
system used, STS HH and TM with medical support provided during office hours showed beneficial effects, 
particularly in reducing all-cause mortality for recently discharged patients with HF; however, these results 
were statistically inconclusive.
Given the variation in usual care and RM strategies, the cost-effectiveness analysis was performed using 
a set of costing scenarios. These scenarios were designed to reflect the different configurations of usual 
care and RM interventions present in the UK. The cost-effectiveness analyses suggest that TM during office 
hours was an optimal strategy in most scenarios.
Research recommendations include:
1. new research should seek to examine the ‘active ingredients’ of RM
2. qualitative research on patient experiences of RM may be useful to understand the processes by which 
RM works
3. RM studies should publish data in such a way as to identify which patient subgroups benefited most 
from the intervention
4. RM studies should include clear descriptions of the interventions and usual care to enable robust 
costing estimations
5. RM studies should report health outcomes at specific time intervals to identify temporal trends 
in effectiveness
6. future studies should provide greater detail on reconfiguration costs and link more clearly with the 
financial impact (e.g. cost variation with scale and over time) on provider organisations.
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Chapter 1 Background
Description of the health problem
Heart failure (HF) is a complex condition in which cardiac abnormality or dysfunction impairs the capacity 
of the heart to maintain output without a rise in filling pressures. Clinical presentation typically includes 
dyspnoea, fatigue, effort intolerance and signs of fluid retention (such as swelling in the extremities).1 HF is 
often defined as impaired left ventricular ejection fraction (LVEF) of ≤ 40%. However, uncertainties remain 
concerning the appropriate threshold for diagnosis.2,3 For formal diagnosis, clinical examination is usually 
supplemented with objective assessments of the underlying structural or functional abnormality of the 
heart and severity of the syndrome, using techniques including electrocardiography, chest radiography and 
laboratory tests.1,4
Aetiology, pathology and prognosis
In Western countries, hypertension and coronary artery disease (CAD) are the most common causes of HF, 
whereas nutritional cardiac disease and valvular heart disease are more common in the developing world.5 
In one Scottish survey, hypertension and CAD (alone or in combination) were identified as the cause 
of HF in > 90% of cases.6 HF has also been associated with neurohormonal changes7 – in particular, to 
brain natriuretic peptide and noradrenaline. Elevated levels of each of these hormones is an independent 
predictor of morbidity and mortality among HF patients.8 Behavioural factors, such as smoking and 
chronic alcoholism, were strongly associated with HF in a large cohort study of men residing in the USA 
(n = 20,900), with men not adhering to any of the six measured health behaviours (normal weight, not 
smoking, regular exercise, moderate alcohol intake, consumption of breakfast cereals, consumption of fruit 
and vegetables) being at the highest risk [21.2%, 95% confidence interval (CI) 16.8 to 25.6%].9 Finally, 
socioeconomic status appears to play a role in the development of HF: a national HF audit commissioned 
by the NHS10 found that people with a home address in the highest quintile of deprivation are admitted to 
hospital with HF on average 5 years earlier than those in the lowest quintile (most affluent). A brief list of 
causal factors is included in Table 1.
Severity of HF is usually assessed using the New York Heart Association (NYHA) system. This system 
classifies HF as mild (stage I–II), moderate (stage III) or severe (stage IV) based on symptomatic markers 
TABLE 1 Causes of HF
CAD Myocardial infarction, ischaemia
Hypertension
Cardiomyopathy Dilated (congestive), hypertrophic/obstructive, restrictive (e.g. amyloidosis, sarcoidosis, 
haemochromatosis)
Valvular and congenital heart 
disease
Mitral valve disease, aortic valve disease, atrial septal defect, ventricular septal defect
Arrhythmias Atrial fibrillation
Alcohol and drugs Alcohol, cardiac depressant drugs (beta-blockers, calcium antagonists)
‘High output’ failure Anaemia, thyrotoxicosis, arteriovenous fistulae, Paget’s disease
Pericardial disease Constrictive pericarditis, pericardial effusion
Primary right HF Pulmonary hypertension, tricuspid incompetence
Source: adapted from Lip et al.5
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(Table 2).11 Although the NYHA class system does not necessarily reflect the severity of underlying heart 
dysfunction, it is a useful clinical tool which provides a standardised description of symptom severity that 
can be used to guide clinical management. Furthermore, NYHA class has been shown to be a strong 
independent predictor of quality of life (QoL) for patients with HF.12
Patients with a new HF diagnosis have a 40% risk of mortality within the first year.13,14 However, post-
discharge mortality incidence varies substantially according to the care setting to which patients are 
admitted. A recent UK HF audit (between April 2010 and March 2011)14 found annual post-discharge 
mortality rates of 26.2%, 38.2% and 42.0% for cardiovascular, general medical and other wards 
respectively (p < 0.001). On average, patients who are discharged have an approximately 28% risk of 
mortality within the first year after HF discharge.14 The highest risk period for further complications 
is immediately after an acute decompensation.15 Between 20% and 30% of patients are readmitted 
within 30 days, rising to 50% at 6 months.16 Prognosis is poor even among people receiving optimal 
pharmaceutical therapy and so preventative strategies should ideally be pursued with at-risk patients.17
Epidemiology
Given the ongoing debate around appropriate HF diagnostic criteria,2,3 it is difficult to provide 
confident estimates of incidence and prevalence of HF. Early epidemiological studies used unreliable 
diagnostic criteria,18 and although some later surveys incorporated objective assessments of LVEF using 
echocardiogram6,19 they were limited by excluding adults > 85 years of age and by restricting HF to 
those with left ventricular systolic dysfunction (LVSD).20 More recently, a UK population survey in 2009, 
drawing on an audit of GP registries, estimated total all-age prevalence of HF to be 0.9% for men and 
0.7% for women.10 The largest recent community-based survey, the Echocardiographic Heart of England 
Screening (ECHOES) study,21 utilised objective European Society of Cardiology (ESC) criteria to determine 
the presence of HF. A LVEF < 40% was found in 1.8% of the population > 45 years of age (95% CI 1.4 to 
2.3%), and definite HF in 2.3% (95% CI 1.9 to 2.8%). In those >75 years of age, prevalence of LVEF of 
< 40% and definite HF rose to 3.7% and 6.9% respectively. A recent British Heart Foundation (BHF) survey 
of the General Practice Research Database (GPRD) found an all-age prevalence rate of 0.9% for the UK, 
which was lowest in England (0.9%) and highest in Northern Ireland (1.1%). In those > 75 years of age, 
prevalence rose to 13.7% and 15.3% respectively.10
Cowie et al.22 found a crude incidence rate of 1.3 cases per 1000 population in a large West London 
cohort, rising to 11.6 cases per 1000 population in those > 85 years of age. The age-adjusted incidence 
was higher among men than among women (incidence ratio 1.75, 95% CI 1.34 to 2.29).22,23 However, 
there are important regional variations in incidence. Using data from the GPRD, the BHF found that the 
incidence of HF in the UK was highest in Northern Ireland and lowest in England (58.1 per 100,000 and 
37.5 per 100,000 respectively), with the overall incidence rate being approximately 75% higher among 
men than among women.10 The Rotterdam cohort study found similar patterns, with an overall incidence 
rate of 14.4 per 1000 person-years (95% CI 13.4 to 15.5) rising to 47.4 per 1000 person-years among 
TABLE 2 New York Heart Association classification system for HF severity11
NYHA 
class Severity Symptoms
I Mild No limitations. No fatigue, breathlessness or palpitations in response to ordinary levels of physical 
activity
II Mild Comfortable at rest with slight limitation of physical activity. Ordinary physical activity leads to 
breathlessness, fatigue or angina pectoris
III Moderate Marked limitation of physical activity. Comfortable at rest but less than ordinary physical activity 
leads to symptoms
IV Severe Inability to carry out any physical activity without discomfort. Symptoms of cardiac insufficiency 
present at rest
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those aged > 90 years, and a higher incidence rate for men than women (17.6 per 1000 man-years, 95% 
CI 15.8 to 19.5 and 12.5 per 1000 woman-years, 95% CI 11.3 to 13.8 respectively).23 The Rochester 
epidemiology project in the USA also found a higher incidence among men than among women (3.78 per 
1000, 95% CI 3.61 to 3.95 and 2.89 per 1000, 95% CI 2.77 to 3.00).24 HF incidence and prevalence in the 
UK are set to increase in conjunction with life expectancy as medical therapies for cardiac conditions such 
as hypertension and myocardial infarction improve.25
Impact of the health problem
Heart failure is associated with high levels of morbidity and mortality, particularly among those aged 
> 60 years.10 One-year mortality for HF patients > 75 years may be twice as high as for those < 75 years.26 
The illness trajectory of HF is unpredictable: NYHA functional classification can improve as well as 
deteriorate, and sometimes changes unevenly over time.10 HF also has a substantial impact on patient QoL. 
In one German cohort study, the Short Form questionnaire-36 items (SF-36) measure was administered 
to 205 HF inpatients.12 Using multiple regressions to control for confounders, this research found that 
NYHA functional class was the only consistent independent predictor of QoL. Evidence suggests a 25–50% 
prevalence of anxiety and a 18–47% prevalence of depression among HF patients, depending on age, time 
since diagnosis and other prognostic indicators.27,28
Heart failure imposes a significant burden on NHS resources. The cost of inpatient bed-days for HF alone 
has been estimated at £563M per year,29 whereas total HF-related costs have been estimated at £625M per 
year.30 HF is a leading cause of hospitalisation in the UK, with 58,164 admissions recorded for HF (as first 
diagnoses) between April 2009 and March 2010 in England and Wales.30 Around 90% of HF admissions 
are to emergency departments,31 with hospitalisations lasting a median of 9 days.30 As the proportion of 
people > 60 years of age in the UK continues to increase, and improvements are made in treatment for and 
survival from cardiac disorders, the burden of HF on the NHS looks set to increase.32,33
Current service provision
Optimal HF treatment can vary depending on aetiology and severity. Evidence-based treatment guidelines 
from the National Institute for Health and Care Excellence (NICE)34 advocate pharmaceutical treatment 
of HF with angiotensin-converting enzyme (ACE) inhibitors and beta-blockers as first line (Table 3). These 
should be administered initially at a low dose and up-titrated at short intervals until the optimal dosage, 
or tolerance limit, is reached. If the patient remains symptomatic despite optimal treatment with these 
agents, a second line of treatment comprising one of three options, an aldosterone antagonist, an 
angiotensin receptor blocker (ARB) or hydralazine in combination with nitrate, should be considered.39 
For stable patients without clinical contraindications to exercise, supervised, exercise-based group 
rehabilitation programmes for HF should be offered. Finally, patients should be regularly monitored, 
although the frequency depends on the clinical status of the patient. Stable patients should be monitored 
at least every 6 months whereas those with recent changes to medication and/or clinical status should be 
monitored every few days to every 2 weeks39 (see Table 3).
Ideally, inpatient treatment should be provided by a specialist centre. Patients admitted to specialist 
cardiology wards have better survival rates while hospitalised and in the first year post discharge – a 
relationship that remains when age, HF aetiology, echocardiology, heart rhythm, sex and symptoms are 
adjusted for.29 Overall, patients admitted to specialist centres are around half as likely to die in hospital as 
those admitted to general wards.10 Post-discharge, multidisciplinary disease management programmes 
comprising patient education, optimal medical treatment and psychosocial care have been associated 
with decreased hospitalisation and improved clinical outcomes.40–43 However, access to these services is 
limited because of funding-related barriers or geographical location.44,45 Furthermore, there are inequalities 
in access to services in terms of sex and age. Only 38% of people referred to the UK’s HF liaison service 
between 2008 and 2009 were women and, although approximately 70% of patients < 45 years of age 
were referred to the liaison service, this figure fell across the age groups to < 21% in those ≥ 95 years.30
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TABLE 3 National and international guidelines for the treatment of HF
Issuing 
body Country Drug therapya Outpatient monitoring
Device based/
surgical
NICE34 England 
and Wales
First line: ACE inhibitors; 
beta-blockers. Second line: 
aldosterone antagonist; 
angiotensin II receptor 
antagonist;b hydralazine in 
combination with nitrateb
Clinical assessment of functional 
capacity, fluid status, cardiac rhythm 
and BNP; regular medication review; 
serum urea, electrolytes, creatinine 
and eGFR; review at least every 
6 months for stable outpatients 
or every few days to 2 weeks if 
recent medication change/clinical 
deterioration; education, support and 
group-based exercise rehabilitation
Coronary 
revascularisation, 
heart 
transplantation, 
CRT
SIGN35 Scotland First line: ACE inhibitors; beta-
blockers. Second line: ARBs;b 
aldosterone antagonists;c 
diuretics/loop diuretics/
metolazone (to relieve 
symptoms of congestion/fluid 
retention); digoxin;d hydralazine 
and isorbide dinitrateb,c
Patient education and communication 
including a nurse-led, home-based 
element; behaviour change (smoking 
cessation, limiting alcohol, supervised 
exercise training, dietary change); 
pharmacist input to assess knowledge 
of drugs and compliance; tailored 
self-management advice; patient 
support groups
CRT; assisted 
ventilation; left 
ventricular assist 
devices; cardiac 
transplantation; 
intra-aortic balloon 
counterpulsation
CREST36 Northern 
Ireland
First line: ACE inhibitors; 
beta-blockers. Second line: 
aldosterone antagonists;c 
diuretics/loop diuretics (for 
congestion/fluid overload); 
digoxin;c nitrates and 
hydralazineb
Multidisciplinary, nurse-led 
management; action plan for all 
patients; education (exercise training, 
sexual activity, smoking cessation, 
alcohol intake, fluid intake, salt 
intake, daily weighing, obesity, 
cachexia, immunisations, travel, 
medication advice); psychological 
management
Heart 
transplantation; 
CRT; coronary 
revascularisation
ESC37 Europe First line: ACE inhibitors; 
beta-blockers. Second line: 
aldosterone antagonists;c,d 
ARBs;b,d hydralazine and 
isorbide dinitrate;b,d digoxin (for 
arrhythmias); diuretics (to relieve 
congestions); statins (for systolic 
dysfunction caused by CAD)
Multidisciplinary approach led by 
HF nurses; early follow-up post-
discharge; patient education with 
emphasis on self-care; physical activity 
training; self-monitoring of weight, 
symptoms, diet, fluid intake and 
alcohol; involve patient in symptom 
monitoring and flexible diuretic use; 
remote monitoring; psychosocial 
support
Revascularisation; 
valvular surgery; 
CRT; heart 
transplantation; 
left ventricular 
assist devices and 
artificial hearts; 
ultrafiltration (to 
relieve congestion)
AHA38 USA First line: ACE inhibitors; beta-
blockers. Second line: ARBs;b 
aldosterone antagonist;c 
hydralazine and nitrates;b,c 
digitalis; diuretics/loop 
diuretics and salt restriction 
(for congestion/fluid overload); 
vasodilators (to relieve 
congestion if adequate blood 
pressure); intravenous inotropes 
(only in patients with low blood 
pressure and cardiac output 
who can be closely monitored)
Close observation and follow-up; 
exercise training; written educational 
materials (activity level, diet, discharge 
medications, follow-up appointment, 
weight monitoring and response to 
symptoms); discharge planning with 
emphasis on medication compliance; 
psychosocial support; access to 
palliative services
CRT; coronary 
revascularisation; 
cardiac 
transplantation; 
left ventricular 
assist device; 
pulmonary 
artery catheter 
placement; 
ultrafiltration (if 
pharmacological 
diuretic strategies 
unsuccessful)
AHA, American Heart Association; BNP, B-type natriuretic peptide; CREST, Clinical Resource Efficiency Support Team; CRT, 
cardiac resynchronisation therapy (including implanted cardiac defibrillators and biventricular pacing); eGFR, estimated 
glomerular filtration rate; SIGN, Scottish Intercollegiate Guidelines Network.
a Drug therapy is specific to LVSD unless otherwise stated.
b Consider as alternative if first-line treatments contraindicated/not tolerated.
c Indicated for patients with moderate to severe HF.
d Consider if patient remains symptomatic despite optimum treatment.
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Description of technology under assessment
Telemedicine is an emerging approach utilising remote monitoring (RM) of prognostic indicators (e.g. 
weight, arrhythmias, blood pressure, intrathoracic impedance, heart rates during rest and exertion) 
to facilitate early detection of clinically significant changes, prevent emergency admissions and avoid 
complications.46 Guidelines from the ESC currently recommend RM for patients with HF (see Table 3). 
Because the highest risk period for rehospitalisation is the first few weeks after discharge, RM interventions 
should be performed at least once in the first 28 days following discharge. RM encompasses a range 
of approaches depending on what physiological data are transferred to clinicians, how the data are 
transferred (e.g. automatically or manually, by telephone contact or through a secure web server) and 
how these data are utilised. Broadly speaking, two main approaches have emerged: telemonitoring (TM), 
in which physiological data are electronically transmitted to a health-care team, and structured telephone 
support (STS), that is, the use of telephone calls, usually by specialist nurses, to deliver self-care support 
and/or management.47,48 For STS, support can be provided by human-to-human contact (HH) or through 
a human-to-machine interface (HM), that is, STS with an interactive response system. For TM, support 
can be provided during office hours (9 am to 5 pm, Monday to Friday) only or 24 hours a day, 7 days a 
week (24/7), although few studies have used the latter approach. Further details are provided in Table 4. 
Cardiovascular implanted monitoring devices such as modern pacemakers, implantable cardioverter 
defibrillators or cardiac resynchronisation devices are also capable of delivering remote physiological 
TABLE 4 Summary of various RM strategies
TM STS
Office hours only 24/7 HH HM
Description Patients take measurements 
(manual or automated) of vital 
parameters (most commonly 
weight, BP and HR) at home, 
which are transmitted to a 
health-care team or HF specialist 
centre by telephone, mobile 
telephone, cable network 
or broadband technology. 
Transmitted data are reviewed 
by medical staff (in some cases 
readings outside of prespecified 
limits may generate automated 
warnings) during office hours 
(including provision of medical 
support) 
Same as TM during 
office hours but 
constant presence of 
medical personnel 
required to operate the 
support system, i.e. 
24 hours a day, 7 days 
a week
Patients followed up 
with regular telephone 
calls by a care provider. 
Calls typically from HF 
specialist nurses and 
include advice on self-
care and medication. 
STS may also incorporate 
basic monitoring of 
physiological parameters 
(e.g. weight) 
Patients 
monitored by 
automated 
telephone-based 
interactive 
response system. 
May include 
questions about 
HF symptoms to 
which patients 
can respond 
on telephone 
keypad
Example Cleland et al.49 provided 
patients with a scale and 
sphygmomanometer. Patients 
took twice daily measurements 
of vital parameters (weight, BP, 
HR and single lead ECG using 
wristband electrodes). Results 
were encrypted and sent via a 
secure web server to a computer 
at each investigator site. Medical 
support was provided during 
office hours
Koehler et al.50 provided 
a wireless Bluetooth 
system with a personal 
digital assistant and 
three integrated 
devices: an ECG lead, a 
BP cuff and weighing 
scales. Encrypted 
measurements were sent 
via a secure server to 
participating sites. These 
sites provided physician-
led medical support 
24 hours a day, 7 days 
a week
Angermann et al.51 
provided telephone-
based structured 
monitoring delivered 
by trained nurses 
(supervised by a 
cardiologist and a 
psychologist), which 
included educational 
material/self-monitoring 
schemes and 
multidisciplinary advice
Chaudhry et 
al.52 used an 
interactive 
system that 
required patients 
to provide daily 
readings of vital 
parameters, 
which were 
sent to a secure 
internet site 
and reviewed 
by clinicians on 
weekdays
BP, blood pressure; ECG, electrocardiogram; HR, heart rate.
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monitoring, often without the need for a patient to trigger the transmission of data.53 The equipment and 
personnel requirements vary according to the type of RM and a number of systems have been described.54
Use of information communication technology may help provide wider access to HF programmes for a 
larger number of patients, including those constrained by geography, transport or infirmity.15 When a 
care plan has been agreed with a patient, TM and STS interventions can promote a rapid response when 
vital clinical signs fall outside agreed parameters, for example by up-titrating medication or arranging 
for a clinical visit. RM could also minimise the incidence of difficult-to-treat complications, and use early 
warning signs to avoid hospitalisation. Conversely, RM may generate false alerts leading to inappropriate 
hospitalisation55 and it may not be feasible for health-care providers to contact all patients regularly or 
provide specialist equipment to all patients who may potentially benefit.
Telemedical interventions for a variety of chronic conditions are currently being investigated and rolled out 
by a number of UK NHS trusts. For example, NHS North Yorkshire and York (NY&Y) has seen approximately 
500 patients with long-term conditions including HF receive a TM intervention. HF patients were supplied 
with RM equipment, which generated medication prompts, along with weighing scales and a blood 
pressure and pulse meter (Julie Ryan, Telehealth Project Manager, NHS NY&Y, 2 April 2012, personal 
communication). NY&Y are in the process of rolling out the initiative to cover 2000 people.56 In addition, 
the UK Department of Health released headline findings from the Whole System Demonstrator (WSD) 
programme for telehealth in December 2011.57 This randomised evaluation of the impact of telehealth 
for people with chronic conditions [diabetes, HF and chronic obstructive pulmonary disease (COPD)] 
included over 6000 patients from sites in Newham, Kent and Cornwall, and reported strongly positive 
results, including a 45% reduction in mortality. However, these results should be interpreted with caution. 
The Department of Health’s release of these findings before peer review makes their robustness difficult 
to evaluate, and data on potential confounding factors, such as face-to-face clinical contact, are not 
yet publicly available. Nevertheless, the early release of these findings underscores the enthusiasm for 
telehealth among some quarters of the UK health-care authorities.
Two recent meta-analyses demonstrated significant benefits of RM interventions in terms of mortality and 
hospitalisation48,58 [it is noteworthy that shortly following approval of this review protocol the original 
Cochrane systematic review published by Clark et al.59 (search date from January 2002 to May 2006) 
was superseded by that by Inglis et al.48 (search date from January 2006 to November 2008)]. However, 
since the publication of the latest of these reviews, randomised controlled trials (RCTs) demonstrating 
minimal or no clinical benefits have been published.50,52,60 Furthermore, neither the review by Klersy et al.58 
nor that of Clark et al.59 (including the recent update by Inglis et al.48) included an economic evaluation 
of telemedicine.
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Chapter 2 Definition of the decision problem
Purpose of the decision to be made
The aim of this assessment was to investigate the clinical effectiveness and cost-effectiveness of home TM 
or STS programmes for adults who have been recently discharged (within 28 days) from an acute care 
setting after a recent exacerbation of HF (including subgroups such as those with transiently or persistently 
severe HF).
Clear definition of the intervention
Telemonitoring, defined as the use of information and communication technologies to monitor and 
transmit items related to patient health status between geographically separated individuals,54 permits 
home monitoring of patients (living at home or in nursing or residential care homes) using external 
electronic devices in conjunction with a telecommunications system (landline or mobile telephone, 
cable network or broadband technology). TM allows frequent or continuous assessment of HF signs 
and symptoms measured by patients, family or caregivers at home, while allowing patients to remain 
under close supervision.37,59 Symptoms reported by patients can be remotely reviewed by a health-care 
professional and appropriate action can be initiated. Telephone support is another form of remote 
management that can be provided through structured telephone contact between patients and health-
care providers (with or without home visits) and reporting of symptoms and/or physiological data.58,59 
Cardiovascular implanted monitoring devices such as modern pacemakers, implantable cardioverter 
defibrillators or cardiac resynchronisation devices are also capable of delivering remote physiological 
monitoring, often without the need for a patient to trigger the transmission of data.53
The highest risk period for rehospitalisation is in the first few weeks after discharge from hospital.15 STS 
and/or home TM interventions should be performed at least once within the first 28 days following 
discharge from hospital and must be targeted towards patients and intended to address patient concerns 
and problems and not those of caregivers.59 The optimum time period for TM is unclear; however, it is 
likely that services will provide TM or STS for at least 4–6 months following discharge from hospital with 
its usefulness evaluated at 30-day intervals thereafter. The review focuses on the use of home TM or STS 
programmes for patients who have been discharged from an acute care setting after a recent exacerbation 
of HF.
Population and relevant subgroups
The population included any adults (defined as ≥ 18 years of age) of either sex or any ethnic group with 
a diagnosis of HF and discharged from an acute care setting (including emergency departments and 
1-day stay procedures) to home (including a relative’s home, nursing home or residential care home). 
The identification of subgroups of patients for whom home TM or STS programmes are appropriate or 
inappropriate was governed by the available evidence; however, on a priori grounds, information was 
sought for people with transiently or persistently severe HF.
Relevant comparators
The relevant comparator was considered to be usual care. This involves standard post-discharge 
multidisciplinary care without regular follow-up and may include (1) in-person follow-up visits to a 
primary care physician, (2) attendance at a clinic-based chronic heart failure (CHF) disease management 
programme and (3) any visits at home by a specialised CHF health-care professional (referred to as 
enhanced conventional care).58,59
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Outcomes
The outcomes of the review were mortality (all-cause), all-cause admission to hospital, HF-related 
admission to hospital, length of stay (days in hospital), health-related quality of life (HRQoL) and 
acceptability of interventions to patients.
Overall aims and objectives of the assessment
The review had the following objectives:
1. update two existing systematic reviews48,58 of TM or STS programmes for patients with HF within the 
scope of the current review
2. evaluate the effectiveness and cost-effectiveness of home TM and/or STS packages compared with 
usual post-discharge care
3. identify key areas for primary research.
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Chapter 3 Assessment of clinical effectiveness
A systematic review of the literature and (network) meta-analysis (where appropriate) was undertaken to evaluate the clinical effectiveness of home TM or STS strategies compared with usual care for adults 
who have been recently discharged (within 28 days) from an acute care setting after a recent exacerbation 
of HF.
A review of the evidence was undertaken in accordance with the general principles recommended in the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement (www.prisma-
statement.org/).
Methods for reviewing effectiveness
Identification of studies
Electronic databases
Studies were identified by searching the following electronic databases and research registers:
 z MEDLINE(R) In-Process & Other Non-Indexed Citations and MEDLINE(R) (Ovid) 1948–January 2012
 z EMBASE (Ovid) 1980–January 2012
 z Science Citation Index Expanded (Web of Science) 1899–January 2012
 z Conference Proceedings Citation Index – Science (Web of Science) 1990–January 2012
 z Cochrane Database of Systematic Reviews (Wiley Online Library) 1996–January 2012
 z Cochrane Central Register of Controlled Trials (Wiley Online Library) 1898–January 2012
 z Health Technology Assessment database (Wiley Online Library) 1995–January 2012
 z Database of Abstracts of Reviews of Effects (Wiley Online Library) 1995–January 2012
 z PsycINFO (Ovid) 1806–January 2012
 z Cumulative Index to Nursing and Allied Health Literature (EBSCOhost) 1982–January 2012
 z Allied and Complementary Medicine Database (Ovid) 1985–January 2012
 z UK Clinical Research Network (CRN) Portfolio Database [National Institute for Health Research (NIHR)] 
2001–January 2012
 z ClinicalTrials.gov (US NIH) 2000–January 2012
 z Institute of Electrical and Electronics Engineers/Institution of Engineering and Technology (IEEE/IET) 
Electronic Library (IEEE Xplore) 1988–January 2012.
Sensitive keyword strategies using free text and, where available, thesaurus terms using Boolean operators 
and database-specific syntax were developed to search the electronic databases. Synonyms relating to 
the condition (e.g. HF) were combined with terms for TM. No language restrictions were used on any 
database; however, the clinical effectiveness searches were restricted by date. The current review updated 
two existing systematic reviews48,58 of TM or STS programmes for patients with HF (within the scope of 
the current review). In the review by Inglis et al.48 the searches examined the period from January 2006 
to November 2008 and in Klersy et al.58 the searches examined the period from January 2000 to October 
2008. As the search strategies from the existing systematic reviews were of good quality (and clearly 
reported) it was assumed that all studies prior to 2008 should have been identified. Thus, the clinical 
effectiveness searches were limited by date from 2008 to January 2012. An example of the MEDLINE 
search strategy is provided in Appendix 1.
Other resources
To identify additional published, unpublished and ongoing studies, the reference lists of all relevant studies 
(including existing systematic reviews) were checked. Citation searches of relevant articles using the Web 
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of Science Science Citation Index was also undertaken to identify articles that cite the relevant articles. In 
addition, key experts in the field were contacted.
All identified citations from the electronic searches and other resources were imported into and managed 
using Reference Manager bibliographic software (version 12; Thomson Reuters, Philadelphia, PA).
Inclusion and exclusion criteria
The inclusion of potentially relevant articles was undertaken using a two-step process. First, all titles were 
examined for inclusion by one reviewer. Any citations that clearly did not meet the inclusion criteria, that 
is, non-human, unrelated to TM and/or HF, were excluded. Second, all abstracts and full-text articles were 
examined independently by two reviewers. Any disagreements in the selection process were resolved 
through discussion. The relevance of each article for the systematic review was assessed according to the 
following criteria.
Study design
All RCTs or observational cohort studies with a contemporaneous control group published from 2008 to 
January 2012 (as well as those identified by the existing systematic reviews) that evaluated home TM or 
STS programmes compared with usual post-discharge multidisciplinary care for adults who have been 
recently discharged (within 28 days) from an acute care setting to home (including a relative’s home, 
nursing home or residential care home) after a recent exacerbation of HF were included. Before-and-after 
studies without a concurrent control group were excluded because the absence of a control group to 
record concurrent changes over time means that changes due to the intervention or due to temporal 
trends, concurrent changes or a Hawthorne effect would be conflated. Such studies therefore represent 
very weak evidence of effectiveness.
Reviews of primary studies were not included in the analysis but were retained for discussion and 
identification of additional studies. Moreover, the following publication types were excluded from the 
review: animal models; preclinical and biological studies; narrative reviews, editorials, opinions; non-
English-language papers and reports published as meeting abstracts only when insufficient methodological 
details are reported to allow critical appraisal of study quality.
Population
The population comprised adults (defined as ≥ 18 years of age) with a diagnosis of HF and discharged 
from an acute care setting to home (including a relative’s home, nursing home or residential care home).
Interventions
The following interventions were included: (1) remote home TM using patient-initiated external electronic 
devices or cardiovascular implanted monitoring devices, with transfer of physiological data from the 
patient to the health-care provider by landline or mobile telephone, cable network or broadband 
technology, (2) STS including regularly scheduled telephone contact between patients and health-care 
providers and reporting of symptoms and/or physiological data. In addition, STS and/or home TM 
interventions were required to be performed at least once within the first 28 days following discharge from 
hospital, and to be targeted towards patients and intended to address patient concerns and problems and 
not those of caregivers.
Relevant comparators
The relevant comparator was considered as usual care. This involved standard post-discharge 
multidisciplinary care without regular follow-up and may include (1) in-person follow-up visits to a primary 
care physician, (2) attendance at a clinic-based CHF disease management programme and (3) any visits at 
home by a specialised CHF health-care professional (referred to as enhanced conventional care).58,59
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Outcomes
The outcomes of the review included mortality (all-cause), all-cause admission to hospital, HF-related 
admission to hospital, length of stay (days in hospital), HRQoL and acceptability of interventions 
to patients.
Data abstraction strategy
Data abstraction was performed by one reviewer into a standardised data extraction form and 
independently checked for accuracy by a second. Discrepancies were resolved by discussion between 
the two reviewers; if agreement could not be reached a third reviewer was consulted. When multiple 
publications of the same study were identified, data were extracted and reported as a single study. 
Moreover, as this was an update of two existing reviews,48,58 all relevant data were extracted from the 
reviews in the first instance and cross-checked for accuracy with the original papers. When necessary, 
additional data were extracted from the original papers or, in cases in which information was missing from 
the articles, authors of the respective studies were contacted to provide further details.
The following information was extracted for all studies when reported: study characteristics (e.g. author, 
year of publication, country, study design, setting, duration of follow-up, funding), participant details 
(e.g. inclusion and exclusion criteria, age, sex, autonomy, comorbidities), intervention and comparator 
details (e.g. description, system activity, frequency of measurement, parameters measured) and outcomes 
(including definitions).
Quality assessment strategy
The methodological quality of each included study was assessed by one reviewer and independently 
checked by another. Disagreements were resolved by discussion between the two reviewers and, if 
agreement could not be reached, a third reviewer was consulted. The study quality characteristics were 
assessed according to (adapted) criteria based on those proposed by Verhagen et al.61 for RCTs and by 
Wells et al.62 for observational studies. Further details are provided in Appendix 2.
Methods of data synthesis
Primary analyses (recently discharged patients with heart failure)
The extracted data and quality assessment variables were presented for each study both in structured 
tables and as a narrative description. Mortality (all-cause), all-cause admission to hospital and HF-related 
admission to hospital were subjected to formal (network) meta-analyses. A network meta-analysis (NMA) 
allows a comprehensive comparison of all interventions that are linked with respect to at least one 
common intervention without breaking the randomisation within studies. The summary statistics that 
were analysed were the number of patients who had an event. In each case the data were analysed using 
a random-effects model (to allow for heterogeneity in treatment effects across studies) implemented 
using the WinBUGS software package, version 1.4.3 (MRC Biostatistics Unit, Cambridge, UK).63,64 The 
statistical model accounted for the variation in follow-up between studies using a complementary log-log 
link function (see Appendix 3). This model assumed that the parameter being analysed was the event rate 
(i.e. hazard) from an exponential survivor function and that an intervention effect relative to the baseline 
treatment was the (log-) hazard ratio (HR). Convergence of the model to its posterior distribution was 
assessed using the Gelman–Rubin convergence statistic.65 In each case, convergence occurred within 
20,000 iterations so the final analysis used a burn-in of 20,000. There was some suggestion of high 
autocorrelation between successive iterations of the Markov chains; to compensate for this the Markov 
chains were thinned every 10 iterations. Parameter estimates were estimated based on 10,000 iterations 
of the Markov chains. The total residual deviance was used to formally assess whether or not the statistical 
model provided a reasonable representation of the sample data. The total residual deviance is the mean 
of the deviance under the current model minus the deviance for the saturated model, so that each data 
point should contribute about 1 to the deviance. Results of the NMA were reported in terms of the HR and 
95% credible interval (CrI) relative to the baseline intervention (i.e. usual care). The posterior median of the 
between-study standard deviation together with the 95% CrI was also presented. To account for potential 
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heterogeneity in intervention effects between studies, the posterior predictive distribution for the HR of a 
new study was also presented.
The original intention was to use meta-regression in an attempt to explain any heterogeneity in the 
effects of the interventions amongst the studies. Potential treatment effect modifiers were quality of usual 
care, different telehealth intervention settings, adherence, age, sex and autonomy (i.e. single vs couple). 
However, because of the lack of availability of data on these study-level covariates, meta-regressions were 
not performed.
Additional analyses (patients with stable heart failure)
Following advice from clinical experts, additional analyses were undertaken to assess whether or not the 
results from the primary analysis differed markedly from results in those with stable HF who were managed 
in the community. In this supplementary analysis the following studies were included: RCTs comparing HF 
management delivered via STS, TM or cardiovascular implanted monitoring devices with HF management 
delivered via usual post-discharge care in stable HF patients (defined as having no acute event or 
deterioration in the past 28 days) who were managed in the community setting (ambulatory or outpatient 
care). Studies that included intensified management with additional home or clinic visits were excluded. 
Although no formal critical appraisal of these studies was undertaken, the results were meta-analysed (as 
per the methods of the primary analysis) and presented for information only. All studies published before 
2008 were identified from Inglis et al.48 and Klersy et al.,58 whereas more recent studies (meeting these 
criteria) were identified using the current review.
Results of the clinical effectiveness review
This section first provides a brief overview of the evidence from the two existing systematic reviews48,58 of 
RM for HF [including a methodological quality assessment using a measurement tool developed by Shea 
et al.66 for the ‘assessment of multiple systematic reviews’ (AMSTAR)]. Second, this section presents the 
results of the current systematic review, including additional analyses.
Overview of existing systematic reviews
The first of the two existing systematic reviews and meta-analyses was published by Clark et al. in 200759 
and later updated by Inglis et al. in 2010.48 The review included RCTs comparing HF management 
strategies delivered via STS or TM with usual post-discharge care in HF patients recently discharged from 
an acute care setting to home or while managed in the community setting. Any interventions that included 
home visits by specialised HF health-care professionals or study personnel for the purpose of education or 
clinical assessment, other than an initial visit to set up equipment, were excluded. The primary outcomes 
of interest were all-cause mortality, HF-related admission to hospital and all-cause readmissions to hospital. 
Secondary outcomes included length of stay, QoL, health-care cost savings in patients with HF and 
acceptability of the intervention to patients with HF. Overall, 30 RCTs of STS and TM were identified (25 
peer-reviewed publications and five abstracts). Of the 25 peer-reviewed studies, 11 evaluated TM and 16 
evaluated STS, with two testing both STS and TM in separate intervention arms compared with usual care.
The second review was conducted by Klersy et al.58 and was published in December 2009. The review 
included RCTs and observational studies comparing HF management strategies delivered via STS (with 
or without home visits), TM or cardiovascular implanted monitoring devices with usual post-discharge 
care in HF patients. Overall, 32 studies were identified (20 RCTs and 12 cohort studies). Of the 20 RCTs, 
11 evaluated STS, 7 evaluated TM (including cardiovascular implanted monitoring devices) and 2 tested 
both STS and TM. Of the 12 cohort studies, 6 were between-arm studies. The outcomes of interest 
included all-cause mortality, all-cause hospitalisation, HF-related hospitalisation and a composite end point 
comprising all-cause hospitalisation or death from any cause. Despite ostensibly being reviews of the same 
literature, as their objectives would suggest (except for studies of cardiovascular implanted monitoring 
devices), there was limited overlap between the two reviews in terms of the primary studies that were 
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included. The lack of overlap of included studies may be largely explained by the differences in their search 
strategies (including search dates) and inclusion/exclusion criteria. For example, Inglis et al.48 searched 15 
electronic databases (including research registers) from 1966 to November 2008 and included RCTs that 
had interventions without home visits or intensified clinic follow-up. In contrast, Klersy et al.58 searched five 
electronic databases from January 2000 to October 2008 and included RCTs and observational studies that 
had interventions with or without home visits. A summary of all of the included studies in both reviews 
(including discordance) is presented in Appendix 4.
The methodological quality of both systematic reviews was judged to be high, indicating low risk of bias: 
Inglis et al.48 met 9 of the 11 criteria whereas Klersy et al.58 met 7 of the 11 criteria (see Appendix 5). Both 
reviews provided an ‘a priori’ design, had at least two authors conduct data extraction independently, 
provided lists and comprehensive details of included studies, assessed the likelihood of publication bias 
and assessed the scientific quality of the meta-analysed trials. In addition, Klersy et al.58 utilised appropriate 
methods for data synthesis and Inglis et al.48 conducted a comprehensive literature search and reported 
potential conflicts of interest from both the review authors and the authors of the included trials. 
However, Klersy et al.58 did not report supplementing their literature search by consulting current contents, 
reviews, textbooks, specialised registers and reference lists of identified literature nor did they explicitly 
state that they searched for reports regardless of their publication type. In addition, they did not refer 
to the quality of the synthesised literature when formulating recommendations and did not refer to the 
sources of support received by authors of the included trials. Inglis et al.48 also did not refer to the quality 
of the included trials when making recommendations and did not use appropriate statistical methods 
for synthesising heterogeneous results (all analyses were performed using a fixed-effects model). It is 
also worth noting that Klersy et al.58 did not specify their HF patient population of interest. Inglis et al.48 
included both recent discharge HF patients and stable HF patients managed in the community, although 
they did not specify their interpretation of recent discharge.
Quantity and quality of research available in the current (and existing48,58) 
systematic reviews
Number of studies identified/included
The literature searches identified 3060 citations. Of these, six RCTs52,60,67–70 met the inclusion criteria and 
were added to the 15 trials49,51,71–83 from the previous systematic reviews.48,58 No trials of cardiovascular 
implanted monitoring devices or observational studies met the inclusion criteria of the current review. A 
flow chart describing the process of identifying relevant literature can be found in Figure 1.
Number and type of studies excluded
A total of 153 full-text articles were excluded as they did not meet all of the prespecified inclusion criteria. 
The majority of the articles were excluded primarily on the basis of inappropriate study design (not RCTs or 
cohort studies without concurrent controls), incorrect intervention (not home TM or STS for patients with 
HF) or unsuitable publication type (reviews, commentaries or editorials). A full list of excluded studies with 
reasons for exclusion is presented in Appendix 6.
Assessment of effectiveness
Description of included studies (design and patient characteristics)
The design and patient characteristics of the 21 included studies that evaluated home TM or STS 
programmes for adults who have been recently discharged (within 28 days) from an acute care setting 
after a recent exacerbation of HF are summarised in Tables 5 and 6 respectively. Of these, 11 studies 
evaluated STS [10 used standard telephone equipment using HH51,69,72,74,77–82 and one provided support via 
an automated telephone interactive response system (HM) with an alert system52], nine studies assessed 
TM,60,67,68,70,71,73,75,76,83 and one study assessed both STS and TM compared with usual care.49 Almost all of 
the studies used different measures and devices as part of the STS and TM interventions.  
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FIGURE 1 Flow chart (adapted): clinical effectiveness.84
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STS programmes generally included regular scheduled telephone contact between patients and health-
care providers (usually on a weekly/monthly basis) and incorporated telephone-based education and 
monitoring of signs and symptoms of worsening HF. The TM programmes generally used patient-initiated 
external electronic devices with daily transfer of physiological data (mainly weight, blood pressure and 
heart rate) from the patient to the health-care provider using a landline, a mobile telephone or broadband 
technology. With the exception of one study (which provided 24/7 medical support),76 all transmitted data 
(including alerts) in TM programmes were reviewed by medical staff (nurses and/or physicians) and support 
provided during office hours (in one study75 nurses reviewed transmitted data on a daily basis 7 days a 
week, 365 days a year; however, the system was not active 24/7).
All studies were published between 1999 and 2011. The studies were carried out in a variety of 
countries and regions including Europe [Austria, n = 1; Belgium, n = 1; Germany, n = 2; Italy, n = 2; 
UK, n = 1; and a combination of countries (Germany, Netherlands and the UK), n = 1], North America 
(USA, n = 10; Canada, n = 2) and South America (Brazil, n = 1). The duration of follow-up ranged from 
3 months69,72,77,83 to 15 months.49 Although all of the included studies were required to perform STS 
and/or home TM interventions at least once within the first 28 days following discharge from hospital, 
two studies performed the intervention outside this period (within 30 days52 or within 6 weeks).49 For 
both of these studies it was assumed that the majority of patients would have received the intervention 
within 28 days of discharge. Of the 21 studies, 10 received funding from one or more commercial 
sponsors.49,60,67,68,70,75,77,79,81,83 The sample sizes of the included studies ranged from 3472 to 165352 patients, 
with the mean age of participants ranging from 57 years73 to 78 years.71 Only three studies recruited more 
women than men,72,79,80 with the number of male participants ranging from 46%80 to 99%.82 One trial 
was restricted to patients with a LVEF of < 35%,75 three trials were restricted to patients with a LVEF of 
≤ 40%,49,51,77 one trial was restricted to patients with a LVEF of < 45%69 and the LVEF inclusion criterion was 
not reported in 16 studies.52,60,67,68,70–74,76,78–83
Quality characteristics
The overall methodological quality of the 21 included studies is summarised in Figure 2 and Table 7. 
Generally, nine studies performed well,49,51,52,67,68,74,75,80,81 receiving a positive assessment of at least six out 
of nine methodological quality items. Potential sources of high bias most frequently identified in studies 
concerned baseline comparability of important prognostic factors (24%), adequate power to detect 
differences in the primary outcome (19%) and reporting of numbers and reasons for loss to follow-up 
Yes (low risk of bias)
Item fulfilled
No (high risk of bias)
Unclear
0
Study powered to detect
differences in outcomes
Intention-to-treat analysis
Reasons for withdrawal stated
Outcome assessment blinded
Allocation concealment
Random sequence generation
Baseline comparability achieved for
important prognostic indicators
Eligibility criteria specified
(including confirmation of diagnosis of HF)
Adequate follow-up of patients
(at least 80%)
20 40
Proportion fulfilled (%)
60 80 100
FIGURE 2 Methodological quality graph: review authors’ judgements about each methodological quality item as 
percentages across all included studies.
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(14%). The majority of publications poorly described the following aspects: random sequence generation 
(52%), allocation concealment (38%), blinding of outcome assessment (76%) and intention-to-treat 
analysis (29%). Although all studies specified eligibility criteria for study entry, the majority (57%) poorly 
described the definition and confirmation of diagnosis of HF.
TABLE 7 Methodological quality summary: review authors’ judgements about each methodological quality item for 
each included study
Author, year
Methodological assessment criteriaa
1 2 3 4 5 6 7 8 9
bAngermann et al. 2011 (INH)51 Y Y Y Y Y Y Y Y Y
Antonicelli et al. 200871 U U U Y Y U N U Y
Barth 200172 U U U U Y U N U U
Capomolla et al. 200473 U U U U Y Y U U U
bChaudhry et al. 2010 (Tele-HF)52 Y Y Y U Y Y Y Y Y
bCleland et al. 2005 (TEN-HMS)49 Y Y U U U Y Y Y Y
bDar et al. 2009 (Home-HF)67 Y Y U Y Y Y Y Y N
bDeBusk et al. 200474 Y Y Y Y Y Y Y Y Y
bDendale et al. 2011 (TEMA-HF 1)68 Y U U U Y Y Y Y Y
Domingues et al. 201169 U U U Y Y Y Y N U
bGoldberg et al. 2003 (WHARF)75 U Y Y Y Y Y Y Y U
Kielblock et al. 200776 N U U Y N U U U U
Kulshreshtha et al. 201060 U N U U Y Y Y Y U
Laramee et al. 200377 U U U Y N N Y U U
Rainville 199978 U Y U U N Y Y N U
Riegel et al. 200279 U Y U U N U U U N
bRiegel et al. 200680 U Y Y U U Y Y Y Y
Scherr et al. 2009 (MOBITEL)70 Y Y U U U Y Y Y N
bTsuyuki et al. 2004 (REACT)81 Y Y U U N Y Y Y Y
Wakefield et al. 200882 Y Y U U Y N Y Y N
Woodend et al. 200883 U U U Y U Y N Y Y
Home-HF, Home Heart Failure Study; INH, Interdisciplinary Network for Heart Failure; MOBITEL, MOBIle TELemonitoring 
in Heart Failure Patients Study; N, no (high risk of bias); REACT, Review of Education on ACE Inhibitors in Congestive 
Heart Failure Treatment; TEMA-HF, TElemonitoring in the MAnagement of Heart Failure; TEN-HMS, Trans-European 
Network – Home-Care Management System; U, unclear (insufficient detail to make judgement); WHARF, Weight 
Monitoring in Heart Failure; Y, yes (low risk of bias).
a 1 = Was the method used to assign participants to the treatment groups really random?; 2 = Was allocation 
concealment to each group performed adequately (e.g. centrally) and group assignment revealed after provision of 
consent?; 3 = Were the outcome assessors/data analysts blinded to the treatment allocations?; 4 = Were the eligibility 
criteria for study entry specified (including confirmation of diagnosis of HF); 5 = Was baseline comparability achieved 
for the most important prognostic indicators?; 6 = Was follow-up of patients adequate (at least 80%)?; 7 = Were 
the reasons for withdrawal stated?; 8 = Was an intention-to-treat analysis included?; 9 = Was the study powered to 
detect differences in outcomes?
b Study received a positive assessment on at least six of the nine quality assessment items.
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Effects of interventions
A NMA was undertaken to compare the comparative efficacy of RM (STS or TM) and usual care. 
Figure 3 presents the network of evidence. A total of 21 studies comparing different pairs or triplets of 
interventions provided information on at least one of the outcomes being analysed, although not all 
studies provided information on each outcome. One study72 was excluded from the network analysis 
because there were no events in each intervention arm and, as a consequence, it provided no information 
about the intervention effects.86 A sensitivity analysis was performed excluding data from Dar et al.67 
(Home Heart Failure Study; Home-HF) because it provided better-than-usual support and optimal medical 
treatment to patients in the control groups and also appeared to be inconsistent with the data from the 
remaining studies (i.e. an outlier). A summary of all of the trials (data) included in the base-case NMA is 
presented in Appendix 7.
Primary analyses (recently discharged patients with heart failure)
All-cause mortality All-cause mortality data were available from 20 studies,49,51,52,60,67–71,73–83 including one 
three-arm study (STS HM, n = 1; STS HH, n = 10; TM with medical support provided during office hours, 
n = 9; TM 24/7, n = 1). Table 8 summarises the all-cause mortality data for the NMA of RM compared with 
usual care.
The NMA model fitted the data reasonably well, with a residual deviance close to the total number of data 
points included in the analysis. The total residual deviance was 42.87, which compared favourably with 
the 40 non-zero data points being analysed. However, the model did not represent the data from the Dar 
et al. (Home-HF)67 and Dendale et al. (TEMA-HF 1; TElemonitoring in the MAnagement of Heart Failure)68 
studies particularly well. The between-study standard deviation was estimated to be 0.34 (95% CrI 0.03 
STS via HM STS via HH
Usual care
TM 24/7a TM office hoursb
Mortality: n = 1
All-cause hospitalisation: n = 1
HF-related hospitalisation: n = 1
Mortality: n = 9
All-cause hospitalisation: n = 6
HF-related hospitalisation: n = 3
Mortality: n = 1
All-cause hospitalisation: n = 1
HF-related hospitalisation: n = 0
Mortality: n = 1
All-cause hospitalisation: n = 1
HF-related hospitalisation: n = 1
Mortality: n = 10
All-cause hospitalisation: n = 9
HF-related hospitalisation: n = 8
FIGURE 3 Network diagram of different RM programmes compared with usual care in recently discharged patients 
with HF. The nodes are the interventions. The numbers against each outcome represent the numbers of times that 
each pair of interventions has been compared. There was one multiarm study comparing STS via HH, TM during office 
hours and usual care. a, Transmitted data reviewed by medical staff (or medical support provided) 24 hours per day, 
7 days per week. b, Transmitted data reviewed by medical staff (or medical support provided) during office hours.
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to 0.75). This indicated that there was small to moderate heterogeneity between studies in the treatment 
effect. All interventions showed a beneficial trend in reducing all-cause mortality compared with usual 
care. The intervention that exhibited the greatest effect was TM 24/7 (HR 0.49; 95% CrI 0.20 to 1.18); 
however, this result should be treated with caution because of the poor methodological quality of the only 
included study in this network.76 STS HH (HR 0.77; 95% CrI 0.55 to 1.08) and TM during office hours (HR 
0.76; 95% CrI 0.49 to 1.18) both had similar effects on all-cause mortality. In addition, the heterogeneity 
in the effect of RM between studies means that the intervention effects in a randomly chosen study vary 
substantially depending on the characteristics of the study.
A sensitivity analysis was performed excluding the Home-HF study67 (Table 9). The heterogeneity in 
intervention effects between studies was considerably reduced. The interventions that exhibited the 
greatest effects were TM 24/7 (HR 0.49; 95% CrI 0.26 to 0.88) (although this result should be treated 
with caution because of the poor methodological quality of the only included study in this network76), TM 
during office hours (HR 0.62; 95% CrI 0.42 to 0.89) and STS HH (HR 0.75; 95% CrI 0.59 to 0.96).
All-cause hospitalisation All-cause hospitalisation data were available from 16 
studies,49,51,52,67,69,70,71,74–77,79–83 including one three-arm study (STS HM, n = 1; STS HH, n = 9; TM with 
medical support provided during office hours, n = 6; TM 24/7, n = 1). Table 10 summarises the all-cause 
hospitalisation data for the NMA of RM compared with usual care.
The NMA model fitted the data reasonably well, with a residual deviance (36.85) close to 33, the total 
number of data points included in the analysis. However, the model did not represent the data from 
Antonicelli et al.71 particularly well. The between-study standard deviation was estimated to be 0.38 
(95% CrI 0.13 to 0.74). This indicated that there was small to moderate heterogeneity between studies 
in the treatment effect. The intervention that exhibited the greatest effect was TM with medical support 
provided during office hours (HR 0.75; 95% CrI 0.49 to 1.10). In addition, the heterogeneity in the effect 
of RM between studies means that the intervention effects in a randomly chosen study vary substantially 
depending on the characteristics of the study.
A sensitivity analysis was performed excluding the Home-HF study67 (Table 11). There was little impact 
on the heterogeneity in intervention effects between studies. As before, the intervention that exhibited 
TABLE 8 All-cause mortality in recently discharged patients with HF: posterior distribution for the HRs relative to usual 
care (random effects)
Treatment
HR and CrI Predictive interval
Median 2.5% 97.5% 2.5% 97.5%
STS
HM 0.98 0.41 2.33 0.30 3.23
HH 0.77 0.55 1.08 0.31 1.86
TM
Office hoursa 0.76 0.49 1.18 0.30 1.91
24/7b 0.49 0.20 1.18 0.14 1.73
Usual care
Reference Reference Reference Reference Reference Reference
Between-study standard deviation (log-HR scale) 0.34 0.03 0.75 – –
a Transmitted data reviewed by medical staff (or medical support provided) during office hours.
b Transmitted data reviewed by medical staff (or medical support provided) 24 hours per day, 7 days per week.
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the greatest effect was TM with medical support provided during office hours (HR 0.67; 95% CrI 0.42 to 
0.97), although the heterogeneity in the effect of RM between studies means that the intervention effects 
in a randomly chosen study vary substantially depending on the characteristics of the study.
Heart failure-related hospitalisation Heart failure-related hospitalisation data were available from 11 
studies,49,51,52,67,74,75,77–81 including one three-arm study (STS HM, n = 1; STS HH, n = 8; TM with medical 
support provided during office hours, n = 3). Table 12 summarises the HF-related hospitalisation data for 
the NMA of RM compared with usual care.
TABLE 9 All-cause mortality in recently discharged patients with HF (excluding Dar et al.67): posterior distribution for 
the HRs relative to usual care (random effects)
Treatment
HR and CrI Predictive interval
Median 2.5% 97.5% 2.5% 97.5%
STS
HM 0.98 0.58 1.62 0.49 1.95
HH 0.75 0.59 0.96 0.45 1.27
TM
Office hoursa 0.62 0.42 0.89 0.35 1.09
24/7b 0.49 0.26 0.88 0.23 1.04
Usual care
Reference Reference Reference Reference Reference Reference
Between-study standard deviation (log-HR scale) 0.14 0.01 0.47 – –
a Transmitted data reviewed by medical staff (or medical support provided) during office hours.
b Transmitted data reviewed by medical staff (or medical support provided) 24 hours per day, 7 days per week.
TABLE 10 All-cause hospitalisation in recently discharged patients with HF: posterior distribution for the HRs relative 
to usual care (random effects)
Treatment
HR and CrI Predictive interval
Median 2.5% 97.5% 2.5% 97.5%
STS
HM 1.06 0.44 2.53 0.31 3.61
HH 0.97 0.70 1.31 0.38 2.43
TM
Office hoursa 0.75 0.49 1.10 0.28 1.91
24/7b 0.81 0.33 2.00 0.23 2.85
Usual care
Reference Reference Reference Reference Reference Reference
Between-study standard deviation (log-HR scale) 0.38 0.13 0.74 – –
a Transmitted data reviewed by medical staff (or medical support provided) during office hours.
b Transmitted data reviewed by medical staff (or medical support provided) 24 hours per day, 7 days per week.
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The NMA model fitted the data reasonably well, with a residual deviance (22.18) close to 23, the total 
number of data points included in the analysis. However, the model did not represent the data from the 
Dar et al. (Home-HF)67 and Rainville78 studies particularly well. The between-study standard deviation was 
estimated to be 0.11 (95% CrI 0.00 to 0.42). This indicated that there was small heterogeneity between 
studies in the treatment effect. The intervention that exhibited the greatest effect was STS HH (HR 0.77; 
95% CrI 0.62 to 0.96).
TABLE 11 All-cause hospitalisation in recently discharged patients with HF (excluding Dar et al.67): posterior 
distribution for the HRs relative to usual care (random effects)
Treatment
HR and CrI Predictive interval
Median 2.5% 97.5% 2.5% 97.5%
STS
HM 1.06 0.48 2.32 0.35 3.22
HH 0.96 0.72 1.27 0.42 2.18
TM
Office hoursa 0.67 0.42 0.97 0.26 1.53
24/7b 0.81 0.36 1.81 0.27 2.50
Usual care
Reference Reference Reference Reference Reference Reference
Between-study standard deviation (log-HR scale) 0.33 0.08 0.69 – –
a Transmitted data reviewed by medical staff (or medical support provided) during office hours.
b Transmitted data reviewed by medical staff (or medical support provided) 24 hours per day, 7 days per week.
TABLE 12 HF-related hospitalisation in recently discharged patients with HF: posterior distribution for the HRs relative 
to usual care (random effects)
Treatment
HR and CrI Predictive interval
Median 2.5% 97.5% 2.5% 97.5%
STS
HM 1.03 0.66 1.54 0.58 1.77
HH 0.77 0.62 0.96 0.50 1.19
TM
Office hoursa 0.95 0.70 1.34 0.59 1.62
24/7b NA NA NA NA NA
Usual care
Reference Reference Reference Reference Reference Reference
Between-study standard deviation (log-HR scale) 0.11 0.00 0.42 – –
NA, not applicable.
a Transmitted data reviewed by medical staff (or medical support provided) during office hours.
b Transmitted data reviewed by medical staff (or medical support provided) 24 hours per day, 7 days per week.
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A sensitivity analysis was performed excluding the Home-HF study67 (Table 13). There was little impact on 
the heterogeneity in intervention effects between studies. As before, the intervention that exhibited the 
greatest effect was STS HH (HR 0.76; 95% CrI 0.61 to 0.94).
Length of stay Of the 11 studies reporting on STS intervention programmes compared with usual 
care,51,52,69,73,74,77–82 six studies reported length of stay data.52,77,79–82 Of these, only the study by Tsuyuki 
et al.81 reported a statistically significant reduction in the length of stay in hospital between the STS 
programme and the usual care group (total: 627 vs 1082 days respectively, p < 0.001; average: 6.6 vs 
11.0 days respectively, p < 0.001). Of the nine studies reporting on TM intervention programmes compared 
with usual care, two studies reported length of stay data.67,83 These studies found no significant differences 
between the groups in the number of days spent in hospital at 180 days (17 vs 13 days respectively, 
p = 0.99)67 or in the first year post discharge (7.13 vs 6.71 days respectively, p = not significant).83 The 
study that assessed both STS and TM intervention programmes reported no significant differences in the 
length of stay for hospital admissions between groups during 240 days of follow up (p = not significant for 
all comparisons).49
Quality of life Quality of life was a secondary outcome measure in eight of the 21 included 
studies.51,67,71,72,75,80,82,83 These were either a direct comparison between intervention and control groups 
at study conclusion51,67,80,83 or a comparison between baseline and study conclusion within the study 
arm.71,72,75,82 A range of psychometric measures were used including both generic and HF-specific 
measures: SF-36,51,71,83 the Short Form questionnaire-12 items (SF-12),76 the Health Distress Score (HDS),75 
the Minnesota Living with Heart Failure Questionnaire (MLHFQ),67,72,75,80,82,83 and the European Quality of 
Life-5 Dimensions (EQ-5D).67,80
Three of the four STS studies reported improvements in QoL, with significant improvements in physical 
(p = 0.03)51 and overall (MLHFQ, p < 0.001)72,82 measures. One study found no significant differences 
between groups in either the MLHFQ or the EQ-5D measure.80 Four TM studies measured QoL.67,71,75,83 Of 
these, two reported improvements in QoL (SF-36 health perception, p = 0.046;71 MLHFQ, p = 0.025 and 
SF-36, p < 0.0583). Although Goldberg et al.75 observed improvements in QoL, none of the measures was 
significant (MLHFQ, p = 0.22; SF-12, p > 0.05; HDS, p = 0.57). Similarly, Dar et al.67 found no significant 
TABLE 13 HF-related hospitalisation in recently discharged patients with HF (excluding Dar et al.67): posterior 
distribution for the HRs relative to usual care (random effects)
Treatment
HR and CrI Predictive interval
Median 2.5% 97.5% 2.5% 97.5%
STS
HM 1.02 0.70 1.49 0.61 1.69
HH 0.76 0.61 0.94 0.51 1.13
TM
Office hoursa 0.86 0.61 1.21 0.54 1.38
24/7b NA NA NA NA NA
Usual care
Reference Reference Reference Reference Reference Reference
Between-study standard deviation (log-HR scale) 0.10 0.00 0.39 – –
NA, not applicable.
a Transmitted data reviewed by medical staff (or medical support provided) during office hours.
b Transmitted data reviewed by medical staff (or medical support provided) 24 hours per day, 7 days per week.
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differences between groups in either the MLHFQ (p = 0.6) or the EQ-5D (p = 0.5) measure over a 6-month 
follow-up period.
System acceptability and patient satisfaction Only 5 of the 21 included studies reported adherence 
(compliance) rates to the intervention.51,52,67,73,75 Adherance was measured at 55.1%52–84.0%51 for STS 
and 81.0%73–98.5%75 for TM. Some further data were available on system acceptability and patient 
satisfaction. Cleland et al.49 reported an overall acceptance rate of 91.2% with 96% of participants 
expressing satisfaction with the system and 97% reporting that the device was easy to use. Riegel et 
al.79 reported significantly higher satisfaction among patients receiving TM than among those receiving 
usual care (p = 0.01), and Laramee et al.77 reported higher satisfaction among STS patients than among 
usual care patients (p < 0.01). Kielblock et al.76 reported very high satisfaction among TM patients, with 
57% rating the programme ‘very good’ and the remaining 43% rating it as ‘quite good’. Woodend et 
al.83 reported satisfaction scores of between 92 and 97 out of 100 on a 10-item checklist. Scherr et al.70 
reported early termination of their study because of an increasing number of patients who were unable 
to operate the TM equipment, with 12 participants (10%) failing to transmit any readings and a further 
four requesting early termination. Finally, Kulshreshtha et al.60 reported that, of 82 patients offered TM, 40 
refused participation: 24 patient refusals and 16 physician refusals.
Additional analyses (patients with stable heart failure)
Additional analyses were undertaken to assess whether or not the results from the primary analysis 
differed markedly from the results in those with stable HF who were managed in the community. In this 
supplementary analysis the following studies were included: RCTs comparing HF management delivered via 
STS, TM or cardiovascular implanted monitoring devices with HF management delivered via usual post-
discharge care in stable HF patients (defined as having no acute event or deterioration in the past 28 days) 
who were managed in the community setting (ambulatory or outpatient care). Studies that included 
intensified management with additional home or clinic visits were excluded. Although no formal critical 
appraisal of these studies was undertaken, the results were meta-analysed (as per the methods of the 
primary analysis) and are presented in this section for information only. All studies published before 2008 
were identified from Inglis et al.48 and Klersy et al.58 whereas more recent studies (meeting these criteria) 
were identified from the current review. The design and patient characteristics of the 21 included studies 
that evaluated home TM (including cardiovascular implanted monitoring devices) or STS programmes for 
adults with stable HF are briefly summarised in Appendix 8. A network of 18 studies comparing different 
pairs or triplets of treatments is shown in Figure 4 (data included in the base-case NMA are presented in 
Appendix 9).
All-cause mortality
Structured telephone support or telemonitoring compared with usual care All-cause mortality data were 
available from 17 studies,50,87–102 including one three-arm study (STS HM, n = 2; STS HH, n = 6; TM with 
medical support provided during office hours, n = 7; TM 24/7, n = 3). Table 14 summarises the all-cause 
mortality data for the NMA of RM compared with usual care.
The residual deviance, 28.76, was < 35, the total number of data points included in the analysis, 
suggesting that the meta-analysis model may not be a good representation of the data. The between-
study standard deviation was estimated to be 0.12 (95% CrI 0.01 to 0.38). This indicated that there was 
little heterogeneity between studies in the treatment effect. All interventions except for STS HM showed 
a beneficial trend in reducing all-cause mortality compared with usual care, although these effects were 
not conclusive.
Cardiovascular implanted monitoring devices compared with non-monitoring cardiovascular implanted 
monitoring devices (usual care) Of the three studies103–105 that compared cardiovascular implanted 
monitoring devices with non-monitoring cardiovascular implanted monitoring devices (usual care), 
there was an indication of small to extreme heterogeneity between the studies in the treatment effect. 
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TABLE 14 All-cause mortality in patients with stable HF: posterior distribution for the HRs relative to usual care 
(random effects)
Treatment
HR and CrI Predictive interval
Median 2.5% 97.5% 2.5% 97.5%
STS
HM 1.35 0.78 2.36 0.71 2.67
HH 0.87 0.69 1.14 0.57 1.42
TM
Office hoursa 0.85 0.59 1.20 0.52 1.37
24/7b 0.85 0.58 1.27 0.47 1.39
Usual care
Reference Reference Reference Reference Reference Reference
Between-study standard deviation (log-HR scale) 0.12 0.01 0.38 – –
a Transmitted data reviewed by medical staff (or medical support provided) during office hours.
b Transmitted data reviewed by medical staff (or medical support provided) 24 hours per day, 7 days per week.
STS via HM STS via HH
Usual care
TM 24/7a TM office hoursb
Mortality: n = 2
All-cause hospitalisation: n = 2
HF-related hospitalisation: n = 2
Mortality: n = 7
All-cause hospitalisation: n = 5
HF-related hospitalisation: n = 2
Mortality: n = 3
All-cause hospitalisation: n = 3
HF-related hospitalisation: n = 3
Mortality: n = 1
All-cause hospitalisation: n = 1
HF-related hospitalisation: n = 1
Mortality: n = 6
All-cause hospitalisation: n = 4
HF-related hospitalisation: n = 5
FIGURE 4 Network diagram of different RM programmes compared with usual care in patients with stable HF. The 
nodes are the interventions. The numbers against each outcome represent the number of times that each pair of 
interventions has been compared. There was one multiarm study comparing STS via HH, TM during office hours and 
usual care. a, Transmitted data reviewed by medical staff (or medical support provided) 24 hours per day, 7 days per 
week. b, Transmitted data reviewed by medical staff (or medical support provided) during office hours.
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The between-study standard deviation was estimated to be 0.26 (95% CrI 0.01 to 1.63). Although 
cardiovascular implanted monitoring devices appeared to be associated with a reduction in mortality 
compared with usual care, this result was inconclusive (Table 15). In addition, the heterogeneity in the 
effect of cardiovascular implanted monitoring devices between studies means that the intervention effect 
in a randomly chosen study varies substantially depending on the characteristics of the study.
All-cause hospitalisation All-cause hospitalisation data were available from 13 studies,50,88,90–93,95,97–102 
including one three-arm study (STS HM, n = 2; STS HH, n = 4; TM with medical support provided during 
office hours, n = 5; TM 24/7, n = 3). Table 16 summarises the all-cause hospitalisation data for the NMA of 
RM compared with usual care.
The NMA model fitted the data well, with a residual deviance (27.11) close to 27, the total number of data 
points included in the analysis. The between-study standard deviation was estimated to be 0.23 (95% CrI 
0.07 to 0.49). This indicated that there was little heterogeneity between studies in the treatment effect. All 
interventions except for TM with medical support provided during office hours showed a beneficial trend 
in reducing all-cause hospitalisation compared with usual care, although these effects were not conclusive.
TABLE 15 All-cause mortality in patients with stable HF: posterior distribution for the HRs relative to non-monitoring 
cardiovascular implanted monitoring devices (random effects)
Treatment
HR and CrI Predictive interval
Median 2.5% 97.5% 2.5% 97.5%
Cardiovascular implanted monitoring devices 0.90 0.31 2.49 0.12 5.21
Usual carea
Reference Reference Reference Reference Reference Reference
Between-study standard deviation (log-HR scale) 0.26 0.01 1.63 – –
a Usual care defined as non-monitoring cardiovascular implanted monitoring devices.
TABLE 16 All-cause hospitalisation in patients with stable HF: posterior distribution for the HRs relative to usual care 
(random effects)
Treatment
HR and CrI Predictive interval
Median 2.5% 97.5% 2.5% 97.5%
STS
HM 0.87 0.54 1.29 0.44 1.74
HH 0.86 0.62 1.17 0.45 1.62
TM
Office hoursa 1.17 0.89 1.59 0.62 2.18
24/7b 0.84 0.54 1.15 0.40 1.47
Usual care
Reference Reference Reference Reference Reference Reference
Between-study standard deviation (log-HR scale) 0.23 0.07 0.49 – –
a Transmitted data reviewed by medical staff (or medical support provided) during office hours.
b Transmitted data reviewed by medical staff (or medical support provided) 24 hours per day, 7 days per week.
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Heart failure-related hospitalisation
Structured telephone support or telemonitoring compared with usual care Heart failure-related 
hospitalisation data were available from 11 studies,50,88,90–93,97,99,100,102,106 including one three-arm study (STS 
HM, n = 2; STS HH, n = 5; TM with medical support provided during office hours, n = 2; TM 24/7, n = 3). 
Table 17 summarises the HF-related hospitalisation data for the NMA of RM compared with usual care.
The NMA model fitted the data reasonably well, with a residual deviance (26.50) close to 23, the total 
number of data points included in the analysis. The between-study standard deviation was estimated to be 
0.31 (95% CrI 0.03 to 1.05). This indicated that there was small to extreme heterogeneity between studies 
in the treatment effect. All interventions showed a beneficial trend in reducing all-cause hospitalisation 
compared with usual care, although these effects were not conclusive. In addition, the heterogeneity 
in the effect of interventions between studies means that the effect in a randomly chosen study varies 
substantially depending on the characteristics of the study.
Cardiovascular implanted monitoring devices compared with non-monitoring cardiovascular implanted 
monitoring devices (usual care) Of the three studies103–105 that compared cardiovascular implanted 
monitoring devices with non-monitoring cardiovascular implanted monitoring devices (usual care), 
there was an indication of small to moderate heterogeneity between studies in the treatment effect. 
The between-study standard deviation was estimated to be 0.24 (95% CrI 0.01 to 0.64). Although 
cardiovascular implanted monitoring devices appeared to be associated with a reduction in HF-related 
hospitalisation, this result was inconclusive (Table 18).
Discussion
The NMA showed that, compared with usual care, STS HH, TM with medical support provided during 
office hours and TM 24/7 were associated with a 23%, 24% and 51% reduction in all-cause mortality, 
respectively, among adults who have been recently discharged (< 28 days) from an acute care setting after 
a recent exacerbation of HF. However, the results for TM 24/7 should be treated with caution because 
of the poor methodological quality of the only included study in this network.76 No beneficial effect on 
mortality was observed with STS HM. TM with medical support during office hours and TM 24/7 were 
associated with a 25% and 19% reduction in all-cause hospitalisations, respectively, whereas there was 
TABLE 17 Heart failure-related hospitalisation in patients with stable HF: posterior distribution for the HRs relative to 
usual care (random effects)
Treatment
HR and CrI Predictive interval
Median 2.5% 97.5% 2.5% 97.5%
STS
HM 0.69 0.34 1.43 0.23 2.11
HH 0.67 0.37 1.05 0.22 1.75
TM
Office hoursa 0.70 0.34 1.50 0.19 2.30
24/7b 0.64 0.34 1.14 0.23 1.89
Usual care
Reference Reference Reference Reference Reference Reference
Between-study standard deviation (log-HR scale) 0.31 0.03 1.05 – –
a Transmitted data reviewed by medical staff (or medical support provided) during office hours.
b Transmitted data reviewed by medical staff (or medical support provided) 24 hours per day, 7 days per week.
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no major effect of STS HM or STS HH. STS HH was associated with a reduction of 23% in HF-related 
hospitalisations. There was no major effect of STS HM and TM with medical support during office hours 
on HF-related hospitalisations. In addition, despite the limited data, STS and TM generally improved QoL 
and were acceptable to patients.
Although the present findings broadly support the conclusions of the latest review and meta-analysis 
by Inglis et al.,48 there were some points on which the results differed. Despite differences between the 
two reviews in the classification of the RM strategies and in the statistical approaches to conducting the 
meta-analyses, STS HH was found to have a larger effect on mortality reduction than the pooled results 
of STS trials in the Inglis et al.48 review [HR 0.77, 95% CrI 0.55 to 1.08 vs risk ratio (RR) 0.88, 95% CI 
0.76 to 1.01]. Effects on all-cause hospitalisation (HR 0.97; 95% CrI 0.70 to 1.31 vs RR 0.92, 95% CI 
0.85 to 0.99) and HF-related hospitalisation (HR 0.77, 95% CrI 0.62 to 0.96 vs RR 0.77, 95% CI 0.68 to 
0.87) were similar between the two reviews. However, the findings from the analysis of STS HM were 
less favourable than those of Inglis et al.48 for all-cause mortality (HR 0.98, 95% CrI 0.41 to 2.33 vs RR 
0.88, 95% CI 0.76 to 1.01), all-cause hospitalisation (HR 1.06, 95% CrI 0.44 to 2.53 vs RR 0.92, 95% CI 
0.85 to 0.99) and HF-related hospitalisation (HR 1.03, 95% CrI 0.66 to 1.54 vs RR 0.77, 95% CI 0.68 to 
0.87). In addition, the present results were less favourable for TM during office hours (i.e. transmitted 
data reviewed by medical staff or medical support provided during office hours) for all-cause mortality 
(HR 0.76, 95% CrI 0.49 to 1.18 vs RR 0.66, 95% CI 0.54 to 0.81, respectively), but more favourable for 
all-cause hospitalisation (HR 0.75, 95% CrI 0.49 to 1.10 vs RR 0.91, 95% CI 0.84 to 0.99), and worse for 
HF-related hospitalisation (HR 0.95, 95% CrI 0.70 to 1.34 vs RR 0.79, 95% CI 0.67 to 0.94). Notably, when 
a sensitivity analysis excluding the results from the Home-HF study67 was conducted, the findings for TM 
effectiveness were similar to those observed in the Inglis et al.48 review.
When interpreting these diverging results, a number of differences in the methodology and data sets 
used in the respective reviews should be borne in mind. Most importantly, the present NMA distinguished 
between two types of STS (HH and HM) and two types of TM (transmitted data reviewed by medical 
staff or support provided during office hours, or transmitted data reviewed by medical staff or support 
provided 24/7). As the analysis showed, effectiveness varied substantially according to the type of system 
used, with, in particular, greater favourability towards STS HH than STS HM. Furthermore, the present 
analysis included the Home-HF study,67 which was excluded from the Inglis et al. review48 because of the 
use of an initial nurse visit (for equipment installation and use) as part of the care package. Inclusion of 
this trial in the analysis substantially reduced TM clinical effectiveness. However, given the low mortality 
rate in the control group of the Home-HF trial,67 the results of this study may not be generalisable to the 
wider HF population. This review also had a more stringent definition of the population of interest than 
the Inglis review48 (i.e. patients who commenced RM ≤ 28 days post discharge). Given what is known 
about the risk of mortality following decompensation,15 it may be that the present review focused on 
a patient population for whom RM is particularly efficacious. If this assumption holds, it might appear 
surprising that the NMA did not find substantially greater benefits of RM than those observed in the Inglis 
TABLE 18 HF-related hospitalisation in patients with stable HF: posterior distribution for the HRs relative to 
cardiovascular implanted non-monitoring devices (random effects)
Treatment
HR and CrI Predictive interval
Median 2.5% 97.5% 2.5% 97.5%
Cardiovascular implanted monitoring devices 0.72 0.32 1.37 0.14 3.01
Usual carea
Reference Reference Reference Reference Reference Reference
Between-study standard deviation (log-HR scale) 0.24 0.01 0.64 – –
a Usual care defined as cardiovascular implanted non-monitoring devices.
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et al. review.48 However, it should be noted that the standard and quality of usual care for HF continues to 
evolve (generally this was poorly reported in all included studies); thus, the impact of the age of the study 
on the treatment effects may have been an important confounding factor in the observed results.
In addition to the studies from the Inglis et al. review,48 six new studies52,60,67–70 of RM were included 
in the present review. These trials were of variable methodological quality with only three studies52,67,68 
performing well and receiving a positive assessment of at least six out of nine methodological quality 
items. Perhaps most notable was the inclusion of the largest trial of STS to date (n = 1653),52 which has 
already generated considerable debate.107–109 The Tele-HF trial52 delivered STS using HM and found no 
benefit over usual care. Although this trial was well designed and reported (see Table 7), a low patient 
adherence rate was observed (55%) and the control group received good quality of care. In response 
to such criticisms of Tele-HF, Chaudhry et al.52 have pointed out that patients were given individual 
counselling to support engagement with RM and thus the 55% adherence rate probably represents the 
‘best case scenario’ for real-world clinical practice.109 These investigators further argued that the > 50% 
event rate (rehospitalisation or death) in the usual care group did not suggest an excellent standard of 
care. There may, however, be further questions raised by the Tele-HF trial. For example, it is possible that 
interpersonal interaction with a care provider is an important active component of STS. It seems plausible 
that regular telephone contact with a care provider provides psychosocial benefits that feed into self-care 
practices and QoL, particularly among socially isolated older people. Similarly, Anker et al.46 suggested that 
remote contact between patients and care providers could help detect depression, which is associated with 
poor outcomes in HF. Furthermore, the mortality rate of 11.4% in the usual care group of the Tele-HF study 
was low compared with usual clinical practice.14
The Home-HF study67 was a RCT that compared TM with usual care. The trial included 182 patients from 
the UK with a recent hospital admission for HF and in NYHA classes II–IV. There was a higher incidence 
of mortality among the TM group than among the usual care group (17 vs 5 using the intention-to-treat 
approach or 14 vs 4 after TM equipment installation). These results may appear surprising at first glance 
and could even be read as showing a detrimental effect of TM compared with usual care. However, the 
6-month mortality rate in the usual care group (5.5%) was substantially lower than would be expected in 
a HF cohort receiving care outside the context of a clinical trial (i.e. between 13% and 21%).14 The authors 
stated that the standard of usual care was of high quality in the Home-HF trial, consisting of an initial 
home visit from a specialist nurse and access to telephone support during working hours. In addition, 
most patients were receiving optimal medical treatment including ACE inhibitors (70%), beta-blockers 
(56%) and loop diuretics (93%). Whatever the reason for the lack of effectiveness in the Home-HF67 and 
Tele-HF52 trials, the results at least serve as caution that all RM interventions (i.e. packages of care) are not 
necessarily effective in all contexts.
One TM study from Germany,76 which was conducted in collaboration with a health insurance company, 
reported provision of round-the-clock support to address participants’ questions about medication and 
the TM system. The 24-hour call centre approach has been reccomended elsewhere on the grounds that 
HF is a dynamic illness and so patients may need quick medical response 24 hours a day.110 In comparison 
with office hours-only services, the 24-hour provision appeared to confer additional benefits for mortality 
but not for all-cause hospitalisation or HF-related hospitalisation. However, the results from the trial of 
24/7 monitoring should be treated with caution as the study had serious methodological shortcomings 
(see Table 7). In particular, the method used to assign groups (i.e. by date of birth) was not ideally random 
and the intervention group (n = 251) was significantly younger than the control group (n = 251) (73 years 
vs 78 years, p < 0.001). Even if the results from this study are interpreted as a reduction in short- and 
medium-term mortality arising from maximisation of medical therapy, it is unlikely that out-of-hours events 
were sufficiently frequent to result in alterations of therapy that would not have occurred in an office 
hours-only system. Moreover, in the UK, an existing round-the-clock response system is available through 
the 999 emergency response route; thus, RM interventions provided by the NHS have been during office 
hours only.
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Additional analyses were performed to assess whether or not the findings from the present review (primary 
analysis) differed markedly in patients with stable HF (i.e. defined as having no acute event or detrioration 
in the past 28 days and managed in an ambulatory or outpatient care setting). These analyses suggested 
that inclusion of stable patients reduced the effectiveness of STS (both HH and HM) for mortality but 
provided additional reductions in both all-cause hospitalisation and HF-specific hospitalisation. With 
respect to TM during office hours, inclusion of stable patients yielded a marginally greater hazard 
reduction for mortality, a substantially greater reduction for HF-related hospitalisation and a substantially 
worse outcome for all-cause hospitalisation. Inclusion of stable patients in the 24/7 TM interventions 
yielded a substantially lower hazard reduction for all-cause mortality, a marginally lower hazard reduction 
for all-cause hospitalisation and a greater hazard reduction for HF-related hospitalisation. It is not clear 
how these apparently contradictory results should be interpreted, particularly given that no formal 
assessment of study quality was conducted on the studies involving stable patients. Finally, inclusion of 
stable patients allowed an analysis of RM effectiveness in three studies of implanted cardiac devices.103–105 
The findings showed a trend towards a reduction in all-cause mortality (HR 0.90, 95% CrI 0.31 to 2.49) 
and HF-related hospitalisation (HR 0.72, 95% CrI 0.32 to 1.37).
There are a number of limitations to the findings of this meta-analysis. Perhaps most importantly, the 
interventions were heterogeneous in terms of the physiological parameters remotely transmitted and the 
type of RM system utilised (see Table 4), so it may be argued that this review is a meta-analysis of a family 
of similar interventions rather than a single standardised intervention. For the 10 included TM studies, 
the most commonly monitored parameters were weight (n = 10) followed by blood pressure (n = 8) and 
heart rate (n = 7). Of the two UK trials, the TEN-HMS (Trans-European Network – Home-Care Management 
System) study49 monitored weight, blood pressure, electrocardiogram and heart rate, whereas the 
Home-HF study67 monitored weight, blood pressure, heart rate, oxygen saturation and symptoms 
(breathlessness, orthopnoea, dizziness and ankle swelling). However, this meta-analysis was unable to 
establish whether or not monitoring different parameters provided different levels of clinical benefit. STS 
interventions were somewhat more homogeneous in terms of monitored parameters, with the majority 
including an educational component and questions about worsening symptoms. However, the frequency 
of monitoring varied widely in these studies, from three times in the first week82 to monthly.49 In addition, 
it is important to note that usual care for HF has improved over recent decades. Diagnosis may occur 
earlier because of initiatives to improve HF awareness among primary care physicians and because of the 
increased availability of diagnostic tests. Furthermore, HF self-management programmes led by specialist 
nurses, which have been shown to reduce mortality and morbidity, are now widely used in HF care.45 The 
estimated 6-month survival rate for HF in the UK rose from 74.5% in 1996–7 (95% CI 70.6% to 77.9%) 
to approximately 85.7% in 2004–5 (95% CI 81.8% to 88.8%).111 With these improvements, it is possible 
that present usual care delivery may confound the effects of RM. A final issue for trial comparability 
was the diagnostic criteria used to confirm HF. More than half of the included trials did not report how 
the presence of HF was assessed,49,52,60,68,70,72,73,78–82 and among the remaining trials a variety of criteria 
were used.
The difficulty in interpreting the findings from these trials is further compounded by the fact that few 
studies presented outcomes in such a way as to allow stratification by age and sex in meta-regression – a 
problem also noted in the previous Inglis et al. review.48 Hence, the analysis was unable to establish 
patient subgroups in which RM is particularly effective. Another limitation concerns the quality of 
reporting in the included studies, which varied widely (see Table 7). In particular, a substantial number 
of studies were underpowered to detect differences in the primary outcome measures,60,67,69,70,72,73,75–79,82 
although this is not a concern in terms of the meta-analysis. However, there was evidence of several 
further potential sources of bias among the included studies. In particular, either outcome assessors were 
unblinded or blinding status was unclear in 16 trials.49,60,67–73,76–79,81–83 Another issue for external validity 
was the commercial funding reported by 10 studies49,60,67,68,70,75,77,79,81,83 as receipt of such funding has 
also been shown to systematically bias trials in favour of the products made by the companies that fund 
the research.112
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Further, foreign language studies were excluded and no cohort studies met the inclusion criteria for this 
review. Although RCTs are generally viewed as representing the most robust form of evidence for treatment 
efficacy, they have been criticised for a narrow focus on highly selected populations and outcomes.113 
Cohort studies, on the other hand, are more open to potential sources of bias but may offer a more 
realistic representation of how outcomes play out in the complex real world of clinical practice.114 A 
previous meta-analysis by Klersy et al.58 included 12 cohort studies of RM. The pooled results showed that 
RM was associated with a significantly lower number of deaths (n = 6 studies, RR 0.53, 95% CI 0.29 to 
0.96, p < 0.001) and hospitalisations (n = 3 studies, RR 0.52, 95% CI 0.28 to 0.96, p < 0.001). However, 
the included studies had a number of internal/external validity issues. In particular, half of the studies 
used a pre/post-test design without a concurrent control (which could result in a Hawthorne effect 
being mistaken for a genuine clinical effect) and several included a programme of home visits in the RM 
intervention (further details are provided in Overview of existing systematic reviews and Appendix 4). 
The literature search for this meta-analysis identified one cohort study of implanted RM devices, which 
included stable HF patients115 and was therefore not eligible for inclusion in the meta-analysis. All of 
the cohort studies from the Klersy et al.58 review were also excluded because of the application of more 
stringent inclusion criteria. Clearly, well-designed cohort studies with concurrent control groups are 
lacking among the RM evidence base. Another limitation of the present meta-analysis was that, given the 
heterogeneity in the RM systems, the analysis was unable to establish the precise ‘active ingredients’ of 
RM. Given that RM is a complex intervention (i.e. made up of a variety of interconnected, socially situated 
factors), it is important to understand not only whether RM works, but also how, why and under what 
circumstances.116 One way to explore these issues would be to include qualitative research on patient 
experiences of RM in subsequent updates.
Finally, it should be noted that this review did not include data from the Department of Health’s WSD 
programme.117 The WSD programme is the largest randomised trial of RM to date, including 6191 patients 
from 238 GP practices across three areas: Newham, Kent and Cornwall. The trial included people with 
one of three chronic conditions (HF, diabetes and COPD) and the headline results57 suggest an even more 
dramatic reduction in mortality (45%) than the pooled results reported here. An effect size as large as 
this has the potential to substantially alter the point estimates of the NMA. However, until data from the 
WSD programme become publicly available in peer-reviewed publications, it is difficult to evaluate the 
true magnitude and direction of effect in recently discharged patients with HF (or people with stable HF). 
As one perceptive commentator has noted, the Department of Health report states that telehealth can 
deliver the stated 45% mortality reduction ‘if used correctly’118 – and at present it is unclear what correct 
usage entails.
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Chapter 4 Assessment of cost-effectiveness
This chapter details the methods and results of the health economic model, which has been developed to compare different strategies for adult patients who have been discharged from an acute care setting 
after a recent exacerbation of HF. It includes a brief review of existing economic evaluations and a detailed 
explanation of the methods and results of a de novo economic model. The first section presents the 
results of the systematic review of economic literature. The modelling approach adopted to estimate the 
cost-effectiveness of RM interventions is then presented followed by the results of the analysis. The chapter 
concludes with a discussion of the results.
Review of cost-effectiveness evidence
The objective of this review was to identify and evaluate studies exploring the cost-effectiveness of TM or 
STS programmes for patients with HF.
Identification of studies
Electronic databases
Studies were identified by searching the following electronic databases:
 z MEDLINE(R) In-Process & Other Non-Indexed Citations and MEDLINE(R) (Ovid) 1948–January 2012
 z EMBASE (Ovid) 1980–January 2012
 z Science Citation Index Expanded (Web of Science) 1899–January 2012
 z Conference Proceedings Citation Index – Science (Web of Science) 1990–January 2012
 z NHS Health Economic Evaluation Database (Wiley Online Library) 1995–January 2012
 z Health Technology Assessment database (Wiley Online Library) 1995–January 2012
 z Database of Abstracts of Reviews of Effects (Wiley Online Library) 1995–January 2012
 z PsycINFO (Ovid) 1806–January 2012
 z Cumulative Index to Nursing and Allied Health Literature (EBSCOhost) 1982–January 2012
 z Allied and Complementary Medicine Database (Ovid) 1985–January 2012
 z Health Economic Evaluations Database (OHE-IFPHA) 1967–January 2012.
Sensitive keyword strategies using free text and, where available, thesaurus terms using Boolean operators 
and database-specific syntax were developed to search the electronic databases. Synonyms relating to the 
condition (e.g. heart failure) were combined with sensitive economic evaluations (where applicable) or 
QoL search filters aimed at restricting results to economic and cost-related studies (used in the searches of 
MEDLINE, Cumulative Index to Nursing and Allied Health Literature and EMBASE). Essentially, the cost-
effectiveness search strategy is the same as the clinical effectiveness search strategy albeit with the addition 
of an economic filter. The MEDLINE search strategy is provided in Appendix 10.
Other resources
To identify additional published, unpublished and ongoing studies, the reference lists of all relevant studies 
(including existing systematic reviews) were hand searched. A citation search of relevant articles (using the 
Web of Science Science Citation Index Expanded) was also undertaken. All identified citations from the 
electronic searches and other resources were imported into and managed using Reference Manager 12.
Inclusion and exclusion criteria
Studies were selected for inclusion according to predetermined inclusion and exclusion criteria. Studies 
were included if they reported an economic evaluation of disease management strategies or RM strategies 
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for HF patients and estimated the benefits in terms of life-years gained (LYG) or quality-adjusted life-years 
(QALYs).
Studies that performed economic evaluations alongside trials were excluded if they did not extrapolate 
the outcomes beyond the trial duration, as these economic analyses are valid only for the trials under 
consideration. Studies that were considered to be methodologically unsound, that were not reported in 
sufficient detail to extract costs and outcome estimates (including abstracts) or that did not report an 
estimate of cost-effectiveness (e.g. costing studies) were also excluded. Papers not published in the English 
language were also excluded.
The inclusion of potentially relevant articles was undertaken using a two-step process. First, all titles were 
examined for inclusion by one reviewer. Any citations that clearly did not meet the inclusion criteria, that 
is, non-human, unrelated to TM and/or HF, were excluded. Second, all abstracts and full-text articles were 
examined independently by two reviewers. Any disagreements in the selection process were resolved 
through discussion.
Quality assessment strategy
The methodological quality of each included study was assessed using a combination of key components 
of the Drummond and Jefferson checklist for economic evaluations119,120 and the Eddy checklist for 
mathematical models used in technology assessments.121 The use of the checklist ensured a consistent 
approach to assessing the quality of each economic evaluation.
Results of the cost-effectiveness review
The electronic literature searches identified 1696 potentially relevant publications. Of these, two 
studies122,123 met the inclusion criteria. A flow chart describing the process of identifying relevant literature 
can be found in Figure 5. A full list of excluded studies is presented in Appendix 11. Further details of the 
included studies including an assessment of methodological quality are provided below.
Miller et al.122 developed a Markov model to assess the long-term effect of a STS programme compared 
with usual care for patients diagnosed with systolic HF. The model considered three levels of severity 
corresponding to (1) NYHA class I, (2) NYHA class II and (3) a combination of NYHA classes III and IV. The 
input data for the model were abstracted from an 18-month trial in 1069 HF patients in south Texas.87 
This study was not included in the NMA as the STS programme included HF disease management from 
registered nurses. The authors used SF-36 data collected from the trial to calculate the utilities for each 
severity class using the methods suggested by Brazier et al.124 The study was carried out from the health-
care system perspective and the analysis estimated the incremental cost-effectiveness ratio (ICER) of the 
disease management group against usual care. STS compared with usual care had an estimated ICER equal 
to $43,650 per QALY gained, and the univariate sensitivity analysis suggested that the incremental cost per 
QALY gained varied from $28,691 (with the use of different death rates for the control and intervention 
groups) to $129,738 (with an increased disease management programme cost of $246 per patient 
per month).
The study by Miller et al.122 performed satisfactorily on the majority of items in the critical appraisal 
checklists119–121 used to assess the overall methodological quality of the model. Costs were extracted from 
the trial data by estimating the resource usage of different patient groups classified by morbidity and 
health state. Most of the costs were presented in a detailed and systematic way; however, the authors 
provided only an average cost of the STS programme and did not provide the breakdown of the individual 
cost components. One-way sensitivity analysis was performed; however, the authors did not perform a 
probabilistic sensitivity analysis (PSA). Both costs and QALYs were discounted at a rate of 3% per year.
Klersy et al.123 assessed the cost-effectiveness of remote home TM for HF compared with usual care from 
a third payer perspective. A decision tree approach was used to compare the two strategies and the only 
outcome measured was admission for HF. To evaluate the clinical effectiveness of RM, a meta-analysis of 
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21 clinical trials assessing RM was carried out for this study. A budget impact analysis was presented and 
the different diagnosis-related group (DRG) reimbursement tariffs were considered with cost savings per 
patient ranging between €306.80 and €992.94.
Klersy et al.123 focused mainly on the effectiveness rather than the costs and used a time horizon of 1 year. 
The study was limited to the budget impact and the cost-effectiveness was evaluated in this study by 
comparing the differences in costs and QALYs between RM and usual care. The effectiveness of RM was 
based on a meta-analysis of diverse studies evaluating interventions ranging from TM with home visits to 
STS. The authors used utilities of 0.612 and 0.662 for the usual care and RM groups respectively, based on 
a RCT reported by Hebert et al.125 However, the study by Hebert et al.125 was undertaken in an ethnically 
diverse urban community in Harlem, New York, and so the results might not be applicable to the UK HF 
population. Regarding costs, only hospitalisation costs were included and other costs such as RM costs, 
outpatient visits and drug costs were not considered. The authors stated that the monitoring costs were 
not considered because of the heterogeneity in the costs of RM. The authors used the DRG reimbursement 
tariff for HF hospitalisations as a proxy for real-life costs of hospitalisations. The authors performed 
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scenario analyses using different DRG costs as part of the budget analysis to address the uncertainty in the 
hospitalisation costs, but neither deterministic sensitivity analysis nor PSA was performed.
Cost-effectiveness review summary
Although two cost-effectiveness analysis studies of RM were identified through the literature searches, 
there are a number of limitations associated with generalising the findings of these studies. The analysis 
reported by Miller et al.122 was based on a single trial of STS, whereas Klersy et al.123 included data from a 
meta-analysis of a wide range of studies of RM and the analysis did not differentiate between the different 
RM approaches. It is important to consider different RM approaches separately as they have different 
clinical effectiveness and costs associated with them.
There was heterogeneity in terms of the components of both usual care and RM interventions reported in 
the cost-effectiveness studies; this was also evident within the clinical effectiveness review (see Chapter 3, 
Results of the clinical effectiveness review). This made the identification of the parameters (e.g. costs) 
associated with the interventions difficult. Standard/specific RM approaches need to be described 
before estimating the cost-effectiveness of the interventions. Potential uncertainty in the description of 
interventions can be overcome by performing scenario analyses and sensitivity analyses.
The review also identified different approaches to the modelling of disease progression in HF 
patients. The analysis reported by Miller et al.122 used the NYHA classification system to model disease 
progression whereas Klersy et al.123 applied a Markov model with constant probabilities for mortality 
and hospitalisation. A systematic review by Goehler et al.126 identified another approach that uses the 
number of rehospitalisations to model the disease progression pathway in HF. Hospital readmission- and 
NYHA classification-based models have significant data requirements (such as transition probabilities 
between NYHA classes) and this information was not reported in all of the RM studies included in the 
meta-analysis in Chapter 3 (see Results of the clinical effectiveness review). For hospital readmission- or 
NYHA classification-based models, a few selected studies that report the transition probabilities will have 
to be chosen to provide data for the models. This is in conflict with the aim of performing a robust analysis 
that takes all relevant evidence into account. Because all of the studies included in the meta-analysis 
provided mortality and/or hospitalisation rates for each type of remote disease management for HF, a 
two-state Markov model consisting of an ‘alive’ state and a ‘death’ state with a constant probability of 
rehospitalisation and changing mortality rate over time was chosen as the preferred approach for the de 
novo economic model detailed in the following section.
Independent economic assessment methods
This section details the methods and assumptions of the de novo economic model constructed to 
evaluate the cost-effectiveness of several strategies for RM compared with usual care for patients recently 
discharged with HF.
Overview of modelling methodology and objectives
A Markov model using a UK NHS perspective was developed to explore the costs and health outcomes 
associated with RM interventions for patients recently discharged with HF. Scenarios for costs of usual care 
and the RM interventions were developed through discussions with an expert advisory group (including 
clinicians and RM experts) and a review of the published literature and other sources that report details 
of resource use and unit costs of equipment, infrastructure and staff time. Data from the Candesartan in 
Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) study127 were used to estimate 
baseline mortality rates for patients in usual care, and the baseline risks associated with hospitalisation 
were estimated from Klersy et al.123 The results from the NMA in Chapter 3 (see Results of the clinical 
effectiveness review) were used to model the HRs of event rates for patients with RM, separating HRs 
for mortality, HF-related hospitalisations and all-cause hospitalisations. Utilities were identified from 
evidence reported in the literature. Input parameters were assigned probability distributions to reflect 
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their imprecision and Monte Carlo simulations were performed to produce expected incremental costs 
and QALYs for each strategy. Results were presented in terms of expected discounted QALYs and costs for 
each strategy, discounted incremental costs per QALY over a lifetime and net benefits using a threshold of 
£20,000 to value QALYs.
The objectives of the cost-effectiveness analysis were to:
1. estimate the cost-effectiveness of strategies for monitoring recently discharged HF patients, in terms of 
the incremental cost-effectiveness of each strategy, and to estimate the subsequent rates of death and 
hospitalisation among the modelled study population
2. identify the strategy that is most likely to be cost-effective for monitoring recently discharged HF 
patients in the NHS, defined as the most cost-effective strategy at a willingness-to-pay (WTP) threshold 
of £20,000–30,000 per QALY gained
3. identify the expected cost of uncertainty in the monitoring of HF patients and whether or not future 
research would be valuable by estimating the expected value of perfect information (EVPI) using a 
target population of 54,779 (number of first admissions for HF estimated from the National Heart 
Failure Audit for April 2010–March 201114).
A brief description of the key aspects of the economic analysis is provided in the following sections.
Model structure
A Markov model was developed to estimate the costs and health outcomes associated with different 
strategies for a hypothetical cohort of patients discharged in the last 28 days with HF-related 
hospitalisations. The model took a lifetime horizon and the economic perspective of the model was the 
NHS in England and Wales. In the model, as shown in Figure 6, two different states were considered:
(a) alive at home
(b) dead.
The Markov model used a monthly cycle length with half-cycle correction and assigned each patient a 
monthly probability of death based on the time since discharge and the type of treatment. In each period 
the patients who were alive were under the risk of an average number of monthly rehospitalisations, that 
is, readmissions to a hospital for HF-related complications or other causes. Each patient then accrued 
lifetime QALYs and health-care costs according to their hospitalisation and treatment status.
Population
To address the research question laid out in the scope, the economic model utilised a hypothetical cohort 
of HF patients, discharged from hospital within 28 days. Patient age was not explicitly modelled because it 
was assumed that HF mortality was the dominant factor and other-cause mortality was implicitly included 
in the all-cause mortality. However, the mean age of HF patients as reported by the authors of the National 
Alive at
home
Dead
HF hospitalisations Other hospitalisations
FIGURE 6 Markov model of recently discharged HF patients.
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Heart Failure Audit for 201030 was 75.85 years, which is similar to the mean age of 77.3 years at first HF 
admission reported in the National Heart Failure Audit for April 2010–March 2011.14
Intervention
The systematic review presented in Chapter 3 identified considerable heterogeneity across studies 
with respect to how the RM activities were performed. As multiple alternative specifications of the RM 
approaches were reported in the studies included within the systematic review, the interventions were 
classified and specified as reported in Chapter 3. In the economic model, the following strategies were 
evaluated compared with current usual care in the NHS:
(a) STS HH
(b) STS HM
(c) TM during office hours (i.e. TM with transmitted data reviewed by medical staff or medical support 
provided during office hours).
A base-case cost scenario, low-cost scenario and high-cost scenario were developed for each of these 
strategies based on discussions with an expert advisory group, as described in Costs.
Comparator
The comparator was usual care for patients recently discharged after HF hospitalisation in the NHS. 
Detailed reporting of the resources involved in usual care was severely lacking in most of the clinical 
trials. The base case for usual care in the economic model was estimated from the TEN-HMS study49 as it 
included patients from the UK. Following discussions with the expert advisory group a high-cost scenario 
for usual care was also developed.
Time horizon
A lifetime time horizon of 30 years was used. Patients progress through the model until they either die 
or reach the end of the 30-year time horizon. The proportion of patients alive in the usual care arm after 
15 years predicted from the model is 5.67%; < 0.5% of the patients were alive after 30 years, suggesting 
that a 30-year time horizon was adequate.
Treatment duration
It was assumed that the interventions and usual care were provided for the first 6 months following 
discharge from hospital. At the end of 6 months all patients were assumed to receive usual care as per the 
NICE clinical guideline for the management of adults with HF,34 irrespective of whether or not they received 
the intervention or post-discharge usual care during the treatment period.
It was assumed that the treatment costs and effectiveness last only for the treatment duration of 
6 months, after which the cost of usual care (as recommended by the NICE guideline on HF34) was applied 
along with the baseline risks of hospitalisation and mortality.
Perspective
A UK NHS perspective was used throughout; hence, productivity lost through illness or costs incurred 
directly by patients were not included.
Discount rate
Both the costs and QALYs were discounted at a monthly discount rate of 0.28709%, which was estimated 
from the annual discount rate of 3.5%, recommended by NICE, using the formula 1 + (monthly discount 
rate/100) = [1 + (annual rate/100)]1/12.128
The key modelling methods together with the evidence sources and assumptions used to populate the 
model are discussed in detail in the following sections.
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Selecting the classification of remote monitoring strategies
The systematic review in Chapter 3 identified heterogeneity in the components of interventions within 
the broad class of RM. Aspects of heterogeneity included the equipment available in the patient’s home, 
the physiological measures monitored (e.g. weight, blood pressure and heart rate), the method of 
communicating the patient information to the RM team, the extent and timing of routine communication 
from the RM team to the patient, the use of automated computerised assessment of information to 
screen for prespecified alert levels, the method of assessment by the team and the staffing levels and types 
of staff.
As shown in Figure 7, the generalised structure of any remote disease management model includes 
monitoring, triage and a protocol for response/follow-up of the patient.
The strategies can differ in terms of monitoring type, frequency and mode. Monitoring type relates to 
the data transmitted; this can include vital signs, physiological symptom monitoring and questionnaires. 
Frequency relates to how often the data are transmitted and is usually instantaneous, daily or weekly. The 
mode of input varies according to the intervention; it can be via the telephone verbally or via a telephone 
keypad, television or electronic device. The transmission can be via cables/wires or wireless (telephone lines, 
modem, 3G, broadband).
Triage involves investigation of the patient’s alert/problem once it is discovered by the RM system. A 
problem could be discovered by software using prespecified algorithms or by manual examination of 
patient data by health professionals. Nurses or physicians will then determine whether it is a false alarm or 
whether the patient needs to be followed up based on the perceived severity of the problem.
If the problem is not labelled as a false alarm, a formal follow-up process is initiated by the health 
professional as shown in Figure 8. Depending on the diagnosis of the alarm, the follow-up process could 
vary from no further action to an emergency admission to the hospital. Based on the severity of diagnosis, 
other forms of follow-up include adjustment of medicine, adjustment of disease management protocol or 
an outpatient clinic visit.
Variation in the RM interventions in terms of differences in the arrangements for monitoring, triage and a 
protocol for response/follow-up of the patient was used to develop a subclassification. RM was classified 
into three distinct categories: (1) STS HH, (2) STS HM and (3) TM during office hours (Table 19 and 
Figure 9). Cost-effectiveness analysis was performed for each of these intervention strategies compared 
with usual care and with each other.
Although a fourth subclassification of 24/7 TM (i.e. transmitted data are reviewed by medical staff or 
medical support is provided 24 hours a day, 7 days a week) was examined separately as part of the NMA in 
Chapter 3, this strategy was not included in the economic analysis. There were two reasons for this. First, 
there were no UK-based 24/7 TM trials identified in the systematic review and the data for 24/7 TM would 
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FIGURE 7 Generalised patient pathway for RM.
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have been based on a single study.76 This study76 was subject to methodological weaknesses as described 
in Chapter 3 (see Results of the clinical effectiveness review). Second, the expert advisory group suggested 
that the 24/7 home monitoring is currently not a realistic option for the UK setting as an existing round-
the-clock response system is already available via the 999 emergency response route.
Baseline mortality and hospitalisation risks related to time since discharge
Patients with HF are at increased risk of both fatal and non-fatal major adverse cardiovascular events. 
The main outcomes of interest were all-cause mortality and hospitalisations. The model estimated the 
subsequent prognosis of each patient by using a monthly probability of death and monthly risks for 
hospitalisation (both HF-related and other causes) depending on the patient characteristics and the type 
of treatment. This section details the baseline risks of hospitalisation and death (i.e. for usual care without 
RM) estimated using data from the literature.
Alert
(possible problem) Technical triage
Request the
patient data
Further monitoring
(no action)
Further investigation
(outpatient visits, etc.)
Therapy
modifications
Hospitalisations
Contact GP
Cardiological
consultations
Missing data or
incorrect data
Clinical triage
FIGURE 8 Follow-up process of RM for HF patients.
TABLE 19 Different RM interventions
TM activity STS HH STS HM TM during office hours
Monitoring Undertaken via timetabled 
structured telephone calls from 
the service to the patient
Undertaken by the patient 
according to a predefined 
schedule related to their wake-
up time
Undertaken via transmission 
of electronic data from the 
equipment in the patient’s home 
to the monitoring centre
Triage Most of the time the triage is 
carried out in real time while 
gathering information from the 
patient
Undertaken daily (5–7 days 
a week) by the nurse at a 
predefined time
Undertaken daily (5–7 days 
a week) by the nurse at a 
predefined time
Protocol for 
response/
follow-up
According to the severity of the case, either the case is handled by the nurse or the physician is consulted
© Queen’s Printer and Controller of HMSO 2013. This work was produced by Pandor et al. under the terms of a commissioning contract issued by the Secretary of State for 
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals 
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be 
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science 
Park, Southampton SO16 7NS, UK.
DOI: 10.3310/hta17320 HealtH tecHnOlOgy assessment 2013 VOl. 17 nO. 32
47
Mortality risk
The influence of time from non-fatal hospitalisation on subsequent mortality rates for HF patients was 
estimated based on the data from the CHARM study,127 which included 7572 patients followed up for 
38 months. The monthly probability of death was also estimated from the CHARM study,127 which showed 
that the mortality risk was highest immediately after hospital discharge and then decreased over time. This 
section describes the process of estimation of the mortality risk for HF patients from the data reported in 
the CHARM study.127
The HRs of all-cause mortality of hospitalised HF patients compared with non-hospitalised HF patients 
in the CHARM127 study are reported and are replicated in Table 20. The mortality risk of non-hospitalised 
patients was estimated from the CHARM study,127 which reported 1233 deaths in 4884 non-hospitalised 
patients over 38 months. The instantaneous mortality hazard rate (r) for non-hospitalised patients was 
calculated as 0.00765 using the formula r = – [ln(1 – Pd)]/t assuming a constant instantaneous rate, where 
Pd (= 0.252, i.e. 1233/4884) was the probability of death for non-hospitalised patients over a period of 
time (t = 38 months).
The instantaneous mortality hazard rates for hospitalised HF patients in different time periods since 
discharge from HF-related hospitalisation, as shown in Table 21, were estimated by multiplying the HRs in 
Table 20 by the constant mortality hazard rate of non-hospitalised HF patients.
The monthly mortality probabilities were then estimated from the instantaneous hazard rates using 
the formula p = 1 – exp(– rate). The risk of death is greatest in the early period after discharge after a 
hospitalisation for HF and subsequently declines over time as seen in Table 22. The probability of death in 
the first month after discharge is an estimated threefold higher than the probability of mortality beyond 
2 years from discharge.
The survival curve showing the proportion of patients alive (under usual care) over time is shown in 
Figure 10. It can be seen that most of the deaths occur in the initial period after discharge, which is in 
line with the assumptions that the mortality risk is higher in the time immediately after discharge and the 
effect of the intervention lasts only for the first 6 months. The survival rate changes at 1 month, 3 months, 
6 months, 12 months and 24 months as expected from Table 22. Finally, the patients are assumed to have 
a constant mortality rate beyond the 24-month period, as seen in the smooth exponential curve.
FIGURE 9 Interventions for remote disease management for patients with HF.
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TABLE 20 Hazard ratios of mortality for HF patients discharged from hospital compared with non-hospitalised HF 
patients according to time since discharge (replicated from the CHARM127 study)
Time since discharge (months) HR 95% CI
0–1 6.18 4.81 to 7.93
> 1–3 4.39 3.50 to 5.50
> 3–6 3.54 2.86 to 4.39
> 6–12 3.11 2.59 to 3.75
> 12–24 2.46 2.06 to 2.94
> 24 1.93 1.48 to 2.52
TABLE 21 Instantaneous mortality hazard rates for HF patients discharged from hospital according to time 
since discharge
Time since discharge (months) Mortality hazard 95% CI
0–1 0.04732 0.03683 to 0.06072
> 1–3 0.03361 0.02680 to 0.04211
> 3–6 0.02711 0.02190 to 0.03361
> 6–12 0.02381 0.01983 to 0.02871
> 12–24 0.01884 0.01577 to 0.02251
> 24 0.01478 0.01133 to 0.01930
TABLE 22 Monthly mortality probability according to time since discharge for HF patients in usual care
Time since discharge (months) Mortality probability per month 95% CI
0–1 0.04622 0.03616 to 0.05891
> 1–3 0.03306 0.02644 to 0.04124
> 3–6 0.02674 0.02166 to 0.03306
> 6–12 0.02353 0.01964 to 0.02831
> 12–24 0.01866 0.01565 to 0.02226
> 24 0.01467 0.01127 to 0.01911
According to the survival curve, 4.7%, 10.8% and 17.7% of HF patients would have died by 1 month, 
3 months and 6 months respectively. Furthermore, 28% of the patients would have died by the end of 
1 year and 43% would have died at 2 years post discharge. This is in line with the findings from the HF 
audit as reported in Chapter 1 (see Aetiology, pathology and prognosis).
Risk of hospitalisation
The other main outcomes included in the model are HF-related and other-cause hospitalisations. The other-
cause hospitalisations are modelled as all-cause hospitalisations minus the HF-related hospitalisations. The 
mean number of annual hospitalisations were estimated from the meta-analysis reported by Klersy et al.123 
and are presented in Table 23. For HF hospitalisations, Klersy et al.123 reviewed 17 trials from different 
countries (2089 patients) and reported an annual incidence rate of 42.1 per 100 patients. For all-cause 
hospitalisations the authors reviewed 18 trials (2332 patients) and reported an annual incidence rate of 
105.1 per 100 patients. These rates of hospitalisation were divided by 12 to estimate the monthly risk of 
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hospitalisations in the economic model. Table 23 shows the parameters used in the model per patient in 
usual care.
Effect of the interventions
Hazard ratios for all-cause mortality, all-cause hospitalisations and HF-related hospitalisations were used 
as effectiveness parameters in the model during the treatment period (i.e. the first 6 months following 
discharge from the hospital). It should be noted that the clinical systematic review identified considerable 
heterogeneity in the manner in which RM and usual care were performed. Clear descriptions of the 
interventions were not provided in many of the studies identified in the systematic review, which made 
it difficult to understand exactly what was provided as part of the intervention and what was provided 
as part of usual care. This lack of detail meant that the HR estimates from the meta-analyses were a 
conglomeration of estimates from heterogeneous comparisons. For example, study 1, which compared 
RM variant 1 with usual care variant 1, was pooled with study 2, which compared RM variant 2 with usual 
care variant 2, and so on. There was insufficient information regarding how usual care variant 1 differed 
from usual care variant 2 to make adjustments to effectiveness difference estimates. Furthermore, as 
some of the studies were undertaken across multiple centres, usual care variant 1 itself could be a pooled 
estimate of usual care variant 1a, usual care variant 1b and usual care variant 1c. Thus, this lack of detail 
in research studies concerning the design of the RM and especially the usual care arm has implications for 
the robustness of any analysis of effectiveness. The statistical analysis of the extent of heterogeneity was 
discussed fully in Chapter 3.
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FIGURE 10 Baseline survival curve of recently discharged HF patients.
TABLE 23 Monthly risk of hospitalisations per patient in usual care
Hospitalisation Source Estimate 95% CI
HF-related hospitalisations Klersy et al.123 0.0350 0.0325 to 0.0375
All-cause hospitalisations Klersy et al.123 0.0875 0.0841 to 0.0908
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The HRs estimated from the NMA, as reported in Chapter 3 (see Results of the clinical effectiveness 
review), for the different categories (i.e. STS HM, STS HM and TM during office hours) are presented in 
Tables 24a and b. All analyses were performed using an intention-to-treat analysis, that is, all patients 
were analysed in the groups to which they were allocated, regardless of whether or not they received 
the treatment.
A sensitivity analysis was performed excluding the Home-HF study67 as described in Chapter 3 (see Results 
of the clinical effectiveness review) and the HRs are presented in Tables 25a and b. For decision-makers 
deciding which of these scenarios is most representative of their setting, the key questions relate to 
the inclusion of the Home-HF study67 in the effectiveness meta-analyses. If one believes that usual care 
is best represented by the usual care arm in the Home-HF study,67 which is the only study showing a 
statistically significant difference in effectiveness of usual care over RM, then perhaps the results including 
the Home-HF study67 might be considered more relevant than those without. If, on the other hand, one 
believes that the performance of usual care is better represented by the other studies and that usual care 
in the Home-HF study67 is not representative of current usual care, then the results excluding the Home-HF 
study67 might be considered more relevant.
The monthly mortality probabilities for the interventions were estimated by applying the HRs to the 
baseline mortality probability using the formula Pintervention = 1 – (1 – Pbaseline)
HR, where Pintervention is the monthly 
mortality probability of the intervention and Pbaseline is the baseline monthly mortality probability. This is 
equivalent to multiplying the HR of the intervention with the baseline hazard rate to estimate the hazard 
rate of the intervention, and then converting the hazard rate into a monthly probability.
Health-related quality of life
This section provides a discussion of the evidence available for four aspects of QoL: baseline HRQoL for 
HF patients under usual care, the impact caused by hospital readmission for HF, the impact caused by 
hospital readmission for other causes and whether or not there is any evidence that patients who are not 
readmitted experience better HRQoL with RM than with usual care.
TABLE 24a Hazard ratios for interventions compared with usual care for mortality (all-cause) and hospitalisations (all-
cause and HF-related) using CrIs
Intervention
All-cause mortality HF-related hospitalisations All-cause hospitalisations
Median HR 95% CrI Median HR 95% CrI Median HR 95% CrI
STS HH 0.77 0.55 to 1.08 0.77 0.62 to 0.96 0.97 0.70 to 1.31
STS HM 0.98 0.41 to 2.33 1.03 0.66 to 1.54 1.06 0.44 to 2.53
TM during office 
hours
0.76 0.49 to 1.18 0.95 0.70 to 1.34 0.75 0.49 to 1.10
TABLE 24b Hazard ratios for interventions compared with usual care for mortality (all-cause) and hospitalisations (all-
cause and HF-related) using predictive distributions
Intervention
All-cause mortality HF-related hospitalisations All-cause hospitalisations
Median HR 95% PrI Median HR 95% PrI Median HR 95% PrI
STS HH 0.77 0.31 to 1.86 0.77 0.50 to 1.19 0.97 0.38 to 2.43
STS HM 0.98 0.30 to 3.23 1.03 0.58 to 1.77 1.06 0.31 to 3.61
TM during office 
hours
0.76 0.30 to 1.91 0.95 0.59 to 1.62 0.75 0.28 to 1.91
PrI, predictive interval.
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To estimate the HRQoL for recently discharged HF patients under usual care, a rapid review was conducted 
and four studies were found. Capomolla et al.73 reported HRQoL for recently discharged CHF patients as 
0.63 and Calvert et al.129 reported the utility to be 0.6 for advanced HF patients (NYHA class III or IV). Iqbal 
et al.130 reported the utility of HF patients as 0.57 but the population had multiple comorbidities. Miller 
and Cox131 estimated the utilities from SF-36 data collected during the trial using the methods suggested 
by Brazier et al.124 and reported them as 0.58 for advanced HF (NYHA class III or IV) and 0.67 for the 
weighted average for patients in NYHA class I or II.
Reviewing the evidence showed that there was uncertainty about the difference in patients’ QoL in 
different arms, that is, whether or not HRQoL is different for patients in the usual care and RM groups. 
In a previous economic model of RM, Klersy et al.123 used utilities of 0.612 and 0.662 for the usual care 
and RM groups respectively. However, the utilities used by Klersy et al.123 were based on a RCT by Herbert 
et al.,125 which was undertaken in an ethnically diverse urban community in Harlem, New York; hence, 
the results might not be applicable to the UK HF patient population. Furthermore, none of the studies 
identified in the systematic review in Chapter 3 reported any difference in the utility of patients in the usual 
care and RM groups. As there was no quantified evidence on the extent to which RM improves HRQoL of 
patients, the same utility values were used for HF patients receiving both usual care and (each of the three) 
RM strategies in the economic model.
Evidence on the disutility caused by rehospitalisation for HF was not clear. A disutility of 0.1 was 
incorporated for every HF-related hospitalisation based on a study by Yao et al.,132 who estimated the 
disutility to be equivalent to the utility of one health state lower in terms of NYHA class. The disutility was 
assumed to last for 1 year.
Evidence on the disutility caused by rehospitalisation for other causes (not directly HF related) was also 
limited. In the absence of evidence it was assumed that there was no disutility caused by rehospitalisation 
for other causes.
TABLE 25a Hazard ratios for interventions compared with usual care for mortality (all-cause) and hospitalisations (all-
cause and HF-related) excluding the Home-HF67 study
Intervention
All-cause mortality HF-related hospitalisations All-cause hospitalisations
Median HR 95% CrI Median HR 95% CrI Median HR 95% CrI
STS HH 0.75 0.59 to 0.96 0.76 0.61 to 0.94 0.96 0.72 to 1.27
STS HM 0.98 0.58 to 1.62 1.02 0.70 to 1.49 1.06 0.48 to 2.32
TM during office 
hours
0.62 0.42 to 0.89 0.86 0.61 to 1.21 0.67 0.42 to 0.97
TABLE 25b Hazard ratios for interventions compared with usual care for mortality (all-cause) and hospitalisations (all-
cause and HF-related) using predictive distribution and excluding the Home-HF67 study
Intervention
All-cause mortality HF-related hospitalisations All-cause hospitalisations
Median HR 95% PrI Median HR 95% PrI Median HR 95% PrI
STS HH 0.75 0.45 to 1.27 0.76 0.51 to 1.13 0.96 0.42 to 2.18
STS HM 0.98 0.49 to 1.95 1.02 0.61 to 1.69 1.06 0.35 to 3.22
TM during office 
hours
0.62 0.35 to 1.09 0.86 0.54 to 1.38 0.67 0.26 to 1.53
PrI, predictive interval.
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In the economic model, different values of utility were used for unstable patients (i.e. recently discharged 
patients) and stable patients (i.e. 1 year since hospitalisation). A utility score of 0.58 was used for 
patients in the first year since discharge and a utility of 0.67 was used after the first year. Any HF-related 
hospitalisation was assumed to result in a disutility of 0.1 for a whole year, that is, the utility of the patient 
for that year was 0.67 – 0.1 = 0.57. Within the PSA, the uncertainty in the utility values was represented 
using a normal distribution using the deterministic value as mean with a standard deviation of 0.015, 
estimated based on the difference between utilities reported by Capomolla et al.73 and Iqbal et al.,130 and 
the disutility was represented using a triangular distribution with (–0.08,0.11) as the range with –0.1 as 
the mode.
Costs
The costs in the model are described in detail in the following sections.
Clear descriptions of the interventions and usual care were not provided in many of the studies identified 
in the systematic review. This lack of detail concerning the design of the RM interventions and especially 
the usual care arms (e.g. communication protocols, routine staff visits, resources used) has implications 
for estimating the costs of interventions and usual care. As the resources used in each intervention variant 
were not always clear, three different cost scenarios for RM interventions (base case, lower and upper) and 
two different cost scenarios for usual care (base case and upper) were developed as described in Costs of 
remote monitoring care interventions and Usual care costs.
Costs of remote monitoring care interventions
The RM costs were highly variable because of the heterogeneity in devices, monitoring and follow-up 
processes. The costs of RM comprised three main components:
 z costs of the RM devices and equipment within the patient’s home, including the device hub, 
peripherals and communication costs
 z maintenance/monitoring costs in the RM centre
 z medical care costs to deal with events/alerts, for example GP and nurse visit costs or further hospital-
based outpatient visits (excludes rehospitalisation costs).
The costs of the RM devices were elicited from the expert advisory group. The maintenance/monitoring 
costs were estimated using activity-based costing for the resources spent by staff on triage and follow-up 
based on evidence from the literature. The costs of medical care were estimated from the TEN-HMS 
study,49 which reported the medical care received in the usual care, STS and TM arms.
The RM device, responsible for the collection and transmission of data (which can include vital signs, 
symptoms and questionnaires), can take different levels of complexity and the cost of the device is based 
on this complexity. Each monitoring device consists of a hub and can have a number of peripherals 
(medical devices with specific functionality that measure the vital signs and transmit them to the hub). 
These peripherals can be wired or wireless with the costs of wireless peripherals being higher than the 
costs of wired peripherals. The communication costs include the cost of data transfer along with server 
costs for the management of patient data.
In terms of monitoring, the characteristics of the system/infrastructure and the composition of the 
monitoring team also have an impact on the cost of the monitoring through triage costs. Triage costs 
also vary depending on whether the triage is performed by individuals (such as technicians, nurses or 
physicians) or a dedicated clerical triage team that monitors the patients. Triage costs also depend on the 
type of software used.
The medical care costs associated with the follow-up of patients consist of A&E visits, GP/cardiologist visits 
and nurse visits (both home and office visits). These were examined in two stages: the mean number of 
visits for each patient and the unit costs per visit.
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Medical care costs to deal with events/alerts: evidence and assumptions used
The evidence used to estimate the mean numbers of medical care visits is taken from the TEN-HMS study,49 
conducted across 16 hospitals in Germany, the Netherlands and the UK between August 2000 and March 
2002. A total of 426 patients were assigned randomly to home TM, nurse telephone support and usual 
care in a 2 : 2 : 1 ratio. This study reported the frequency of different health visits for each of the three arms 
over a 240-day period as shown in Table 26.
The unit costs of staff time were estimated based on data from the Personal Social Services Research 
Unit (PSSRU)133 and NHS Reference Costs 2009–10.134 The unit costs of staff time used in estimating the 
intervention costs are shown in Table 27.
TABLE 26 Frequency of medical care visits based on the TEN-HMS study49
Medical care visits Usual care STS TM
Number of patients 85 170 163
Total days at risk 16,089 33,803 33,641
Emergency room visits
Visits 8 54 60
Total/1000 days at risk (95% CI) 0.5 (0.2 to 0.8) 1.6 (1.2 to 2.0) 1.8 (1.3 to 2.2)
Office visits
Family practitioner 119 602 454
Specialist 34 117 100
Nurse and other 36 104 100
Total 189 823 654
Total/1000 days at risk (95% CI) 11.7 (10.1 to 13.4) 24.3 (22.7 to 26.0) 19.4 (18.0 to 20.9)
Home visits
Family practitioner 42 185 162
Specialist 0 3 1
Nurse and other 27 206 128
Total 69 394 291
Total/1000 days at risk (95% CI) 4.3 (3.3 to 5.9) 11.7 (10.5 to 12.8) 8.7 (7.7 to 9.6)
All face-to-face patient contacts
Total 300 1388 1115
Total/1000 days at risk (95% CI) 18.6 (16.6 to 20.7) 41.1 (38.9 to 43.2) 33.1 (31.2 to 35.1)
Telephone calls
Total 90 914 1180
Total/1000 days at risk (95% CI) 5.6 (4.4 to 6.8) 27.0 (25.3 to 28.8) 35.1 (33.1 to 37.0)
All patient contacts
Total contacts 390 2302 2295
Total/1000 days at risk (95% CI) 24.2 (21.9 to 26.6) 68.1 (65.4 to 70.8) 68.2 (65.5 to 70.9)
NIHR Journals Library www.journalslibrary.nihr.ac.uk
assessment Of cOst-effectIVeness
54
Scale of typical remote monitoring service
Three alternative scenarios for each RM classification (i.e. STS HM, STS HH and TM during office hours) 
were developed and their costs were estimated after discussions with the expert advisory group. The three 
alternative scenarios for each RM classification correspond to a base-case scenario, a low-cost scenario 
and a high-cost scenario. These scenarios were designed to reflect the different configurations of the RM 
systems present in the UK.
The costs of RM interventions were estimated for a RM centre that monitored 250 patients for a period 
of 6 months. This was based on the median size of NHS foundation trusts in the UK and the proportion 
of those people eligible for RM. According to the National Heart Failure Audit for 2010-11,14 the median 
number of HF patients discharged annually with HF as their primary diagnosis from the different hospital 
foundation trusts in England and Wales was 380. Hull Foundation Trust, which had 380 HF patients 
admitted in 2011, has 250 CHF patients under RM. Thus, taking into consideration that the number of HF 
patients admitted to the Hull and East Yorkshire Hospitals NHS Trust was equal to the median number of 
HF patients admitted to different foundation trusts in England and Wales, it was assumed that a typical 
RM centre would have an average capacity to monitor 250 patients. This number was also deemed 
sensible by the expert advisory group.
Cost of the structured telephone support human-to-machine interface intervention
The breakdown of the costs of the device, maintenance/monitoring costs and medical care costs for the 
base-case STS HM intervention is shown in Table 28.
The costs of the telephone and peripherals for STS HM were elicited from the expert advisory group and 
a baseline yearly cost of £78 was used. For the low-cost STS HM scenario a yearly cost of £32 was used 
for a basic telephone device, and for the high-cost STS HM scenario a yearly cost of £235 was used for a 
telephone device with more peripherals (see Table 31).
The costs of monitoring for STS HM were estimated from Boyne et al.,135 who conducted a RCT at three 
hospitals in the South-Limburg area of the Netherlands. The study included 382 patients with 197 in the 
RM group and 185 in the usual care group. Boyne et al.135 reported that an average time of 2 minutes 
and 20 seconds was dedicated by the triage nurse each day for monitoring an individual patient. This 
TABLE 27 Unit costs of staff time
Medical staff Unit of time
Cost 
(£) Source
GP One office visit 46 PSSRU 2011,133 section 10.8b, p. 149a
Specialist One office visit 46 PSSRU 2011133b
GP One home visit 104 PSSRU 2011,133 section 10.8b, p. 150c
Community nurse One home visit 38 Department of Health,134 District Nursing Services: 
Adult: Face To Face, Currency Code: CN301AF
Community nurse One office visit 25 PSSRU 2011,133 section 10.7, p. 147d
Hospital nurse 1 hour 40 PSSRU 2011,133 section 14.3, p. 193e
Clinical support worker (hospital) 1 hour 20 PSSRU 2011,133 section 14.5, p. 195
a Per clinic consultation lasting 17.2 minutes (complex consultation).
b Assumed to be equivalent to GP.
c Per home visit lasting 23.4 minutes (includes travel time), excluding staff costs.
d Surgery consultation by clinical nurse specialist.
e Per hour, nurse (day ward), including qualification.
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time spent daily was multiplied by 182.5 to estimate the staff time spent for each patient over 6 months; 
this gave a total of 7 hours. The costs associated with monitoring over 6 months were estimated by 
multiplying this nurse time by their hourly rate. It was assumed in the model that the triage is performed 
by a hospital nurse and a £40 per hour rate was used according to the PSSRU.133 Also, the cost of the 
patient management software (£5000) for the RM centre was converted into a cost per patient based on 
a 3-year depreciation period (i.e. assuming that new software will be required in 3 years) and sharing the 
overall cost of the software out amongst the number of patients who would benefit from the service over 
3 years (estimated as 1500 patients, i.e. 250 every 6 months, assuming a 6-month treatment duration and 
no delays for removal and installation of the monitoring device).
The costs of medical care (excluding hospital readmissions) were estimated based on the data from the 
TEN-HMS trial.49 The numbers of visits reported in the trial for patients in the nurse telephone support 
arm (n = 170) over a 240-day period (see Table 26) were used to estimate the average numbers of 
visits per patient over 6 months (see Table 28). These average numbers of visits were multiplied by the 
corresponding unit cost per contact, based on the staff involved, to estimate medical costs of £392 per 
patient over 6 months.
Thus, the total cost per patient for the STS HM intervention over 6 months was estimated to be £715, that 
is, a monthly cost of £119 per patient.
Cost of the structured telephone support human-to-human contact intervention
For STS HH intervention costs, it was assumed that only the monitoring costs were different between the 
STS HM and STS HH interventions. The costs of monitoring for STS HH were estimated from Riegel et 
al.,79 who reported the workload of the staff responsible for implementing a STS intervention to be equal 
to 16 hours per patient for 6 months. Using the same device and medical costs as for STS HM, the total 
base-case cost per patient receiving the STS HH intervention for 6 months was estimated to be £1075, that 
is, a monthly cost of £179 per patient (Table 29).
Cost of telemonitoring during office hours
The total costs of TM during office hours were broken down into the costs of the device, maintenance/
monitoring costs and medical care costs for the TM during office hours as shown in Table 30.
The cost of the TM device was elicited from the expert advisory group – a baseline yearly cost of £708 
was used. For the high-cost TM scenario a yearly cost of £1176 was used for a TM device with more 
peripherals, as detailed in Table 31.
The costs of monitoring were assumed to be the same as the STS HM monitoring costs estimated from 
Boyne et al.135 as the triage and follow-up process was similar for both interventions. The cost of the 
software was also assumed to be the same and was estimated using a 3-year depreciation period for 1500 
patients (i.e. for six cohorts of 250 patients each). For the low-cost TM scenario it was assumed that the 
time spent by the hospital nurse on triage and follow-up was 1 hour for each patient for 6 months.
The data from the TEN-HMS trial49 were used to estimate the medical costs. The numbers of visits reported 
in the trial for patients in the home TM arm (n = 163) over a 240-day period, reproduced in Table 26, were 
used to estimate the average numbers of visits per patient for 6 months as reported in Table 30. These 
average numbers of visits were multiplied by the corresponding unit cost per contact, based on the staff 
involved, to estimate medical costs of £336 per patient over 6 months.
The total cost per patient for the office hours TM intervention for 6 months was estimated to be £1051, 
that is, a monthly cost of £173 per patient (see Table 30).
NIHR Journals Library www.journalslibrary.nihr.ac.uk
assessment Of cOst-effectIVeness
56
Cost scenarios for the remote monitoring interventions
It was not possible to validate the robustness of the costs of the base-case scenarios as clear descriptions 
of the interventions were not provided in the trials of RM. Furthermore, large variation was observed in the 
costs of the devices from the pricing data accessed and there was uncertainty in the monitoring resources 
used within studies reporting different estimates. This heterogeneity made it difficult to provide a single 
description (and cost) of the interventions in each RM classification.
To this end, two further costing scenarios were developed for each RM classification, that is, STS HM, 
STS HH and TM during office hours, and their costs were estimated. These costing scenarios evaluate a 
high and low estimate of the costs for each RM classification to understand the impact of cost on the 
cost-effectiveness of the interventions. The differences in assumptions between the new scenarios and the 
base-case scenarios along with the new estimated costs (per patient for 6 months) are shown in Table 31.
TABLE 28 Breakdown of the base-case STS HM intervention costs per patient for 6 months
Resource 
usage Source
Unit cost 
(£) Source
Cost per 
6 months 
(£)
Breakdown of device costs
Cost of telephone + peripherals 
(scale and blood pressure cuff)
0.5 (for 
6 months)
Based on advice from 
clinical experts
78 (per 
year)
Expert advisory 
input
39
Total cost of the device per patient for 6 months 39
Breakdown of monitoring costs
Triage, decision-making by 
nurse
7 hours Boyne et al.135 40 (per 
hour)
PSSRU 2011133 280 
Data management software 1/1500a 5000 
(per site 
licence)
3
Total STS HM monitoring cost per patient for 6 months 283
Frequency 
per 
patient Source
Unit 
cost per 
contact 
(£) Source
Cost per 
6 months 
(£)
Breakdown of medical care costs
Emergency room visits 0.30 Cleland et al. (TEN-HMS)49 130 Department of 
Health134
39 
Office visits: family practitioner 3.37 Cleland et al. (TEN-HMS)49 46 PSSRU 2011133 155 
Office visits: specialist 0.66 Cleland et al. (TEN-HMS)49 46 PSSRU 2011133 30 
Office visits: nurse and other 0.58 Cleland et al. (TEN-HMS)49 25 PSSRU 2011133 15 
Home visits: family practitioner 1.04 Cleland et al. (TEN-HMS)49 104 PSSRU 2011133 108 
Home visits: specialist 0.02 Cleland et al. (TEN-HMS)49 104 PSSRU 2011133 2 
Home visits: nurse and other 1.15 Cleland et al. (TEN-HMS)49 38 Department of 
Health134
43
Total medical care costs per patient for 6 months 392
Total cost of STS HM intervention per patient for 6 months 715
a 1500 patients (assuming 250 patients monitored for 6 months over 3 years).
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Usual care costs
There is variation between different local settings in the usual care applied in current clinical practice, 
as described in Chapter 1 (see Current service provision). The current NICE guidelines34 provide 
recommendations for the management of adults with HF; however, a clear description of the current 
service is not available. The recommendations in the NICE guidelines state that: ‘The frequency of 
monitoring should depend on the clinical status and stability of the patient. The monitoring interval should 
be short (days to 2 weeks) if the clinical condition or medication has changed, but is required at least 
6-monthly for stable patients with proven heart failure’.
Furthermore, the studies identified in the systematic review presented in Chapter 3 did not report clearly or 
in detail what was involved in the usual post-discharge care, thus making it difficult to estimate the costs 
of usual care. The key resource costs for usual care for HF patients are the visits to the GP and the nurse 
visits immediately after discharge. As the usual post-discharge care was not reported clearly in the studies 
within the systematic review, it was assumed that the cost of the base-case usual post-discharge care was 
TABLE 29 Breakdown of the base-case STS HH intervention costs per patient for 6 months
Resource 
usage Source
Unit cost 
(£) Source
Cost per 
6 months 
(£)
Breakdown of device costs
Cost of telephone + peripherals 
(scale and blood pressure cuff)
0.5 (for 
6 months)
Based on advice from 
clinical experts
78 (per 
year)
Expert advisory 
input
39
Total cost of the device per patient for 6 months 39
Breakdown of monitoring costs
Triage, decision-making by 
nurse
16 hours Riegel et al.79 40 (per 
hour)
PSSRU 2011133 640 
Data management software 1/1500a 5000 
(per site 
licence)
Expert advisory 
input
3
Total STS HH monitoring cost per patient for 6 months 643
Frequency 
per 
patient Source
Unit 
cost per 
contact 
(£) Source
Cost per 
6 months 
(£)
Breakdown of medical care costs
Emergency room visits 0.30 Cleland et al. (TEN-HMS)49 130 Department of 
Health134
39 
Office visits: family practitioner 3.37 Cleland et al. (TEN-HMS)49 46 PSSRU 2011133 155 
Office visits: specialist 0.66 Cleland et al. (TEN-HMS)49 46 PSSRU 2011133 30 
Office visits: nurse and other 0.58 Cleland et al. (TEN-HMS)49 25 PSSRU 2011133 15 
Home visits: family practitioner 1.04 Cleland et al. (TEN-HMS)49 104 PSSRU 2011133 108 
Home visits: specialist 0.02 Cleland et al. (TEN-HMS)49 104 PSSRU 2011133 2 
Home visits: nurse and other 1.15 Cleland et al. (TEN-HMS)49 38 Department of 
Health134
43
Total medical care costs per patient for 6 months 392 
Total cost of STS HH intervention per patient for 6 months 1075
a 1500 patients (assuming 250 patients monitored for 6 months over 3 years).
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the same as that described in the TEN-HMS study.49 A high-cost usual post-discharge care scenario was 
also developed based on discussions with the expert advisory group.
Base-case usual post-discharge care cost scenario
Data from the TEN-HMS study49 were used to estimate the costs of usual post-discharge care in the 
base-case scenario, which consisted of nurse visits, GP/cardiologist visits and A&E visits. The numbers of 
visits reported in the trial for patients in the usual care arm (n = 85) over a 240-day period, reproduced in 
Table 26, were used to estimate the average numbers of visits per patient for 6 months (Table 32). These 
average numbers of visits were multiplied by the corresponding unit cost per contact, based on the staff 
involved, to estimate usual care costs of £161 per patient for 6 months.
TABLE 30 Breakdown of the base-case TM during office hours costs per patient for 6 months
Resource 
usage Source
Unit cost 
(£) Source
Cost per 
6 months 
(£)
Breakdown of device costs
Cost of hub + peripherals 0.5 (for 
6 months)
Based on advice from 
clinical experts
703 (per 
year)
Based on advice 
from clinical 
experts
352
Communication (patient to 
centre) 
0.5 (for 
6 months)
Based on advice from 
clinical experts
160 (per 
year)
Based on advice 
from clinical 
experts
80
Total cost of the device per patient for 6 months 433
Breakdown of monitoring costs
Triage, decision-making 7 hours Boyne et al.135 40 (per 
hour)
PSSRU 2011133 280 
Data management software 1/1500a 5000 3
Total monitoring cost per patient for 6 months 283
Frequency 
per 
patient Source
Unit 
cost per 
contact 
(£) Source
Cost per 
6 months 
(£)
Breakdown of medical care costs
Emergency room visits 0.35 Cleland et al. (TEN-HMS)49 130 Department of 
Health134
45 
Office visits: family practitioner 2.65 Cleland et al. (TEN-HMS)49 46 PSSRU 2011133 122 
Office visits: specialist 0.58 Cleland et al. (TEN-HMS)49 46 PSSRU 2011133 27 
Office visits: nurse and other 0.58 Cleland et al. (TEN-HMS)49 25 PSSRU 2011133 15 
Home visits: family practitioner 0.95 Cleland et al. (TEN-HMS)49 104 PSSRU 2011133 98 
Home visits: specialist 0.01 Cleland et al. (TEN-HMS)49 104 PSSRU 2011133 1 
Home visits: nurse and other 0.75 Cleland et al. (TEN-HMS)49 38 Department of 
Health134
28
Total medical care costs per patient for 6 months 336
Total costs 1051
a 1500 patients (assuming 250 patients monitored for 6 months over 3 years).
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High-cost usual post-discharge care cost scenario
As the usual care was not reported clearly in the studies in the systematic review, a high-cost usual post-
discharge care scenario was developed after discussions with the expert advisory group. It was assumed 
that on discharge one HF hospital nurse visits the patient at home on a weekly basis for 3–4 weeks, and 
subsequently the district nurse visits a further three to four times in the period between week 4 and week 
8 after discharge. It was assumed that patients also have monthly GP consultations. It was also assumed 
that monitoring costs include the medical costs of patients such as the costs of diagnostic and pathology 
laboratory tests once every 6 months. These numbers of visits were multiplied by the corresponding unit 
cost per contact, based on the data from PSSRU 2011133 reported in Table 27, to estimate a cost for each 
patient of £592 for 6 months (Table 33).
Usual care beyond the treatment duration of 6 months
It was assumed that at the end of the 6-month treatment period all patients receive usual care as 
recommended in the NICE clinical guidelines for the management of adults with HF,34 irrespective of 
whether they received the intervention or post-discharge usual care during the treatment period. Usual 
care for patients beyond the 6-month treatment period, based on the description in the NICE guidelines, is 
shown in Table 34.
Hospitalisation costs
The hospitalisation costs are one of the major cost drivers for HF; the estimated mean costs of 
the hospitalisations are presented in Table 35. The mean inpatient admission cost for HF-related 
hospitalisations was calculated from the weighted average of the costs for the Healthcare Resource Group 
(HRG) ‘Heart Failure or Shock’ (EB03H, EB03I) based on the data obtained from the NHS Reference Costs 
2009–10.134 For hospital admissions for any cause other than HF it was assumed that the cost was the 
same as the mean cost of hospital admission for the general population. This was estimated as a weighted 
average of elective inpatient admissions and non-elective inpatient admissions (including both short and 
long stay) based on data from the NHS Reference Costs 2009–10.134
TABLE 31 Costs of RM scenarios per patient for 6 months
Scenario Assumption Source Total cost (£)
STS HM scenarios
Base-case scenario – – 715
Low-cost scenario Telephone cost of £31.60 per year Clinical input 623 
High-cost scenario Telephone cost of £235 per year (with more 
peripherals)
Clinical input 794
STS HH scenarios
Base-case scenario – – 1075
Low-cost scenario Telephone cost of £31.60 per year Clinical input 1051
High-cost scenario Telephone cost of £235 per year (with more 
peripherals)
Clinical input 1152
TM during office hours scenarios
Base-case scenario – – 1051
Low-cost scenario 1 hour of triage and follow-up per patient Clinical input/Dar et al.67 801.20
High-cost scenario Device cost of £1176 per year (with more 
peripherals)
Clinical input 1287.50
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Drug costs
Drug costs were not clearly reported for many of the trials and there was little description of the difference 
in drug use or drug costs between usual care and RM amongst studies identified in the systematic review; 
thus, it was assumed in the model that the drug costs were the same in the usual care and RM groups.
TABLE 32 Usual post-discharge care costs based on data from the TEN-HMS trial49
Medical care
Frequency 
per patient Source
Unit cost per 
contact (£) Source
Cost per 
6 months (£)
Emergency room visits 0.09 Cleland et al. 
(TEN-HMS)49
130 Department of 
Health134
12
Office visits: family 
practitioner
1.33 Cleland et al. 
(TEN-HMS)49
46 PSSRU 2011133 61
Office visits: specialist 0.38 Cleland et al. 
(TEN-HMS)49
46 PSSRU 2011133 18
Office visits: nurse and 
other
0.40 Cleland et al. 
(TEN-HMS)49
25 PSSRU 2011133 10
Home visits: family 
practitioner
0.47 Cleland et al. 
(TEN-HMS)49
104 PSSRU 2011133 49
Home visits: specialist – Cleland et al. 
(TEN-HMS)49
104 PSSRU 2011133 –
Home visits: nurse and 
other
0.30 Cleland et al. 
(TEN-HMS)49
38 Department of 
Health134
11
Total medical care costs per patient for 6 months 161
TABLE 33 Usual care cost scenarios for 6 months
Scenario Assumption Source Total cost (£)
Base-case usual care cost – Cleland et al. (TEN-HMS)49 161
High-cost usual care cost Expert advisory group PSSRU 2011133 592
TABLE 34 Usual care for patients post treatment
Medical care
Frequency per 
patient Source
Unit cost per 
contact (£) Source
Cost per 
6 months (£)
Clinical assessment 1 aNICE clinical 
guidelines34
46 bPSSRU 2011133, 
section 10.8b, 
p. 149
46
Laboratory testsc 1 dNICE clinical 
guidelines34
3 eDepartment of 
Health134
3
Total medical care costs per patient for 6 months 49
a Recommendation 1.4.1.3.
b Complex consultation lasting 17.2 minutes.
c Serum urea, electrolytes, creatinine and estimated glomerular filtration rate.
d Recommendation 1.4.1.1.
e Equivalent to haematology (code: DAP823).
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Summary of modelling input parameters
The Markov model assigned each patient a monthly probability of death, and in each monthly period 
the patients who are alive were under monthly risks of HF-related hospitalisations or other-cause 
hospitalisations. The risks of death and hospitalisation for RM interventions were estimated by applying 
the HRs from the meta-analysis to the baseline risks of mortality and hospitalisation. The effect of the 
intervention was assumed to last for a period of 6 months and after this it was assumed that patients 
reverted back to usual care. Each patient alive accumulated costs and QALYs every period based on their 
hospitalisation and treatment status. The model used a 30-year time horizon and the economic perspective 
of the model was the NHS in England and Wales. A summary of the model parameters is provided in 
Table 36.
Methods to estimate cost-effectiveness
The cost-effectiveness of the different interventions was estimated using both the ICER and the net benefit 
approaches. Uncertainty was incorporated in the modelling by performing PSA. Descriptions of these 
terms and approaches are provided in the following sections.
Definitions of cost-effectiveness terms
The ICER measures the relative value of two strategies and is calculated as the mean incremental cost 
divided by the mean incremental benefits. A strategy is dominated when another strategy accrues more 
QALYs for less cost. Extended dominance occurs when a combination of two alternative strategies can 
produce the same QALYs as a chosen strategy but at a lower cost. Strategies that are neither dominated 
nor extendedly dominated constitute the cost-effectiveness frontier, and the ICER is reported for these 
strategies compared with the next least effective strategy.
The WTP threshold is the amount of money that the decision-maker is willing to pay to gain 1 additional 
QALY. The usual threshold for decision-making at NICE is considered to be around £20,000–30,000 
per QALY.
The net monetary benefit (NMB) is defined as the QALYs multiplied by a value for the QALYs (e.g. £20,000) 
minus the costs of obtaining them, that is, NMB = QALYs × lambda – cost, where lambda is the WTP 
threshold. The NMB approach is simpler to calculate and gives equivalent findings (but requires an explicit 
assumption regarding the value of lambda).
Uncertainty analysis
The results presented in the following section include the effects of accounting for uncertainty in the 
model parameters (the costs, utilities, risks and HRs for mortality, HF-related hospitalisations and all-cause 
hospitalisations), characterised as probability distributions. PSA is undertaken whereby the model is rerun 
(10,000 times), each time with a different value for the risks, HRs, costs and utilities, which is sampled 
from the probability distributions.
The cost-effectiveness plane shows the incremental costs (y-axis) and incremental QALYs (x-axis) compared 
with usual care. In this chart, if a model run for a strategy had exactly the same costs and QALYs as usual 
care then the ‘sample’ for that model run would appear at the origin. Samples plotted to the right of the 
TABLE 35 Heart failure-related and other-cause hospitalisation costs 
Hospitalisation Average cost (lower and upper quartile) (£)
HF-related hospitalisationsa 2514.49 (1857.10 to 2809.95)
Other-cause hospitalisationsb 1529.79 (1129.84 to 1709.55)
a ‘Heart Failure or Shock’ (EB03H, EB03I): non-elective inpatient (long stay) including excess bed-days.134
b Non-elective inpatient (long and short stay) including excess bed-days.134
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TABLE 36 Summary of model parameters 
Parameter
Central 
estimate Distribution Source
Monthly mortality probability
Months 0–1 0.04622a 0.005716b Solomon et al. (CHARM)127
Months > 1–3 0.03306a 0.003719b Solomon et al. (CHARM)127
Months > 3–6 0.02674a 0.002864b Solomon et al. (CHARM)127
Months > 6–12 0.02353a 0.002178b Solomon et al. (CHARM)127
Months > 12–24 0.01866a 0.001661b Solomon et al. (CHARM)127
Months > 24 0.01467a 0.001970b Solomon et al. (CHARM)127
Number of monthly hospitalisations
HF-related 0.0350a 0.001256b Klersy et al.123
All-cause 0.0875a 0.001700b Klersy et al.123
HR for mortality
STS HM 0.98c Samples NMA
STS HH 0.77c Samples NMA
TM 0.76c Samples NMA
HR for HF-related hospitalisations
STS HM 1.03c Samples NMA
STS HH 0.77c Samples NMA
TM 0.95c Samples NMA
HR for all-cause hospitalisations
STS HM 1.06c Samples NMA
STS HH 0.97c Samples NMA
TM 0.75c Samples NMA
HRQoL
Year 1 0.58a 0.015b Miller et al.131
> Year 1 0.67a 0.015b Miller et al.131
Disutility for HF-related hospitalisation –0.1a Triangular (–0.08, –0.1, 0.11) Yao et al.132
Cost (£) per 6 months
Usual care 161d 592e Cleland et al. (TEN-HMS),49 
clinical input
STS HM 715d 623–794f Clinical input
STS HH 1075d 1051–1152f Clinical input
TM 1051d 801–1288f Clinical input
Cost (per month) (£) after 6 months
Usual care after 6 months 8.23 – NICE clinical guidelines34
a Mean estimate.
b Standard deviation.
c Median value.
d Base-case cost.
e High-cost scenario.
f Low- and high-cost scenarios.
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y-axis have more QALYs than usual care and samples plotted above the x-axis have more costs. Samples 
plotted to the right of a straight line with slope lambda passing through the origin are cost-effective 
whereas those plotted to the left are not. The cost-effectiveness acceptability curve (CEAC) shows the 
proportion of model runs for which each strategy is cost-effective over a range of potential WTP thresholds 
(i.e. lambda).
Another measure of uncertainty is the overall EVPI. This calculation is carried out based on the theory 
that the decision-maker will choose the most cost-effective option but could acquire additional evidence 
to reduce the uncertainties in the decision, for example know exactly what the HRs for mortality and 
hospitalisations are for each treatment. In the EVPI calculation it can be estimated how often making the 
decision based on current evidence could be wrong, and also how many QALYs (and costs) would be lost 
by choosing the strategy that is expected to be most cost-effective given current evidence when in fact one 
of the other strategies is truly the most cost-effective. One can estimate a monetary value lost by making 
a ‘wrong’ decision to choose a strategy based on current evidence by valuing the QALYs using the WTP 
threshold for this possible loss, that is, the net benefit lost on each of the occasions when another strategy 
would be optimal. This can be multiplied by the number of patients per year and the expected lifetime of 
the decision to estimate the population EVPI. The interpretation of this number is that if one could fund 
research to eliminate the uncertainty in effectiveness for all of the HRs for each strategy (e.g. by a large or 
infinitely large four-arm clinical trial) then the value of eliminating the uncertainty through such research 
would be expected to be the population EVPI.
Results of the independent economic assessment
This section details the results of the cost-effectiveness analyses estimated for a single HF patient as mean 
values of 10,000 PSA runs, each PSA run with a different estimate for the risks, HRs, costs and utilities 
sampled from the probability distributions reported in Table 36.
Results are presented using different effectiveness parameters (i.e. HRs) estimated from the NMA 
summarised in Tables 24 and 25. The cost-effectiveness analysis was performed using the base-case costs 
shown in Table 31 for these four estimates of effectiveness, that is, HRs based on CrIs and predictive 
distributions from the NMA, both including and excluding data from the Home-HF study.67 Results are 
also presented for five cost scenarios: (1) higher usual care cost scenario, (2) lower cost scenario of TM 
during office hours, (3) higher cost scenario of TM during office hours, (4) lower STS cost scenario and 
(5) higher STS cost scenario. The cost-effectiveness for each of these scenarios was performed using the 
four estimates of effectiveness, that is, HRs based on CrIs and predictive distributions from the NMA, both 
including and excluding data from the Home-HF study.67
This approach was taken to address the uncertainty in the cost and effectiveness evidence. For decision-
makers deciding which of these sets of results is most representative of their setting, the key questions 
relate to the inclusion of the Home-HF study in the effectiveness meta-analyses. If one believes that usual 
care is best represented by the usual care arm in the Home-HF study,67 which is the only study showing 
a statistically significant difference in effectiveness between usual care over RM, then perhaps the results 
including the Home-HF study67 might be considered more relevant than those without. If, on the other 
hand, one believes that the performance of usual care is better represented by the other studies and that 
usual care in the Home-HF trial67 is not representative of current usual care, then the results excluding 
this trial might be considered more relevant. Similarly, the users of the results should decide which cost 
scenario best reflects their local practice.
In each case, the expected estimates of cost-effectiveness and the uncertainty around them are presented, 
along with the probability that each of the four strategies, STS HM, STS HH, TM during office hours and 
usual care, is the most cost-effective. The EVPI, a measure of how valuable it would be to eliminate all of 
the existing uncertainty, is also provided for each scenario.
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Results of the primary analyses
Results for base-case costs
The results of the NMA with HRs based on CrIs and including the Home-HF study67 suggest that both TM 
during office hours and STS HH are similar in terms of mean HRs for mortality (0.779 for TM during office 
hours vs 0.780 for STS HH). STS HH is the most effective in terms of HF-related hospitalisation reduction 
with TM during office hours being the second most effective (mean HR 0.778 for STS HH vs 0.966 for TM 
during office hours). However, STS HH is the second most effective in terms of all-cause hospitalisation 
reduction after TM during office hours (mean HR 0.977 for STS HH vs 0.761 for TM during office hours) 
(Table 37). All mean HRs for STS HM are > 1, suggesting that STS HM is not effective in reducing mortality 
or hospitalisations. It should be noted that the mean HRs are calculated as an average of the 10,000 PSA 
HR samples provided by the NMA for input into the model.
Structured telephone support with human-to-human contact is the most costly strategy over a 6-month 
period (average monthly cost over treatment duration of first 6 months = £179 for STS HH compared 
with £175 for TM during office hours). Thus, it is necessary to estimate the incremental cost-effectiveness 
compared with the other interventions to answer the question, ‘Is the additional effect estimated for STS 
HH using the NMA worth the additional costs of the strategy?’
The survival results suggest that the lower HR for mortality would result in an estimated survival gain for 
TM during office hours over usual care of 0.202 years (mean undiscounted life expectancy = 4.912 years 
for TM vs 4.710 for usual care). This 0.202 life-years (just over 10 weeks, i.e. 73 days) mean additional 
survival for TM during office hours is slightly higher than the additional 0.199 LYG with STS HH, which has 
a mean life expectancy of 4.909 years. Similar survival benefits for STS HH and TM during office hours can 
be attributed to their similar mean HRs for mortality as seen in Table 37.
However, the QALY results show a reverse pattern to those for survival, with STS HH showing a higher 
QALY gain over usual care of 0.1059 compared with an additional 0.1038 QALYs gained with TM during 
office hours (equivalent to an additional 37.7 and 38.6 quality-adjusted days average gain for STS HH and 
TM respectively). This is because of fewer QALYs lost to HF hospitalisation by STS HH (–0.1638) than TM 
(–0.1673), in line with the higher effectiveness of STS HH in terms of HF-related hospitalisation reduction 
(HR of 0.778 for STS HH vs 0.966 for TM).
The expected costs over a lifetime (30-year time horizon) differ for each strategy, with STS HH having 
the highest costs at £9604 followed by TM during office hours (£9470), STS HM (£9001) and usual 
care (£8478). The main contribution to the overall costs comes from the hospitalisation costs, with the 
intervention and usual care costs being significantly lower.
Compared with usual care, STS HH has an additional discounted cost of approximately £1126; the majority 
of this cost difference was due to the difference in the costs of treatment in the treatment period, that is, 
the first 6 months (it was assumed that all of the patients revert to standard usual care after 6 months). 
There were also slightly higher hospitalisation costs, which were dependent on the number of people 
alive and the risks of hospitalisation for each intervention, that is, the HRs for mortality and hospitalisation 
respectively. For example, STS HH has an additional HF-related hospitalisation cost of around £70 per 
person over and above that of usual care and an additional £207 for other-cause hospitalisations. This 
is because STS HH patients live longer than usual care patients and, despite the lower risk of HF-related 
hospitalisation per month (HR 0.778) and the slightly lower risk of all-cause hospitalisation (HR 0.977), this 
leads to higher hospitalisation costs.
The additional discounted cost of £1126 for STS HH is higher than that of TM during office hours, which 
has an additional expected lifetime cost over and above that of usual care of £992 per person. This is 
because the higher HF-related hospitalisation costs of TM during office hours are offset by lower costs of 
other hospitalisations.
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TABLE 37 Results of the economic analysis using base-case costs 
Usual care STS HM STS HH
TM during 
office hours
Central estimates of HRs used as input 
Mortality HR 1.000 1.074 0.780 0.779
HF-related hospitalisation HR 1.000 1.045 0.778 0.966
All-cause hospitalisation HR 1.000 1.173 0.977 0.761
Treatment costs assumed per month (£) 27 119 179 175
Survival results (undiscounted)
1 year (%) 72.14 71.45 75.34 75.38
5 years (%) 33.75 33.43 35.25 35.27
Life expectancy over 30 years (years) 4.710 4.666 4.909 4.912 
Difference in life expectancy vs usual care (years) – –0.04 0.199 0.202 
Cost results (£)
Discounted cost of usual care 491 343 362 362
Discounted cost of treatment 0 632 978 957
Discounted cost of HF-related hospitalisations 4187 4169 4257 4348
Discounted cost of other hospitalisations 3800 3858 4007 3803
Total costs 8478 9001 9604 9470
Difference in costs from usual care (£)
Discounted cost of usual care 0 –148 –129 –129
Discounted cost of treatment 0 632 978 957
Discounted cost of HF-related hospitalisations 0 –19 70 161
Discounted cost of other hospitalisations 0 57 207 3
Total difference in costs 0 523 1126 992
Overall cost rank (1 = lowest cost) 1 2 4 3
Discounted QALY results
QALYs with no hospitalisation decrement 2.5748 2.5509 2.6834 2.6848 
HF-related hospitalisation decrement –0.1611 –0.1604 –0.1638 –0.1673 
Total discounted QALYs 2.4137 2.3905 2.5196 2.5175 
Difference in QALYs from usual care
QALYs with no hospitalisation decrement 0.0000 –0.0239 0.1086 0.1100 
HF-related hospitalisation decrement 0.0000 0.0007 –0.0027 –0.0062 
Total difference in discounted QALYs 0.0000 –0.0232 0.1059 0.1038 
Total discounted QALYs rank (1 = highest) 3 4 1 2
Probabilistic ICER vs usual care (£/QALY) Dominated 10,629 9552
Probabilistic sequential ICER (£/QALY) Dominated 63,240a 9552
continued
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Usual care STS HM STS HH
TM during 
office hours
Uncertainty analyses using net benefit at £20,000 per QALY 
Probability that strategy is most cost-effective (%) 2 18 36 44
Expected total costs from PSA (£) 8478 9001 9604 9470
Expected total QALYs from PSA 2.4137 2.3905 2.5196 2.5175
Expected net benefit from PSA (£) 39,795 38,809 40,788 40,880
Difference from usual care costs (£) 0 523 1126 992
Difference from usual care QALYs 0.0000 –0.0232 0.1059 0.1038 
Difference from usual care net benefit (£) 0 –986.75 993 1084
Net benefit rank (1 = highest) 3 4 2 1
Overall EVPI per patient at WTP of 20,000 per 
QALY (£)
826
Population EVPI (£) 45,247,202
a Last strategy in the cost-effectiveness frontier.
To assess whether or not the additional costs are worthwhile, the incremental cost per QALY 
gained is estimated. Comparing STS HH with usual care, the incremental cost per QALY gained is 
£1126/0.1059 = £10,629, which is below the typical NICE threshold of £20,000–30,000 per QALY gained. 
The ICER for TM during office hours compared with usual care is £992/0.1038 = £9552, which is also 
below the threshold of £20,000–30,000 per QALY gained.
However, when there are multiple possible strategies, one needs to calculate ICERs between different 
pairs, comparing each strategy with the next most effective strategy. Strategies that are dominated 
(or extendedly dominated) are removed from the cost-effectiveness frontier and the ICER is reported 
for these strategies compared with the next least effective strategy. Here, STS HM is dominated as 
usual care resulted in better health outcomes (2.4137 QALYs) and lower costs (£8478) than STS HM 
(2.3905 QALYs and £9001). As TM during office hours is the next most effective strategy compared 
with usual care, the ICER of TM during office hours against usual care is estimated at £9522 per 
QALY. The ICER of STS HH compared with TM during office hours is estimated as (£9604 – £9470)/
(2.5196 – 2.5175) = £136/0.0021 = £63,240 per QALY, which suggests that STS HH cannot be considered 
more cost-effective than TM during office hours at the typical NICE threshold of £20,000–30,000 per QALY 
gained. In this situation, TM during office hours is estimated to be the most cost-effective option with an 
ICER of £9522 per QALY.
Another way to present these results is to calculate the NMB of each strategy. The NMB of TM 
during office hours is (2.5175 × £20,000) – £9470 = £40,880. This approach takes away the need to 
calculate the ICER and simplifies the interpretation for decision-makers as the strategy with the highest 
expected incremental NMB is the most cost-effective. Using a threshold value of £20,000 per QALY, 
the estimated incremental NMB of TM during office hours compared with usual care is estimated to be 
£40,880 – £39,795 = £1084. Mathematically, as this difference is positive (i.e. > 0), the ICER must be 
< £20,000 (the ICER of TM during office hours compared with usual care is £9522 per QALY).
In terms of NMB then, if one accepts a cost-effectiveness threshold of £20,000 per QALY, the results show 
that TM during office hours is estimated to be the most cost-effective, with STS HH second and STS HM 
the least cost-effective.
TABLE 37 Results of the economic analysis using base-case costs (continued)
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In the cost-effectiveness plane shown in Figure 11, the samples to the right of the dotted line through the 
origin would have an incremental cost per QALY compared with usual care of < £20,000 and so would be 
considered cost-effective compared with usual care. Figure 11 shows that the majority of the TM during 
office hours and STS HH samples fall to the right of the dotted line, suggesting that they have a high 
chance of being cost-effective compared with usual care. The figure shows that the uncertainty in QALYs 
is larger for STS HM than it is for the other two strategies, because of the greater uncertainty in the HRs 
reported. There is less uncertainty in costs than QALYs in this base-case scenario. This is because in this 
scenario we have assumed that the monthly costs of the interventions are fixed at £119, £179 and £175 
during the treatment period of 6 months for STS HM, STS HH and TM during office hours respectively. 
Thus, the uncertainty in costs shown in Figure 11 is actually a function of the uncertainty in the HRs for 
hospitalisations (more or fewer hospitalisations occurring, which are then multiplied by fixed unit costs) 
and mortality (more or less time alive, during which there is a risk of hospitalisation per month).
The model is rerun 10,000 times, each time with a different value for the HRs, costs and utilities sampled 
from the probability distribution, and in some of the sampled model runs TM during office hours could 
be more effective than STS HH because of the overlap in the probability distributions of their HRs. There 
is a chance that the HR for TM during office hours could be lower, that is, better, than that for STS HH. 
The CEAC in Figure 12 shows the proportion of model runs for which each strategy is cost-effective over a 
range of potential WTP thresholds. The percentage of model runs in which TM during office hours was the 
most cost-effective strategy (at a £20,000 per QALY threshold) was 44%, with the percentage of model 
runs in which STS HH, STS HM and usual care were the most cost-effective being 36%, 18% and 2% 
respectively.
A CEAC in which the best strategy is cost-effective less than half of the time (44%) indicates that there is 
substantial uncertainty as to which strategy is the optimal in terms of net benefit. This uncertainty can also 
be measured as the overall EVPI, which is the average of the net benefits lost by making the decision now 
to choose TM during office hours. The EVPI in this case is £826 per patient for whom the decision is made, 
and the population EVPI per annum was estimated at £45,247,202 by multiplying the EVPI per patient 
with the annual incidence of first HF-related hospital admissions in England and Wales (i.e. £826 × 54,779).
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FIGURE 11 Cost-effectiveness plane for the economic analysis using base-case costs with effectiveness data from the 
NMA including the Home-HF study.67
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Results for base-case costs using effectiveness data from predictive distributions
The same analyses were performed using HRs from predictive distributions of the NMA including the 
Home-HF study67 and the results are presented in Table 38. As explained in Chapter 3 (see Results of the 
clinical effectiveness review), the predictive distributions place more emphasis on heterogeneity between 
studies and provide wider estimates than CrIs. In this analysis, the most effective strategy in terms of the 
mortality HR is again TM during office hours (mean HR 0.843), with STS HH being the second best strategy 
(mean HR 0.849).
In terms of NMB, TM during office hours has the highest followed by STS HH, with mean incremental 
NMBs of £656 and £534, respectively, compared with usual care, suggesting that the ICERs for TM during 
office hours and STS HH compared with usual care are < £20,000 per QALY. In terms of incremental 
analysis, again TM during office hours is the most cost-effective option assuming a NICE cost-effectiveness 
threshold of £20,000 per QALY gained, with an ICER for TM during office hours compared with usual care 
of £11,873 per QALY gained, whereas STS HH has an ICER of £228,035 per QALY gained compared with 
TM during office hours.
The cost-effectiveness results estimated here were similar to the results with effectiveness data from the 
CrIs of the NMA including the Home-HF study.67 However, the ICER for TM during office hours compared 
with usual care using HRs from the predictive distributions is £11,873, which is slightly higher than 
the ICER of £9522 estimated using HRs from the CrIs. This is due to the higher estimates of HRs in the 
predictive distributions (mean mortality HR 0.843) than the HRs based on CrIs (mean mortality RR 0.779).
Furthermore, the results using HRs from the predictive distributions are also more uncertain, as seen 
in the wider distribution of the samples in the cost-effectiveness plane shown in Figure 13 than in the 
cost-effectiveness plane shown in Figure 11, estimated using HRs based on CrIs. This is because the HRs 
estimated from the predictive distributions of the NMA have more uncertainty than those estimated from 
HRs based on CrIs.
The proportion of model runs in which TM during office hours was the most cost-effective strategy 
(at a £20,000 per QALY threshold) was 40%, with the proportion of model runs in which STS HH, STS 
HM and usual care were the most cost-effective being 35%, 19% and 6% respectively (Figure 14). As 
described earlier, the results are slightly more uncertain when HRs from predictive distributions are used 
[the proportion of model runs in which TM during office hours was the most cost-effective strategy (at a 
£20,000 per QALY threshold) when HR estimates from CrIs were used was 44%]. This uncertainty is also 
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FIGURE 12 Cost-effectiveness acceptability curve for the economic analysis using base-case costs.
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TABLE 38 Results of the economic analysis using the base-case costs with effectiveness data from predictive 
distributions of the NMA including the Home-HF study67 
Usual care STS HM STS HH
TM during 
office hours
Central estimates of HRs used as input 
Mortality HR 1.000 1.180 0.849 0.843
HF-related hospitalisation HR 1.000 1.063 0.790 0.982
All-cause hospitalisation HR 1.000 1.302 1.074 0.835
Treatment costs assumed per month (£) 27 119 179 175
Survival results (undiscounted)
1 year (%) 72.14 70.61 74.58 74.66
5 years (%) 33.75 33.04 34.89 34.93
Life expectancy over 30 years (years) 4.710 4.614 4.862 4.867 
Difference in life expectancy vs usual care (years) – –0.10 0.151 0.157 
Cost results (£)
Discounted cost of usual care 491 339 358 359
Discounted cost of treatment 0 627 972 951
Discounted cost of HF-related hospitalisations 4187 4130 4221 4316
Discounted cost of other hospitalisations 3800 3869 4023 3811
Total costs 8478 8965 9574 9437
Difference in costs from usual care (£)
Discounted cost of usual care 0 –152 –132 –132
Discounted cost of treatment 0 627 972 951
Discounted cost of HF-related hospitalisations 0 –57 33 129
Discounted cost of other hospitalisations 0 69 223 11
Total difference in costs 0 487 1096 959
Overall cost rank (1 = lowest cost) 1 2 4 3
Discounted QALY results
QALYs with no hospitalisation decrement 2.5748 2.5223 2.6575 2.6605 
HF-related hospitalisation decrement –0.1611 –0.1589 –0.1624 –0.1661 
Total discounted QALYs 2.4137 2.3633 2.4950 2.4944 
Difference in QALYs from usual care
QALYs with no hospitalisation decrement 0.0000 –0.0525 0.0827 0.0857 
HF-related hospitalisation decrement 0.0000 0.0022 –0.0013 –0.0050 
Total difference in discounted QALYs 0.0000 –0.0504 0.0814 0.0808 
Total discounted QALYs rank (1 = highest) 3 4 1 2
Probabilistic ICER vs usual care (£/QALY) Dominated 13,473 11,873
Probabilistic sequential ICER (£/QALY) Dominated 228,035a 11,873
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Usual care STS HM STS HH
TM during 
office hours
Uncertainty analyses using net benefit at £20,000 per QALY 
Probability that strategy is most cost-effective (%) 6 19 35 40
Expected total costs from PSA (£) 8478 8965 9574 9437
Expected total QALYs from PSA 2.4137 2.3633 2.4950 2.4944
Expected net benefit from PSA (£) 39,795 38,301 40,327 40,452
Difference from usual care costs (£) 0 487 1096 959
Difference from usual care QALYs 0.0000 –0.0504 0.0814 0.0808 
Difference from usual care net benefit (£) 0 –1494.07 531 656
Net benefit rank (1 = highest) 3 4 2 1
Overall EVPI per patient at ICER of £20,000 per 
QALY (£)
1831
Population EVPI (£) 100,299,791
a Last strategy in the cost-effectiveness frontier.
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FIGURE 13 Cost-effectiveness plane for the economic analysis using base-case costs with effectiveness data from 
predictive distributions.
TABLE 38 Results of the economic analysis using the base-case costs with effectiveness data from predictive 
distributions of the NMA including the Home-HF study67 (continued)
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reflected in the higher EVPI of £1831 per patient when HR estimates from predictive distributions were 
used compared with £826 when HR estimates from CrIs were used (as reported in Results for base-case 
costs). The population EVPI per annum was £100M compared with £45M when HR estimates from CrIs 
were used.
Results for base-case costs using effectiveness data excluding the Home-HF study67
The results of the NMA excluding the Home-HF study67 suggest that TM during office hours is substantially 
more effective in terms of mortality risk reduction (HR 0.627) than the second most effective strategy STS 
HH (HR 0.757), with STS HM slightly worse than usual care (HR 1.007). Cost-effectiveness analysis was 
performed with these HR estimates and the results are presented in Table 39.
Telemonitoring during office hours was estimated to be the most cost-effective option with an ICER 
of £6616 per QALY gained, with STS HM and STS HH being dominated and extendedly dominated 
respectively. In terms of the incremental NMB compared with usual care, again TM during office hours 
was the best strategy with an incremental NMB of £2371; STS HH was the second best strategy with an 
incremental NMB of £1181. These estimates for TM during office hours show improved cost-effectiveness 
(i.e. lower ICER and higher incremental NMB) than the estimates when the Home-HF study67 was 
included in the NMA (ICER of £9522 per QALY and NMB of £1084). This is because the heterogeneity in 
intervention effects between studies was considerably reduced when the Home-HF study67 was excluded, 
resulting in better effectiveness in terms of mortality risk reduction than when the Home-HF study67 was 
included (HR 0.627 vs HR 0.779).
This can also be observed in the cost-effectiveness plane, with the samples based on estimates of 
effectiveness when the Home-HF study67 was excluded from the NMA shifting to the right in the cost-
effectiveness plane, as shown in Figure 15, compared with the samples in the cost-effectiveness plane 
shown in Figure 11, which is based on the estimates of effectiveness when the Home-HF study67 was 
included in the NMA.
The proportion of model runs in which TM during office hours was the most cost-effective strategy 
(at a £20,000 per QALY threshold) was 83%, with STS HH at 12%, STS HM at 5% and usual care at 
0% (Figure 16). This proportion of model runs (83%) in which TM was the most cost-effective strategy 
at £20,000 per QALY is much higher than the proportion of model runs in which TM was the most 
cost-effective strategy (44%) when the Home-HF study67 was included in the NMA. This reduction in 
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FIGURE 14 Cost-effectiveness acceptability curve for the economic analysis using base-case costs with effectiveness 
data from predictive distributions.
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TABLE 39 Results of the economic analysis using base-case costs with effectiveness data from the NMA excluding the 
Home-HF study67
Usual care STS HM STS HH
TM during 
office hours
Central estimates of HRs used as input 
Mortality HR 1.000 1.007 0.757 0.627
HF-related hospitalisation HR 1.000 1.042 0.766 0.872
All-cause hospitalisation HR 1.000 1.134 0.969 0.678
Treatment costs assumed per month (£) 27 119 179 175
Survival results (undiscounted)
1 year (%) 72.14 72.14 75.67 77.63
5 years (%) 33.75 33.75 35.40 36.32
Life expectancy over 30 years (years) 4.710 4.7103 4.930 5.052 
Difference in life expectancy vs usual care (years) – 0.0003 0.220 0.342 
Cost results (£)
Discounted cost of usual care 491 346 363 373
Discounted cost of treatment 0 635 981 972
Discounted cost of HF-related hospitalisations 4187 4206 4269 4426
Discounted cost of other hospitalisations 3800 3873 4021 3879
Total costs 8478 9060 9635 9650
Difference in costs from usual care (£)
Discounted cost of usual care 0 –144 –127 –118
Discounted cost of treatment 0 635 981 972
Discounted cost of HF-related hospitalisations 0 18 82 239
Discounted cost of other hospitalisations 0 73 221 79
Total difference in costs 0 582 1157 1172
Overall cost rank (1 = lowest cost) 1 2 3 4
Discounted QALY results
QALYs with no hospitalisation decrement 2.5748 2.5747 2.6949 2.7612 
HF-related hospitalisation decrement –0.1611 –0.1619 –0.1643 –0.1703 
Total discounted QALYs 2.4137 2.4128 2.5306 2.5908 
Difference in QALYs from usual care
QALYs with no hospitalisation decrement 0.0000 –0.0002 0.1200 0.1864 
HF-related hospitalisation decrement 0.0000 –0.0007 –0.0032 –0.0092 
Total difference in discounted QALYs 0.0000 –0.0009 0.1169 0.1772 
Total discounted QALYs rank (1 = highest) 3 4 2 1
Probabilistic ICER vs usual care (£/QALY) Dominated 9897 6616
Probabilistic sequential ICER (£/QALY) Dominated Extendedly 
dominated
6616a
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Usual care STS HM STS HH
TM during 
office hours
Uncertainty analyses using net benefit at £20,000 per QALY 
Probability that strategy is most cost-effective 
(%)
0 5 12 83
Expected total costs from PSA (£) 8478 9060 9635 9650
Expected total QALYs from PSA 2.4137 2.4128 2.5306 2.5908
Expected net benefit from PSA 39,795 39,196 40,976 42,167
Difference from usual care costs (£) 0 582 1157 1172
Difference from usual care QALYs 0.0000 –0.0009 0.1169 0.1772 
Difference from usual care net benefit (£) 0 –599.54 1181 2371
Net benefit rank (1 = highest) 3 4 2 1
Overall EVPI per patient at ICER of £20,000 per 
QALY (£)
133
Population EVPI (£) 7,285,566
a Last strategy in the cost-effectiveness frontier.
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FIGURE 15 Cost-effectiveness plane for the economic analysis using base-case costs with effectiveness data excluding 
the Home-HF study.67
TABLE 39 Results of the economic analysis using base-case costs with effectiveness data from the NMA excluding the 
Home-HF study67 (continued)
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uncertainty is also reflected in the lower EVPI of £133 per patient when the Home-HF study67 was excluded 
from the NMA compared with £826 when the Home-HF study67 was included (as reported in Results for 
base-case costs).
Therefore, excluding the Home-HF study67 from the NMA suggests that TM during office hours is the most 
cost-effective strategy and that there is less uncertainty involved in suggesting that this is the most cost-
effective strategy than when the Home-HF study67 is included in the NMA. Users can decide which of these 
analyses is most representative of the UK setting, that is, whether or not the usual care in the Home-HF 
study67 is representative of usual care in the UK and whether or not this study should be included in the 
meta-analysis.
Results for base-case costs with effectiveness data from predictive distributions 
excluding the Home-HF study67
The results of the cost-effectiveness analysis using HRs from predictive distributions of the NMA excluding 
the data from the Home-HF study67 suggest that the most effective strategy in terms of mortality reduction 
is TM during office hours (mean mortality HR 0.642), with STS HH the second most effective strategy 
(mean mortality HR 0.776) and STS HM worse than usual care (mean mortality HR 1.032). The cost-
effectiveness analysis was performed with these HRs and the results are presented in Table 40.
In terms of incremental analysis, STS HM and STS HH are dominated and extendedly dominated 
respectively, with TM during office hours being the most cost-effective option with an ICER of £6942 per 
QALY. In terms of NMB, TM during office hours is again the most cost-effective strategy with a NMB of 
£2233; STS HH is the second most cost-effective strategy with a NMB of £1006.
The cost-effectiveness results estimated here were similar to the results using effectiveness data based 
on CrIs of the NMA excluding the Home-HF study.67 However, the central estimates are slightly higher 
with an ICER of £6942 for TM during office hours compared with usual care using HRs from predictive 
distributions compared with an ICER of £6616 using HRs based on CrIs. This is due to the higher estimates 
of the HRs in the predictive distributions (mean mortality HR 0.642) than the HRs based on CrIs (mean 
mortality RR 0.627).
Furthermore, the results using predictive distributions are also more uncertain, as seen in the wider 
distribution of the samples in the cost-effectiveness plane shown in Figure 17 compared with the 
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FIGURE 16 Cost-effectiveness acceptability curve for the economic analysis using base-case costs with effectiveness 
data excluding the Home-HF study.67
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TABLE 40 Results of the economic analysis using base-case costs with effectiveness data from predictive distributions 
of the NMA excluding the Home-HF study67 
Usual care STS HM STS HH
TM during 
office hours
Central estimates of HRs used as input 
Mortality HR 1.000 1.032 0.776 0.642
HF-related hospitalisation HR 1.000 1.058 0.778 0.883
All-cause hospitalisation HR 1.000 1.235 1.048 0.731
Treatment costs assumed per month (£) 27 119 179 175
Survival results (undiscounted)
1 year (%) 72.14 71.89 75.44 77.44
5 years (%) 33.75 33.63 35.30 36.23
Life expectancy over 30 years (years) 4.71 4.69 4.92 5.04 
Difference in life expectancy vs usual care (years) 0.00 –0.02 0.21 0.33 
Cost results (£)
Discounted cost of usual care 491 345 362 372
Discounted cost of treatment 0 634 979 971
Discounted cost of HF-related hospitalisations 4187 4200 4262 4422
Discounted cost of other hospitalisations 3800 3909 4055 3901
Total costs 8478 9087 9658 9665
Difference in costs from usual care (£)
Discounted cost of usual care 0 –145 –128 –119
Discounted cost of treatment 0 634 979 971
Discounted cost of HF-related hospitalisations 0 12 75 234
Discounted cost of other hospitalisations 0 108 255 101
Total difference in costs 0 609 1180 1187
Overall cost rank (1 = lowest cost) 1 2 3 4
Discounted QALY results
QALYs with no hospitalisation decrement 2.5748 2.5659 2.6870 2.7548 
HF-related hospitalisation decrement –0.1611 –0.1616 –0.1640 –0.1701 
Total discounted QALYs 2.4137 2.4043 2.5230 2.5847 
Difference in QALYs from usual care
QALYs with no hospitalisation decrement 0.0000 –0.0089 0.1122 0.1800 
HF-related hospitalisation decrement 0.0000 –0.0004 –0.0029 –0.0090 
Total difference in discounted QALYs 0.0000 –0.0093 0.1093 0.1710 
Total discounted QALYs rank (1 = highest) 3 4 2 1
Probabilistic ICER vs usual care (£/QALY) Dominated 10,798 6942
Probabilistic sequential ICER (£/QALY) Dominated Extendedly 
dominated
6942a 
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Usual care STS HM STS HH
TM during 
office hours
Uncertainty analyses using net benefit at £20,000 per QALY 
Probability that strategy is most cost-effective (%) 1 7 19 73
Expected total costs from PSA (£) 8478 9087 9658 9665
Expected total QALYs from PSA 2.4137 2.4043 2.5230 2.5847
Expected net benefit from PSA (£) 39,795 39,000 40,801 42,029
Difference from usual care costs (£) 0 609 1180 1187
Difference from usual care QALYs 0.0000 –0.0093 0.1093 0.1710 
Difference from usual care net benefit (£) 0 –795.73 1006 2233
Net benefit rank (1 = highest) 3 4 2 1
Overall EVPI per patient at ICER of £20,000 per 
QALY (£)
410
Population EVPI (£) 22,459,265
a Last strategy in the cost-effectiveness frontier.
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FIGURE 17 Cost-effectiveness plane using base-case costs with effectiveness data from predictive distributions 
excluding the Home-HF study.67
TABLE 40 Results of the economic analysis using base-case costs with effectiveness data from predictive distributions 
of the NMA excluding the Home-HF study67 (continued)
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cost-effectiveness plane shown in Figure 15, estimated using HRs from CrIs. This is because the HRs for 
the predictive distribution of a new study are more uncertain than the HRs for the population mean of 
the studies.
The percentage of model runs in which TM during office hours was the most cost-effective strategy (at 
a £20,000 per QALY threshold) was 73%, with the percentage of model runs in which STS HH, STS HM 
and usual care were the most cost-effective being 19%, 7% and 1% respectively (Figure 18). The lower 
percentage of model runs in which TM during office hours was the most cost-effective strategy when 
estimates from the predictive NMA were used compared with when estimates from CrIs were used (83%) 
reflects the higher uncertainty in the HRs estimated from the predictive NMA than in those estimated 
based on CrIs.
Summary of the results for base-case costs
Table 41 provides the summary of the cost-effectiveness results using the base-case costs. TM during 
office hours appears to be the most cost-effective strategy at a threshold of £20,000 per QALY in all four 
analyses, that is, HRs based on CrIs and predictive distributions of the NMA, including and excluding the 
Home-HF study.67 TM during office hours is also the most effective strategy (i.e. highest QALYs gained) in 
the analyses that excluded the Home-HF study.67 TM during office hours is not the most effective strategy 
in the analyses that included the Home-HF study,67 with STS HH providing the highest number of expected 
QALYs. However, the additional QALYs gained by STS HH are not worth the additional costs of the strategy 
as seen in the ICERs (compared with TM during office hours), which are greater than the threshold of 
£20,000 per QALY.
In the analyses that included the Home-HF study,67 the cost-effectiveness of TM during office hours has 
high uncertainty as there is a 44% and 40% chance of TM during office hours being cost-effective for 
analyses using HR estimates from CrIs and predictive distributions respectively. However, this uncertainty is 
lower in the analyses using HRs from the NMA that excluded the Home-HF study,67 with TM during office 
hours having an 83% and 73% chance of being cost-effective for analyses using estimates from CrIs and 
predictive distributions respectively.
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FIGURE 18 Cost-effectiveness acceptability curve for the economic analysis using base-case costs with effectiveness 
data from predictive distributions excluding the Home-HF study.67
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TABLE 41 Summary of the economic analysis results using base-case costs
Usual care STS HM STS HH TM during office hours 
Total costs (£)
CrI 8478 9001 9604 9470
PrI 8478 8965 9574 9437
CrI excluding Home-HF67 8478 9060 9635 9650
PrI excluding Home-HF67 8478 9087 9658 9665
Difference in costs (£)
CrI – 523 1126 992
PrI – 487 1096 959
CrI excluding Home-HF67 – 582 1157 1172
PrI excluding Home-HF67 – 609 1180 1187
Total QALYs
CrI 2.4137 2.3905 2.5196 2.5175 
PrI 2.4137 2.3633 2.4950 2.4944 
CrI excluding Home-HF67 2.4137 2.4128 2.5306 2.5908 
PrI excluding Home-HF67 2.4137 2.4043 2.5230 2.5847 
Difference in QALYs
CrI – –0.0232 0.1059 0.1038 
PrI – –0.0504 0.0814 0.0808 
CrI excluding Home-HF67 – –0.0009 0.1169 0.1772 
PrI excluding Home-HF67 – –0.0093 0.1093 0.1710 
ICER (£/QALY)
CrI – Dominated 63,240a 9552
PrI – Dominated 228,035a 11,873
CrI excluding Home-HF67 – Dominated Extendedly 
dominated
6616a
PrI excluding Home-HF67 – Dominated Extendedly 
dominated
6942a
Expected incremental NMB (£)
CrI – –986.75 993 1084
PrI – –1494.07 531 656
CrI excluding Home-HF67 – –599.54 1181 2371
PrI excluding Home-HF67 – –795.73 1006 2233
Probability of cost-effectiveness (%)
CrI 2 18 36 44
PrI 6 19 35 40
CrI excluding Home-HF67 0 5 12 83
PrI excluding Home-HF67 1 7 19 73
Prl, predictive interval.
a Last strategy in the cost-effectiveness frontier.
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Scenario analyses
Results for the high usual care cost scenario
A high cost usual care scenario in which the cost of usual care was £98.70 per patient per month during 
the treatment period (compared with the base-case usual care cost of £27), as described in Usual care 
costs, was incorporated to address the heterogeneity and uncertainty in the usual care cost data. All of the 
other parameters in this analysis were the same and the results summarised in Table 42 are also presented 
in detail in Appendix 12.
In general, the higher usual care cost makes only a small difference to the results. For the high usual care 
cost scenario analysis, all of the intervention strategies showed an increase in cost-effectiveness. The ICER 
for TM during office hours compared with usual care decreased from £9522 per QALY in the base-case 
TABLE 42 Summary of the economic analysis results using the high usual care cost
Usual care STS HM STS HH TM during office hours
Total costs (£)
CrI 8861 9001 9604 9470
PrI 8861 8965 9574 9437
CrI excluding Home-HF67 8861 9060 9635 9650
PrI excluding Home-HF67 8861 9087 9658 9665
Difference in costs (£)
CrI – 140 743 609
PrI – 104 713 576
CrI excluding Home-HF67 – 199 774 789
PrI excluding Home-HF67 – 226 797 804
Total QALYs
CrI 2.4137 2.3905 2.5196 2.5175 
PrI 2.4137 2.3633 2.4950 2.4944 
CrI excluding Home-HF67 2.4137 2.4128 2.5306 2.5908 
PrI excluding Home-HF67 2.4137 2.4043 2.5230 2.5847 
Difference in QALYs
CrI – –0.0232 0.1059 0.1038 
PrI – –0.0504 0.0814 0.0808 
CrI excluding Home-HF67 – –0.0009 0.1169 0.1772 
PrI excluding Home-HF67 – –0.0093 0.1093 0.1710 
ICER (£/QALY)
CrI – Dominated 63,240a 5864
PrI – Dominated 228,035a 7133
CrI excluding Home-HF67 – Dominated Extendedly 
dominated
4455a
PrI excluding Home-HF67 – Dominated Extendedly 
dominated
4703a
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Usual care STS HM STS HH TM during office hours
Expected incremental NMB (£)
CrI – –603.90 1375 1467
PrI – –1111.22 914 1039
CrI excluding Home-HF67 – –216.70 1564 2754
PrI excluding Home-HF67 – –412.88 1389 2616
Probability of cost-effectiveness (%)
CrI 1 18 36 44
PrI 4 19 35 41
CrI excluding Home-HF67 0 5 12 83
PrI excluding Home-HF67 1 7 19 73
Prl, predictive interval.
a Last strategy in the cost-effectiveness frontier.
cost scenario to £5864 per QALY in the high usual care cost scenario estimated using HRs from CrIs of 
the NMA. Similarly, the probability of TM being cost-effective increased from 44% in the base-case cost 
scenario to 45% in the high usual care cost scenario, and the probability of usual care being cost-effective 
decreased from 2% to 1%. Similar patterns were observed in the other analyses (using HRs based on CrIs 
excluding the Home-HF study67 as well as predictive distributions of the NMA including and excluding 
the Home-HF study67). This is because the difference in costs between the interventions and usual care 
decreases as the cost of usual care increases, resulting in better cost-effectiveness for the interventions.
Results of the lower cost of telemonitoring during office hours scenario
Similar scenario analysis using a lower cost for TM during office hours of £133.50 per patient per month 
was repeated using effectiveness evidence from all four NMAs (HRs based on CrIs as well as predictive 
distributions of NMA, including and excluding the Home-HF study67). The results of this analysis are 
presented in Appendix 13 and summarised in Table 43.
For the lower cost of TM during office hours scenario analysis, TM during office hours showed an increase 
in cost-effectiveness. The ICER of TM during office hours compared with usual care estimated using HRs 
from CrIs of the NMA decreased from £9522 per QALY in the base-case cost scenario to £7367 per QALY 
in the low-cost TM scenario. Similarly, the probability of TM during office hours being cost-effective 
increased from 44% in the base-case cost scenario to 50% in the low-cost TM scenario. Similar patterns 
were observed in the other analyses (using HRs based on CrIs excluding the Home-HF study67 as well as 
predictive distributions of the NMA including and excluding the Home-HF study67). Again, this is because 
delivering the same health outcomes at a lower cost increases the cost-effectiveness.
Results of the higher cost of telemonitoring during office hours scenario
Similar scenario analysis using a higher cost of TM during office hours of £215 per patient per month 
was repeated using effectiveness evidence from all four NMAs (HRs based on CrIs as well as predictive 
distributions of the NMA, including and excluding the Home-HF study67). Results of these analyses are 
presented in Appendix 14 and are summarised in Table 44.
The probability of TM during office hours being cost-effective decreased from 44% in the base-case cost 
scenario to 38% in the high-cost TM during office hours scenario estimated using HRs from CrIs of the 
NMA. Furthermore, TM during office hours is dominated by STS HH when the expected values of the 
TABLE 42 Summary of the economic analysis results using the high usual care cost (continued)
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TABLE 43 Summary of the economic analysis results using a lower cost for TM during office hours
Usual care STS HM STS HH TM during office hours 
Total costs (£)
CrI 8478 9001 9604 9243
PrI 8478 8965 9574 9211
CrI excluding Home-HF67 8478 9060 9635 9420
PrI excluding Home-HF67 8478 9087 9658 9435
Difference in costs (£)
CrI – 523 1126 765
PrI – 487 1096 733
CrI excluding Home-HF67 – 582 1157 942
PrI excluding Home-HF67 – 609 1180 957
Total QALYs
CrI 2.4137 2.3905 2.5196 2.5175 
PrI 2.4137 2.3633 2.4950 2.4944 
CrI excluding Home-HF67 2.4137 2.4128 2.5306 2.5908 
PrI excluding Home-HF67 2.4137 2.4043 2.5230 2.5847 
Difference in QALYs
CrI – –0.0232 0.1059 0.1038 
PrI – –0.0504 0.0814 0.0808 
CrI excluding Home-HF67 – –0.0009 0.1169 0.1772 
PrI excluding Home-HF67 – –0.0093 0.1093 0.1710 
ICER (£/QALY)
CrI – Dominated 170,629a 7367
PrI – Dominated 605,112a 9080
CrI excluding Home-HF67 – Dominated Extendedly dominated 5315a
PrI excluding Home-HF67 – Dominated Extendedly dominated 5595a
Expected incremental NMB (£)
CrI – –986.75 993 1311
PrI – –1494.07 531 882
CrI excluding Home-HF67 – –599.54 1181 2602
PrI excluding Home-HF67 – –795.73 1006 2463
Probability of cost-effectiveness (%)
CrI 2 17 31 50
PrI 6 18 33 44
CrI excluding Home-HF67 0 4 9 87
PrI excluding Home-HF67 1 6 16 77
Prl, predictive interval.
a Last strategy in the cost-effectiveness frontier.
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TABLE 44 Summary of the economic analysis results using a higher cost of TM during office hours
Usual care STS HM STS HH TM during office hours
Total costs (£)
CrI 8478 9001 9604 9686
PrI 8478 8965 9574 9652
CrI excluding Home-HF67 8478 9060 9635 9870
PrI excluding Home-HF67 8478 9087 9658 9884
Difference in costs (£) 
CrI – 523 1126 1207
PrI – 487 1096 1174
CrI excluding Home-HF67 – 582 1157 1392
PrI excluding Home-HF67 – 609 1180 1406
Total QALYs
CrI 2.4137 2.3905 2.5196 2.5175 
PrI 2.4137 2.3633 2.4950 2.4944 
CrI excluding Home-HF67 2.4137 2.4128 2.5306 2.5908 
PrI excluding Home-HF67 2.4137 2.4043 2.5230 2.5847 
Difference in QALYs
CrI – –0.0232 0.1059 0.1038 
PrI – –0.0504 0.0814 0.0808 
CrI excluding Home-HF67 – –0.0009 0.1169 0.1772 
PrI excluding Home-HF67 – –0.0093 0.1093 0.1710 
ICER (£/QALY)
CrI – Dominated £10,629a Dominated
PrI – Dominated £13,473a Dominated
CrI excluding Home-HF67 – Dominated Extendedly 
dominated
7854a
PrI excluding Home-HF67 – Dominated Extendedly 
dominated
8223a
Expected incremental NMB (£)
CrI – –986.75 993 869
PrI – –1494.07 531 442
CrI excluding Home-HF67 – –599.54 1181 2152
PrI excluding Home-HF67 – –795.73 1006 2014
Probability of cost-effectiveness (%)
CrI 3 19 40 38
PrI 7 20 37 37
CrI excluding Home-HF67 0 6 16 78
PrI excluding Home-HF67 1 8 23 68
Prl, predictive interval.
a Last strategy in the cost-effectiveness frontier.
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ICERs are estimated. The reason for this difference is the similarity in the estimates of the effectiveness 
parameters, which means that the ICERs are estimated based on very small differences in benefits (STS HH 
results in 0.0021 QALYs more than TM during office hours). Thus, a small change in the incremental costs 
of TM during office hours compared with STS HH (from –£134 to +£82) led to a marked change in the 
ICER of TM during office hours compared with STS HH.
In the analyses performed using HRs from the predictive distributions of the NMA that excluded the 
Home-HF study,67 TM during office hours is still the most cost-effective strategy with an ICER of £8223 per 
QALY compared with usual care (STS HH is extendedly dominated by a combination of usual care and TM 
during office hours). Threshold analysis suggested that the monthly cost of TM during office hours needs 
to be > £390 for it not to be cost-effective, that is, to have an ICER > £20,000 per QALY compared with 
STS HH. At this monthly cost of £390, TM during office hours has an ICER of £13,357 per QALY compared 
with usual care.
Results of the high-cost structured telephone support human-to-human contact 
scenario
Scenario analysis was also performed using a higher STS HH cost of £192 per patient per month during 
the treatment period. This scenario analysis was performed with effectiveness evidence from all four NMAs 
(HRs based on CrIs as well as predictive distributions of the NMA, including and excluding the Home-HF 
study67). The results of this analysis are presented in Appendix 15 and summarised in Table 45.
TABLE 45 Summary of the economic analysis results using a higher STS HH cost
Usual care STS HM STS HH TM during office hours
Total costs (£)
CrI 8478 9001 9675 9470
PrI 8478 8965 9645 9437
CrI excluding Home-HF67 8478 9060 9706 9650
PrI excluding Home-HF67 8478 9087 9729 9665
Difference in costs (£) 
CrI – 523 1197 992
PrI – 487 1167 959
CrI excluding Home-HF67 – 582 1228 1172
PrI excluding Home-HF67 – 609 1251 1187
Total QALYs
CrI 2.4137 2.3905 2.5196 2.5175 
PrI 2.4137 2.3633 2.4950 2.4944 
CrI excluding Home-HF67 2.4137 2.4128 2.5306 2.5908 
PrI excluding Home-HF67 2.4137 2.4043 2.5230 2.5847 
Difference in QALYs
CrI – –0.0232 0.1059 0.1038 
PrI – –0.0504 0.0814 0.0808 
CrI excluding Home-HF67 – –0.0009 0.1169 0.1772 
PrI excluding Home-HF67 – –0.0093 0.1093 0.1710 
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Usual care STS HM STS HH TM during office hours
ICER (£/QALY)
CrI – Dominated 97,300a 9552
PrI – Dominated 346,341a 11,873
CrI excluding Home-HF67 – Dominated Extendedly 
dominated
6616a
PrI excluding Home-HF67 – Dominated Extendedly 
dominated
6942a
Expected incremental NMB (£)
CrI – –986.75 922 1084
PrI – –1494.07 460 656
CrI excluding Home-HF67 – –599.54 1110 2371
PrI excluding Home-HF67 – –795.73 935 2233
Probability of cost-effectiveness (%)
CrI 2 19 34 46
PrI 6 19 34 41
CrI excluding Home-HF67 0 5 11 84
PrI excluding Home-HF67 1 7 18 74
Prl, predictive interval.
a Last strategy in the cost-effectiveness frontier.
For the high-cost STS scenario analyses, the probability of STS HH being cost-effective decreased whereas 
the probability of TM during office hours being cost-effective increased compared with the analysis 
with base-case costs. Similar patterns were also observed in the other analyses (using HRs based on CrIs 
excluding the Home-HF study67 as well as predictive distributions of the NMA including and excluding the 
Home-HF study67).
Results of the low-cost structured telephone support human-to-human 
contact scenario
Scenario analysis was also performed using a lower cost of STS HH of £175 per patient per month during 
the treatment period. This scenario analysis was performed using the effectiveness evidence from all four 
NMAs (HRs based on CrIs as well as predictive distributions of NMA, including and excluding the Home-HF 
study67). The results of this analysis are presented in Appendix 16 and summarised in Table 46.
Structured telephone support with human-to-human contact is still not cost-effective at a threshold of 
£20,000 per QALY, although the ICER of STS HH compared with TM during office hours estimated using 
the HRs from CrIs of the NMA decreased from £63,240 per QALY in the base-case scenario to £52,951 per 
QALY in the low-cost STS HH scenario. Assuming that the effectiveness parameters are constant, STS HH 
has to cost < £163 per month to be cost-effective at a threshold of £20,000 per QALY compared with TM 
during office hours. In the analyses excluding the Home-HF study,67 STS HH has to cost < £105 per month 
to not be extendedly dominated by a combination of usual care and TM during office hours.
Scenario analysis using 12 months’ treatment duration
Scenario analysis using 12 months’ treatment duration was performed using effectiveness evidence from 
all four NMAs (HRs based on CrIs as well as predictive distributions of the NMA, including and excluding 
TABLE 45 Summary of the economic analysis results using a higher STS HH cost (continued)
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TABLE 46 Summary of the economic analysis results using a lower STS HH cost
Usual care STS HM STS HH TM during office hours
Total costs (£)
CrI 8478 9001 9582 9470
PrI 8478 8965 9553 9437
CrI excluding Home-HF67 8478 9060 9613 9650
PrI excluding Home-HF67 8478 9087 9636 9665
Difference in costs (£)
CrI – 523 1104 992
PrI – 487 1075 959
CrI excluding Home-HF67 – 582 1135 1172
PrI excluding Home-HF67 – 609 1158 1187
Total QALYs
CrI 2.4137 2.3905 2.5196 2.5175 
PrI 2.4137 2.3633 2.4950 2.4944 
CrI excluding Home-HF67 2.4137 2.4128 2.5306 2.5908 
PrI excluding Home-HF67 2.4137 2.4043 2.5230 2.5847 
Difference in QALYs
CrI – –0.0232 0.1059 0.1038 
PrI – –0.0504 0.0814 0.0808 
CrI excluding Home-HF67 – –0.0009 0.1169 0.1772 
PrI excluding Home-HF67 – –0.0093 0.1093 0.1710 
ICER (£/QALY)
CrI – Dominated 52,951a 9552
PrI – Dominated 193,206a 11,873
CrI excluding Home-HF67 – Dominated Extendedly dominated 6616a
PrI excluding Home-HF67 – Dominated Extendedly dominated 6942a
Expected incremental NMB (£)
CrI – –986.75 1014 1084
PrI – –1494.07 553 656
CrI excluding Home-HF67 – –599.54 1203 2371
PrI excluding Home-HF67 – –795.73 1028 2233
Probability of cost-effectiveness (%)
CrI 2 18 36 43
PrI 6 19 35 40
CrI excluding Home-HF67 0 5 12 83
PrI excluding Home-HF67 1 7 19 72
Prl, predictive interval.
a Last strategy in the cost-effectiveness frontier.
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the Home-HF study67). The results of this analysis are presented in Appendix 17 and summarised in 
Table 47.
In general, the 12-month treatment duration scenario produced similar results. The probability of the 
different interventions being cost-effective remained the same as in the 6-month treatment duration 
scenario. The ICER of TM during office hours compared with usual care estimated using the HRs from CrIs 
of the NMA increased from £9522 per QALY in the base-case 6-month treatment duration scenario to 
£10,353 per QALY in the 12-month treatment duration scenario. Similar patterns were observed in the 
other analyses (using HRs based on CrIs excluding the Home-HF study67 as well as predictive distributions 
of the NMA including and excluding the Home-HF study67).
TABLE 47 Summary of the economic analysis results using 12 months’ treatment duration
Usual care STS HM STS HH TM during office hours
Total costs (£)
CrI 8562 9571 10,603 10,353
PrI 8562 9564 10,582 10,326
CrI excluding Home-HF67 8562 9645 10,655 10,663
PrI excluding Home-HF67 8562 9708 10,707 10,698
Difference in costs (£)
CrI – 1009 2040 1791
PrI – 1002 2019 1764
CrI excluding Home-HF67 – 1082 2093 2101
PrI excluding Home-HF67 – 1146 2145 2136
Total QALYs
CrI 2.4137 2.3857 2.5935 2.5898 
PrI 2.4137 2.3536 2.5589 2.5576 
CrI excluding Home-HF67 2.4137 2.4155 2.6117 2.7159 
PrI excluding Home-HF67 2.4137 2.4044 2.6005 2.7065 
Difference in QALYs
CrI – –0.0280 0.1798 0.1761 
PrI – –0.0601 0.1452 0.1439 
CrI excluding Home-HF67 – 0.0019 0.1980 0.3022 
PrI excluding Home-HF67 – –0.0093 0.1868 0.2928 
ICER (£/QALY)
CrI – Dominated 68,189a 10,167
PrI – Dominated 205,812a 12,257
CrI excluding Home-HF67 – Dominated Extendedly 
dominated
6953a
PrI excluding Home-HF67 – Dominated Extendedly 
dominated
7296a
continued
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Telemonitoring during office hours for 12 months was also compared with TM during office hours for 
6 months to identify whether or not it was cost-effective to keep the patients on TM during office hours 
beyond 6 months. In the analysis using HRs from CrIs of the NMA, TM during office hours for 12 months 
was still cost-effective compared with TM during office hours for 6 months with an ICER of £12,213 per 
QALY. Similar patterns were observed in the other analyses as shown in Table 48 (£8097 per QALY using 
HRs based on CrIs excluding the Home-HF study,67 £14,066 per QALY using predictive distributions of 
the NMA including the Home-HF study67 and £8481 per QALY using predictive distributions of the NMA 
excluding the Home-HF study67).
More importantly, given the potential capacity constraints for the TM devices, health organisations might 
choose to treat double the number of patients with TM during office hours for 6 months rather than using 
TM during office hours for 12 months. For example, assuming a capacity of 100 TM devices at a local 
health organisation, 200 patients could be treated in 1 year using TM during office hours for 6 months 
compared with 100 patients treated using TM during office hours for 12 months with the rest of the 100 
patients under usual care (because of the lack of TM devices). This scenario was evaluated to find the most 
cost-effective strategy. In the analysis using HRs from CrIs of the NMA, treating 2n patients with TM during 
office hours for 6 months was cost-effective with an ICER of £793 per QALY compared with a combination 
of treating n patients with TM during office hours for 12 months and treating n patients under usual care. 
Again, similar patterns were observed in the other analyses as shown in Table 49. These results suggest 
that, in situations with a limited number of TM devices, it is cost-effective to treat patients with TM during 
office hours for 6 months rather than with TM during office hours for 12 months with the rest of the 
patients under usual care.
Discussion of the cost-effectiveness results
The effectiveness parameters (HRs of mortality and hospitalisation) are the key drivers in the model. 
Mortality reduction leads to a gain in QALYs whereas reduction in hospitalisations leads to fewer costs and 
less disutility. As the intervention costs are only a small part of the overall costs (hospitalisation costs are 
the main contributor), RM is likely to be cost-effective if it can save lives and reduce hospitalisations.
Usual care STS HM STS HH TM during office hours
Expected incremental NMB (£)
CrI – –1568.71 1555 1732
PrI – –2202.89 884 1114
CrI excluding Home-HF67 – –1045.41 1868 3942
PrI excluding Home-HF67 – –1331.28 1590 3720
Probability of cost-effectiveness (%)
CrI 2 18 35 44
PrI 7 19 34 40
CrI excluding Home-HF67 0 5 12 83
PrI excluding Home-HF67 1 7 19 73
Prl, predictive interval.
a Last strategy in the cost-effectiveness frontier.
TABLE 47 Summary of the economic analysis results using 12 months’ treatment duration (continued)
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The results of the base-case cost-effectiveness analyses suggest that TM during office hours is expected 
to be the most cost-effective strategy at a threshold of £20,000 per QALY. However, there is uncertainty 
involved in suggesting that TM during office hours is the most probable cost-effective strategy and, in 
particular, there is higher uncertainty when the Home-HF study67 is included in the NMA than when it is 
excluded. This uncertainty also increased marginally when the HRs from the predictive distributions of the 
NMA were used instead of the HRs based on the CrIs of the NMA.
Scenario analyses performed using a higher usual care cost, lower TM during office hours cost and higher 
STS cost did not substantially change the conclusions regarding the relative cost-effectiveness of TM during 
office hours.
In the scenario analysis performed using a higher cost for TM during office hours (£215 per month) with 
HRs based on the predictive distributions of the NMA that included the Home-HF study,67 TM during office 
hours is dominated by STS HH. This is because a small change in the difference between the cost of TM 
during office hours and the cost of STS HH led to a marked change in the ICER, given the small difference 
in expected QALYs (0.0006) between STS HH and TM during office hours. However, the same scenario 
analysis (i.e. a higher cost of TM during office hours of £215 per month) performed using the HRs from 
the NMA that excluded the data from the Home-HF study67 suggested that TM during office hours is 
still the most cost-effective strategy. This is because of the much larger difference in the expected QALYs 
TABLE 48 Cost-effectiveness of TM during office hours for 12 months compared with TM during office hours for 
6 months
TM during office hours for 
6 months
TM during office hours for 
12 months
ICER (TM for 
12 months 
vs TM for 
6 months) 
(£/QALY)Cost (£) QALYs Cost (£) QALYs
CrI 9470 2.5175 10,353 2.5898 12,213
PrI 9437 2.4944 10,326 2.5576 14,066
CrI excluding Home-HF67 9650 2.5908 10,663 2.7159 8097
PrI excluding Home-HF67 9665 2.5847 10,698 2.7065 8481
Prl, predictive interval.
TABLE 49 Cost-effectiveness of TM during office hours for 12 months compared with TM during office hours for 6 
months in situations with a limited number of TM devices
2n patients on TM during office 
hours for 12 monthsa
2n patients on TM during 
office hours for 6 monthsb
ICER (TM for 
6 months 
vs TM for 
12 months) 
(£/QALY)Cost (£) QALYs Cost (£) QALYs
CrI 18,915 5.0035 18,940 5.0350 793
PrI 18,888 4.9713 18,874 4.9888 Dominant
CrI excluding Home-HF67 19,225 5.1296 19,300 5.1816 1442
PrI excluding Home-HF67 19,260 5.1202 19,330 5.1694 1423
Prl, predictive interval.
a The costs and QALYs of n patients under TM during office hours for 12 months plus the costs and QALYs of n patients 
under usual care.
b The costs and QALYs of 2n patients under TM during office hours for 6 months.
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between STS HH and TM during office hours (0.0617), meaning that the small change in the difference 
between the cost of TM during office hours and the cost of STS HH did not lead to a marked change in 
the ICER.
Scenario analysis using a 12-month treatment duration produced similar results as in the 6-month 
treatment duration scenarios. The ICER of TM during office hours compared with usual care increased 
from £11,873 per QALY in the base-case 6-month treatment duration scenario to £12,257 per QALY in 
the 12-month treatment duration scenario. TM during office hours for 12 months was also cost-effective 
compared with TM during office hours for 6 months with an ICER of £14,066 per QALY, which suggests 
that it is cost-effective to keep patients on TM during office hours beyond 6 months. However, in situations 
with a limited number of TM devices, it is cost-effective to treat patients with TM during office hours for 
6 months rather than 12 months with the rest of the patients under usual care.
Users can decide which of these base-case analyses is most representative of the UK setting, that is, 
whether or not the usual care in the Home-HF study67 is representative of usual care in the UK. If the usual 
care in the Home-HF study67 is not representative of usual care in the UK, then the modelling suggests that 
TM during office hours becomes the most cost-effective strategy with much reduced uncertainty.
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Chapter 5 Assessment of factors relevant to the 
NHS and other parties
Chronic conditions are set to be the major challenge for the NHS over coming years, and already account for approximately 70% of health-care expenditure in the UK.137 RM may be an opportunity to optimise 
care quality while controlling costs by bringing care to patients in a way that would be difficult to achieve 
in conventional hospital-based clinical pathways. For example, in the clinic, collection of vital signs tends 
to be organised around hospital routine rather than patient needs, and the information is sometimes left 
in handwritten notes until the patient has another consultation with a senior clinician. Also contrary to 
usual clinical care, in which follow-up appointments tend to be organised for a prespecified time, RM can 
be more responsive to important changes in physiological parameters. Furthermore, RM is gradually being 
shown to be a viable addition to conventional service delivery for chronic conditions, with more than 100 
telehealth pilots currently taking place in the NHS.137 For instance, in Sheffield, 30 high-risk patients with 
COPD were offered a TM intervention for a period of 5 months. Throughout that time, patients measured 
their own vital signs, which were remotely transmitted to the care provider. The use of RM decreased 
hospital admissions by around 50%, saving the trust between £35,000 and £40,000.37 As previously 
discussed, early results from the largest trial of RM (the WSD study) also seem promising.117 However, a 
number of issues need to be considered if the NHS is to roll out RM as standard care for HF.
First, NHS purchasers need to consider the business model by which RM is provided. As pointed out by 
Inglis et al.,48 purchasing RM equipment will involve large start-up costs and relatively low running costs, 
whereas renting the equipment would involve relatively low start-up costs and high running costs. Another 
relevant consideration is the speed with which RM equipment is changing and developing, which brings a 
series of further challenges and opportunities for care provision. Purchasing RM equipment may offer the 
benefits of stability with the risk of equipment rapidly becoming outdated. Conversely, renting may allow 
the NHS to maintain up-to-date service provision while running the risk of uncertainty, high costs of new 
technologies and start-up difficulties for new systems. More generally, the logistical and cost challenges 
of rolling out RM should not be underestimated.138 The WSD trial cost over £30M to run, and provision of 
RM as standard for HF patients would require considerable reorganisation of services in the short term.
Second, selection of appropriate patients for RM is an important consideration. Although the acceptability 
of RM technologies was generally high in the synthesised literature, they will not be suited to everyone. 
Nor will RM necessarily be effective among those for whom it is acceptable: in the meta-analysed trials, 
compliance was inconsistently reported, with one large, high-quality trial reporting a low rate.52 Best 
practice patient selection methods are therefore critical to guarantee the success of RM interventions. 
These might include selection of patients who are keen to incorporate RM into their care, and using 
physiological parameters, such as those described by Fonarow et al.,139 to identify particularly at-risk 
patients prior to discharge. Indeed, it has been argued that null results in some trials [Telemedical 
Interventional Monitoring in Heart Failure (TIM-HF50) and Tele-HF52] may have been attributable to patients 
with less severe, well-controlled HF.140
The NHS should also consider the duration of RM interventions, as this will have important implications for 
clinical effectiveness and cost-effectiveness. The highest risk period for mortality and rehospitalisation for 
patients with a new diagnosis of HF is the period immediately following hospitalisation,15 so offering early 
RM is likely to deliver the maximum benefit. What is less clear is the time period for which use of RM could 
continue to confer benefits. The duration of the RM interventions included in this meta-analysis varied 
from 2 months72 to 12 months.74,78,104 However, because of inconsistent reporting of intervention duration, 
it was not possible to evaluate the relative efficacy of RM interventions by duration in a meta-regression. 
Further research is required to inform NHS decisions on how long to offer RM to patients with HF.
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Finally, as Kaplan and Litewka141 note, RM ‘is not only a technological improvement, but a reengineering of 
healthcare processes requiring consideration of socio-technical aspects of their design and development’ 
(p. 402). This raises two important issues. First, health-care providers will require appropriate training to 
ensure stable and high-quality provision. Experience from the system-wide use of RM technologies in the 
US Veterans Health Administration suggests national or common training support facilities could be one 
viable way to achieve this.137 Second, by further shifting the onus of health care from hospital to home, 
RM has the potential to fundamentally change what it means to be a patient with a chronic condition, 
which raises ethical issues that go beyond confidentiality and secure data transfer.141 It is beyond the 
scope of this review to comprehensively address these issues here but, at the very least, frameworks and 
guidelines are required to ensure that RM is conducted to deliver benefits to patients in an equitable and 
genuinely empowering way.142
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Chapter 6 Discussion
Statement of principal findings
For adults who have recently (< 28 days) been discharged from an acute care setting after a recent 
exacerbation of HF, the NMA found that, compared with usual care, RM was beneficial in reducing all-
cause mortality by 23%, 24% and 51% for STS HH (HR 0.77, 95% CrI 0.55 to 1.08), TM with medical 
support provided during office hours (HR 0.76, 95% CrI 0.49 to 1.18) and TM 24/7 (HR 0.49, 95% CrI 
0.20 to 1.18) respectively. However, the results for TM 24/7 should be treated with caution because of the 
poor methodological quality of the only included study in this network. No beneficial effect on mortality 
was observed with STS HM. TM with medical support during office hours and TM 24/7 were associated 
with a 25% (HR 0.75, 95% CrI 0.49 to 1.10) and a 19% (HR 0.81, 95% CrI 0.33 to 2.00) reduction in 
all-cause hospitalisations, respectively, whereas there was no major effect of STS HM (HR 1.06, 95% CrI 
0.44 to 2.53) or STS HH (HR 0.97, 95% CrI 0.70 to 1.31). Although there was no major effect of STS HM 
(HR 1.03, 95% CrI 0.66 to 1.54) and TM with medical support during office hours (HR 0.95, 95% CrI 0.70 
to 1.34) on HF-related hospitalisation, STS HH (HR 0.77, 95% CrI 0.62 to 0.96) was associated with a 
reduction of 23%. No trials of cardiovascular implanted monitoring devices or observational studies met 
the inclusion criteria of the current review. Although data were limited, care packages that included STS 
and TM generally improved QoL and were acceptable to recently discharged patients with HF.
A sensitivity analysis, which excluded data from the Home-HF trial67 (as it appeared to be inconsistent with 
the data from the remaining studies, i.e. an outlier), found that TM with medical support provided during 
office hours was generally more effective than STS HH for all-cause mortality (TM during office hours: 
HR 0.62, 95% CrI 0.42 to 0.89; STS HH: HR 0.75, 95% CrI 0.59 to 0.96) and all-cause hospitalisations 
(TM during office hours: HR 0.67, 95% CrI 0.42 to 0.97; STS HH: HR 0.96, 95% CrI 0.72 to 1.27) but not 
HF-related hospitalisations (TM during office hours: HR 0.86, 95% CrI 0.61 to 1.21; STS HH: HR 0.76, 95% 
CrI 0.61 to 0.94). By excluding this study from the NMA, larger reductions in effect were observed for 
all-cause mortality, all-cause hospitalisations and HF-related hospitalisations for TM during office hours.
Additional analyses were undertaken to assess whether or not the results from the primary analysis 
differed markedly from the results in those with stable HF who were managed in the community. Of the 
21 included studies of TM (including cardiovascular implanted monitoring devices) or STS programmes 
for adults with stable HF, 18 studies contributed to the network comparing different pairs or triplets of 
treatment using TM or STS programmes and usual care. For all-cause mortality, the NMA found that the 
effects of STS HH and TM during office hours were similar to the effects in patients who have recently 
(< 28 days) been discharged from an acute care setting after a recent exacerbation of HF. In terms of 
all-cause hospitalisations and HF-related hospitalisations, RM appears to be beneficial, although the effects 
of each intervention are not consistent relative to adults who were recently discharged. An analysis of the 
effect of cardiovascular implanted monitoring devices compared with cardiovascular implanted non-
monitoring devices (n = 3 studies) found a trend in favour of a reduction in all-cause mortality (HR 0.90, 
95% CrI 0.31 to 2.49) and HF-related hospitalisations (HR 0.72, 95% CrI 0.32 to 1.37). However, these 
effects were not conclusive.
Base-case monthly costs per patient were estimated using microcosting methods as £27 for usual care, 
£119 for STS HM, £179 for STS HH and £175 for TM during office hours. Five cost scenarios were 
also developed to calculate lower and higher estimates of costs of STS HH (£175 and £192 per month 
respectively) and TM during office hours (£133.50 and £215 per month respectively) along with a higher 
estimate of usual care costs (£92 per month).
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The results of the full incremental cost-effectiveness analysis using the base-case costs suggest that TM 
during office hours is likely to be the most cost-effective strategy at a threshold of £20,000 per QALY for 
both analysis using CrIs and PrIs of the NMA as HRs in the model. In the analysis performed using PrIs from 
NMA as HRs, TM during office hours had an estimated ICER of £11,873 per QALY, compared with usual 
care whereas STS HH had an ICER of £228,035 per QALY compared with TM during office hours. STS HM 
was dominated by usual care. Thus, although STS HH is the most effective strategy providing the highest 
number of expected QALYs (2.4950), with TM the second most effective (2.4944 QALYs), the additional 
QALYs gained by STS HH are not worth the additional costs of the strategy, as seen in the ICER, which is 
greater than the threshold of £20,000 per QALY.
The PSA showed substantial uncertainty over the most probable cost-effective strategy. TM during office 
hours was the most cost-effective strategy in 40% of the PSA runs whereas STS HH was most cost-effective 
in 35% of the PSA runs. STS HM and usual care were the most cost-effective in 19% and 6% of the 
runs respectively. The EVPI per patient was estimated at £1831 and the population EVPI per annum was 
estimated at £100,299,791 assuming an annual incidence of first HF admissions in England and Wales 
of 54,779.
Cost-effectiveness analysis performed using the HRs from the predictive distributions of the NMA that 
excluded the data from the Home-HF trial67 showed an improvement in the cost-effectiveness of TM during 
office hours. STS HM and STS HH were dominated and extendedly dominated, respectively, with the ICER 
for TM during office hours compared with usual care estimated as £6492 per QALY. In this analysis, TM 
during office hours is also the most effective strategy (2.5847 QALYs for TM vs 2.5230 QALYs for STS HH). 
Furthermore, the results from the uncertainty analysis suggest that TM during office hours is cost-effective 
in 73% of the runs whereas STS HH and STS HM are cost-effective in 19% and 7% of the runs respectively. 
This reduction in the uncertainty was also reflected in the lower EVPI per patient, estimated as £410, and 
the lower population EVPI per annum, estimated as £22,459,265.
Scenario analysis performed using a higher cost of TM during office hours (£215 per month) increased 
the uncertainty. Both TM during office hours and STS HH were cost-effective in 37% of the PSA runs. But, 
TM during office hours is dominated by STS HH. This is because the estimated ICER is based on very small 
differences in benefits (STS HH results in 0.0006 QALYs more than TM during office hours) and so a small 
increase in the difference between costs of TM during office hours and STS HH leads to a marked change 
in the ICER. The same scenario analysis (i.e. a higher cost of TM during office hours of £215 per month), 
performed using the HRs from the NMA that excluded the data from the Home-HF trial,67 suggested that 
TM during office hours would still be the most cost-effective strategy with an ICER of £8223 per QALY 
compared with usual care (STS HH is extendedly dominated by a combination of usual care and TM during 
office hours). Threshold analysis suggested that the monthly cost of TM during office hours has to be 
> £390 to produce an ICER > £20,000 per QALY compared with STS HH. At a monthly cost of £390, the 
ICER of TM during office hours compared with usual care is £13,357 per QALY.
Scenario analyses performed using a higher cost of usual care, a higher cost of STS HH and a lower cost of 
TM during office hours do not substantially change the conclusions. TM during office hours was estimated 
to be the most cost-effective strategy in all of these scenarios.
Strengths and limitations of the assessment
Although an extensive literature search was conducted, it is possible that some relevant studies may 
have been missed. However, such omissions are likely to have been minimal as the search included all 
identifiable publications in the grey literature (including contact with clinical experts in the field).
The data were analysed by assuming a binomial likelihood function for the sample data. The statistical 
model acknowledged the fact that events accumulate over time by adjusting for the varying durations of 
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each study using a complementary log-log links function. Parameter estimates, including the between-
study standard deviation, were estimated using Markov chain Monte Carlo (MCMC), which allows for 
uncertainty in the estimate of the between-study standard deviation; it also allowed the estimation of the 
predictive distribution of the effect of each intervention in a new study.
The clinical effectiveness findings had a number of limitations. In particular, the RM interventions were 
heterogeneous in terms of monitored parameters and selection criteria for HF. This was the case even 
within each of the four specific types of RM (STS HH, STS HM, TM with medical support during office 
hours, TM with medical support 24/7). Clear descriptions of the RM interventions were not provided in 
many of the studies included in the systematic review, making it difficult to understand exactly what was 
provided as part of the intervention. In addition, a number of trials were underpowered to detect the 
clinical outcome of interest and did not report blinding of outcome assessors. A limitation of the statistical 
model (as a consequence of having only one observation from each study) was that it assumed that the 
hazards and relative intervention effects were constant over time; nevertheless, this is better than assuming 
that study duration has no impact on the data. Moreover, because of the differences in the HF populations 
(e.g. definition of HF, LVEF inclusion criteria) of the included studies the true estimate of treatment effect 
may be unclear. However, the NMA analysis used a random-effects distribution together with 95% CrIs 
to reflect the uncertainty associated with the population mean. In addition, the predictive distribution 
of a randomly chosen study in the population was presented. This reflects not only uncertainty in the 
population mean but also the heterogeneity in treatment effects between studies. Unfortunately, it was 
not possible to model the heterogeneity between studies using a meta-regression technique because of 
the lack of suitable data on potential treatment effect modifiers.
The cost-effectiveness analysis has been undertaken assuming that the NMA results represent the best 
knowledge regarding the relative uncertainty between treatments. Therefore, although the treatment 
effects estimated from the NMA were statistically inconclusive, the joint uncertainty about these 
effectiveness parameters was used to populate the economic model. The expected values of costs and 
QALYs produced, which were used to estimate the cost-effectiveness of the RM interventions, thus are also 
aligned with the best knowledge on relative effectiveness. The uncertainty within the cost-effectiveness 
results was quantified by estimating the probability of each intervention being the most cost-effective 
at different WTP thresholds, and the EVPI was calculated to explicitly quantify the cost of reducing the 
decision uncertainty by undertaking further research.
Any limitations in the evidence base also manifest as limitations of the cost-effectiveness model. Most of 
the included studies in the NMA provided information on mortality and/or hospitalisation rates, which 
allowed synthesis using meta-analytical methods, but only a few studies reported any data about other 
potentially relevant states/events (such as stroke, having a pacemaker fitted), which did not extend to 
reporting any differences between the usual care and RM arms. Given the lack of evidence, it was deemed 
prudent to use a two-state Markov model even though it involved simplifications and assumptions that 
may not exactly reflect clinical practice. An advantage of using this simple model is that it can be easily 
updated to include other states or events should there be future evidence demonstrating differences 
between the usual care and RM arms.
A limitation of the cost-effectiveness model was that there was no age-specific analysis. Another 
limitation was that the constant hazards and relative intervention effects over time were applied to the 
time-dependent baseline mortality hazard (which is greatest in the early period after discharge after a 
hospitalisation for HF and subsequently declines over time) and constant risk of hospitalisation. If the 
studies reported observations at different time points, time-dependent effectiveness parameters can be 
estimated and used in the cost-effectiveness model. Furthermore, the optimal duration for each of the RM 
interventions can also be identified.
None of the studies identified in the review provided an estimate for the utility of the patients and whether 
or not there was a difference between the RM and usual care groups. Thus, in the economic model, 
NIHR Journals Library www.journalslibrary.nihr.ac.uk
DIscussIOn
96
similar utility values were used for HF patients in both the RM and usual care groups; however, the validity 
of this assumption is unclear. Furthermore, the lack of detail provided in research studies concerning 
the components of RM packages and usual care (e.g. communication protocols, routine staff visits and 
resources used) made it difficult to estimate costs. Costing scenarios for different RM classifications 
were developed and their costs were estimated using microcosting methods. Although the users can 
decide which of these analyses is most representative of their setting, uncertainties still remain about the 
assumptions made in the estimation of these costs. This uncertainty in the costs is a limitation, especially 
as, given the small difference in QALYs between STS HH and TM during office hours, a small change in the 
difference between the cost of TM during office hours and the cost of STS HH can lead to marked changes 
in the ICER. A further limitation is that the effectiveness remained the same for the different cost scenarios 
whereas in reality there might be some correlation between the cost and the effectiveness of different 
RM strategies.
Uncertainties
In the cost-effectiveness model, the HRs of mortality and hospitalisation were the key drivers as mortality 
reductions lead to a gain in QALYs whereas reductions in hospitalisations lead to fewer costs and more 
QALYs. The intervention costs were only a small part of the overall costs (hospitalisation costs are the main 
contributor); thus, RM is likely to be cost-effective if it can save lives and reduce hospitalisations to a large 
enough extent. However, there was still some uncertainty in the effectiveness parameters as suggested in 
the EVPI analysis.
At the time of writing, the long-awaited results of the WSD programme117 had not been published in a 
peer-reviewed journal. This study is a large UK-based RCT of telehealth compared with usual care, which 
included over 6000 patients with HF, diabetes mellitus or COPD. Although early headline results, published 
by the UK Department of Health,57 suggest a substantial reduction in mortality by 45%, the magnitude 
and direction of effect in recently discharged patients with HF is unclear (including people with stable HF). 
Given the large sample size, it is anticipated that the effectiveness results from the WSD programme will 
help reduce some of the uncertainty reported in the model results for recently discharged patients with HF.
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Chapter 7 Conclusions
Implications for service provision
In general, although the effectiveness of the interventions varied widely according to the type of RM 
system used, STS HH and TM with medical support provided during office hours showed beneficial effects, 
particularly in reducing all-cause mortality for recently discharged patients with HF; however, these effects 
were statistically inconclusive.
Given the variation in usual care and RM strategies, the cost-effectiveness analysis was performed using 
a set of costing scenarios. These scenarios were designed to reflect the different configurations of usual 
care and RM interventions present in the UK. The cost-effectiveness analyses suggest that TM during office 
hours was an optimal strategy in most of the scenarios.
Suggested research priorities
Despite the growing evidence base for RM, a number of key questions are yet to be addressed. First, it 
would be helpful to have more direct comparisons of STS and TM. To our knowledge, only one study of 
recently discharged patients (TEN-HMS49) has made this comparison. The results of this trial suggested 
that TM was somewhat more beneficial than STS – in particular, TM had a substantially greater effect 
on reducing the duration of hospitalisation and the number of home or clinical visits. This broadly 
coheres with our findings (particularly from the sensitivity analyses excluding the Home-HF study67) 
that TM interventions showed a greater risk reduction than STS for mortality and hospitalisation. In 
addition, patients with HF are at increased risk of atrial fibrillation, which can lead to deterioration and 
hospitalisation. Further research on the precipitants of admission for HF (including atrial fibrillation, 
infection and non-compliance) and how they might be detected and managed early is required.
Given the complex nature of RM interventions, new research should seek to examine the ‘active 
ingredients’ of RM. For instance, the NMA was unable to compare the effectiveness of TM interventions 
that monitored different physiological parameters. Well-known risk factors such as low LVEF, NYHA 
class and heart rate perform well in predicting mortality but it is not yet clear which factors in which 
combination can provide optimal clinical benefit for RM. As a complex intervention (i.e. made up of 
multiple, socially meaningful, interconnected factors), it is important to understand the processes by which 
RM works, and qualitative research on patient experiences of RM may help throw light on the issue.116 
In relation to STS, one interesting question is whether contact with a care professional is required to 
deliver benefits, or whether it can work as an automated human-to-machine interface. RCTs of STS that 
manipulate the presence of a human caregiver as the primary experimental variable could help address 
this issue. It also remains unclear how RM affects clinical decision-making. Further research should seek 
to establish in what ways RM might improve such decision-making, and conversely whether it may, 
in some circumstances, act as an impediment to good care. More importantly, it is worth echoing the 
recommendation made by Inglis et al.48 that future RM studies should publish data in such a way as to 
identify which patient subgroups benefited most from the intervention. For example, there might be 
differential effectiveness in different age groups and future trials should explore these issues. If particular 
groups tend to benefit more, the potential for RM to exacerbate health inequalities should be carefully 
considered, and strategies should be pursued to minimise this.
Furthermore, to aid robust cost-effectiveness estimations, the costs associated with usual care and RM 
interventions need to be reported in detail (including the costs of HF treatment pathways). The costs 
need to be linked to the activities or items involved in the intervention using activity-based costing or unit 
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costing approaches respectively. In addition, QoL, patient severity status transitions (e.g. NYHA class) and 
hospitalisations need to be reported with observations at specific time points to enable the estimation 
effectiveness of RM over time and also to identify the optimal duration of RM interventions.
Implementation costs (such as set-up costs, staff training costs, costs for dual running of usual care and 
RM services) were often missing from the studies in the review. Future studies should provide greater detail 
of the costs of reconfiguration and link more clearly with the financial impact (e.g. cost variation with 
scale and over time) on provider organisations. Wider adaptation of RM in the NHS can be facilitated by 
providing financial impact data along with the cost-effectiveness information.
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Appendix 1 Home telemonitoring or structured 
telephone support programmes for patients with heart 
failure: literature search strategy, a MEDLINE example
Database searched: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R).Platform or provider used: Ovid SP.
Date of coverage: 1948–January 2012.
Search undertaken: January 2012.
1. exp Heart Failure/
2. ((heart or cardiac) adj failure).tw.
3. 1 or 2
4. exp Telecommunications/
5. Telemetry/
6. (telemetr$or telemed$or tele-med$or telehealth$or tele-health$or telecare or tele-care or 
telecardiol$or tele-cardiol$or telehome or tele-home).tw.
7. (telemonitor$or tele-monit$or teleconsult$or tele-consult$or teleconferenc$or tele-conferenc$or 
telecommunicat$or tele-communicat$).tw.
8. (telephon$or phone$).tw.
9. Remote consultation/
10. (remote$adj3 (consult$or monitor$)).tw.
11. remote patient monitoring.tw.
12. Monitoring, Ambulatory/
13. ((implantable or wearable) and (monitor$or system$or sensor$)).tw.
14. Patient Care Planning/
15. Case Management/
16. disease management/
17. disease management.tw.
18. exp Comprehensive Health Care/
19. Home Care Services/
20. Home Care Services, Hospital-Based/
21. Clinical Protocols/
22. Nurse Clinicians/
23. Nurse Practitioners/
24. (nurse adj led).tw.
25. or/4–24
26. 3 and 25
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Appendix 2 Methodological assessment (adapted) 
criteria for randomised controlled trials61 and 
observational studies62
Criteria
Criteria 
met Criteria defined (if applicable)
RCTs
1. Was the method used to 
assign participants to the 
treatment groups really 
random?
Yes Computer-generated random numbers, random number tables, 
random permuted blocks, sealed assignment, sequentially 
numbered sealed opaque envelopes
No Use of alternation, case record numbers, date of birth or days of 
the week
Unclear Insufficient detail to make judgement 
2. Was the allocation of 
treatment concealed?
Yes Allocation to each group performed adequately (e.g. centrally) and 
group assignment revealed after provision of consent
No Group assignment revealed prior to subject consent, non-opaque 
sealed envelopes, case record numbers, date of birth or days of the 
week, open random number lists
Unclear Insufficient detail to make judgement
3. Were the outcome assessors/
data analysts blinded to the 
treatment allocations (it was 
not considered plausible that 
patients could be blinded to 
these types of interventions)? 
Yes Independent outcome assessors and data analysts were blinded to 
which group patients belonged to
No Outcomes assessed and data analysed by those involved in the 
intervention, or those who are aware of group membership
Unclear Insufficient detail to make judgement
4. Were the eligibility criteria 
for study entry specified 
including confirmation of 
diagnosis of HF?
Yes Eligibility criteria for study entry specified and diagnosis of HF 
(systolic or preserved) recorded and confirmed using clinical criteria, 
echocardiography or BNP
No Eligibility criteria for study entry not specified or diagnosis of HF 
not defined
Unclear Insufficient detail to make judgement
5. Was baseline comparability 
achieved for the most 
important prognostic 
indicators?
Yes The baseline characteristics of each study group (in particular age, 
NYHA class and/or LVEF) were clearly outlined and any differences 
identified were accounted for
No The baseline characteristics (in particular, age, NYHA class and/or 
LVEF) of each study group were not outlined or differences were 
not accounted for
Unclear Insufficient detail to make judgement
6. Adequate follow-up of 
patients (at least 80%)
Yes Proportion and characteristics of those participants lost to follow-
up (≤ 20%) clearly reported for each group and outcome. A clear 
outline is provided as to how losses of participants were handled
No Proportion and characteristics of those participants lost to 
follow-up > 20%. No clear outline is provided as to how losses of 
participants were handled
Unclear Insufficient detail to make judgement
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Criteria
Criteria 
met Criteria defined (if applicable)
7. Were the reasons for 
withdrawal stated?
Yes
No
Unclear Insufficient detail to make judgement
8. Was an intention-to-treat 
analysis included?
Yes All patients randomly assigned to one of the treatments are 
analysed together, regardless of whether or not they completed or 
received that treatment
No All patients randomly assigned to one of the treatments are not 
analysed together, regardless of whether or not they completed or 
received that treatment, e.g. per protocol
Unclear Insufficient detail to make judgement
9. Was the study powered 
to detect differences in 
outcomes?
Yes A power calculation was performed and reported. The study was 
adequately powered to detect differences in outcomes
No A power calculation was not performed; a power calculation 
was performed and reported but the study was not adequately 
powered to detect differences in outcomes; or a power calculation 
was performed but not reported – the study states that it was 
adequately powered to detect differences in outcomes
Unclear Insufficient detail to make judgement
Observational studies
1. Was the sample 
representative of the average 
HF patient?
Yes
No
Unclear
2. Were the intervention and 
control cohort drawn from 
the same community?
Yes
No
Unclear
3. Were groups comparable in 
terms of major confounding/
prognostic factors?
Yes
No
Unclear
4. Was the attrition rate 
acceptable (≤ 20%)?
Yes
No
Unclear
5. Was the length of follow-
up sufficiently long for the 
outcome to occur?
Yes
No
Unclear
6. Were all potential 
confounding factors 
and outcomes measured 
accurately and objectively?
Yes
No
Unclear
7. Was an attempt made to 
control for confounders in 
the analysis (e.g. regression 
or stratification)?
Yes
No
Unclear
BNP, B-type natriuretic peptide.
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Appendix 3 Statistical model used to analyse the 
data
The analysis assumed that the studies are exchangeable in the sense that the investigators would be willing to assign each of the patients in the studies to any of the interventions.
A random-effects NMA was conducted with the baseline treatment being defined as usual care.
The studies presented data in terms of the number of patients who had an event (i.e. all-cause mortality, 
all-cause hospitalisation and HF-related hospitalisation). To account for the variation in follow-up between 
studies,86 it was assumed that the data arose according to a Poisson process for each trial arm, with a 
constant event rate, lik, for arm k in study i, so that Tik, the time until an event occurs in arm k of study i, is 
distributed exponentially such that:
Tik ~ Exp(lik) (1)
Therefore, the probability that there are no events by time fi in arm k of study i (i.e. the survivor function of 
an exponential distribution) is:
S(fi ) = P Tik > fi( ) =1− F(fi ) = e–λikfi  (2)
Then for each study, i, pik, the probability of an event in arm k of study i after follow-up time fi, can be 
written as:
Pik =1− P(Tik > fi ) =1− e
–λikfi  (3)
which is time dependent.
Therefore, the event rate, lik, was modelled using the complimentary log-log link function such that:
qik = cloglog(pik) 
= ln(–ln(1 – pik)) 
= ln (–ln(1 – [1 – exp(–likfi)])) 
= ln(–ln[exp(–likfi)]) 
= ln(–(–likfi)) = ln(likfi) 
= ln(lik) + ln(fi) 
= mi + di,bkI{k ≠ 1} + ln(fi) (4)
where di,bk are the treatment effects of interest and are also the log-HRs relative to the baseline treatment.
This model assumes that the hazards for each intervention are constant irrespective of follow-up. Although 
this is a strong assumption, it is preferable to assuming that the follow-up has no impact on the number 
of events that are accumulated over time.
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Appendix 4 Comparison of included studies from 
existing reviews
Author, year
Comment
Studies included 
by Inglis et al.48a
Studies included by 
Klersy et al.58b
STS vs usual care; TM vs usual care
Cleland et al. 2005 
(TEN-HMS)49
Cleland et al. 2005 
(TEN-HMS)49
RCT (three arm), patients discharged from hospital (and received 
intervention) within 28 days of exacerbation of HF (assumed majority 
received intervention < 28 days from discharge)
Mortara et al. 2009 
(HHH)88,143
RCT (three arm), stable HF patients
STS vs usual care
Angermann et 
al. 2007 (INH) 
(Abstract)144
RCT, patients discharged from hospital (and received intervention) within 
28 days of exacerbation of HF, telephone-based human interaction
Barth 200172 Barth 200172 RCT, patients discharged from hospital (and received intervention) within 
28 days of exacerbation of HF, telephone-based human interaction
DeBusk et al. 200474 DeBusk et al. 200474 RCT, patients discharged from hospital (and received intervention) within 
28 days of exacerbation of HF, telephone-based human interaction
Laramee et al. 
200377
Laramee et al. 200377 RCT, patients discharged from hospital (and received intervention) within 
28 days of exacerbation of HF, telephone-based human interaction
Rainville 199978 RCT, patients discharged from hospital (and received intervention) within 
28 days of exacerbation of HF, telephone-based human interaction
Riegel et al. 200279 Riegel et al. 200279 RCT, patients discharged from hospital (and received intervention) within 
28 days of exacerbation of HF, telephone-based human interaction
Riegel et al. 200680 Riegel et al. 200680 RCT, patients discharged from hospital (and received intervention) within 
28 days of exacerbation of HF, telephone-based human interaction
Tsuyuki et al. 2004 
(REACT)81
RCT, patients discharged from hospital (and received intervention) within 
28 days of exacerbation of HF, telephone-based human interaction; 
excluded by Klersy et al.58 because of the following reason: not pertinent 
Wakefield et al. 
200882
RCT, patients discharged from hospital (and received intervention) within 
28 days of exacerbation of HF, telephone-based human interaction
DeWalt et al. 200689 RCT, stable HF patients, telephone-based human interaction
Galbreath et al. 
200487
Galbreath et al. 200487 RCT, stable HF patients, telephone-based human interaction
Gattis et al. 1999 
(PHARM)90
RCT, stable HF patients, telephone-based human interaction
GESICA investigators 
2005 (DIAL)91
GESICA investigators 
2005 (DIAL)91
RCT, stable HF patients, telephone-based human interaction
Ramachandran et al. 
2007106
RCT, stable HF patients, telephone-based human interaction; excluded by 
Klersy et al.58 because of the following reason: not pertinent 
Sisk et al. 200692,125 Sisk et al. 200692,125 RCT, stable HF patients, telephone-based human interaction
Tonkin et al. 
2009 (CHAT) 
(Abstract)93,145,146
RCT, stable HF patients, telephone-based interactive response system, 
telephone-based human interaction; excluded by Klersy et al.58 because 
of the following reason: not pertinent 
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Author, year
Comment
Studies included 
by Inglis et al.48a
Studies included by 
Klersy et al.58b
TM vs usual care
Antonicelli et al. 
200871
RCT, patients discharged from hospital (and received intervention) within 
28 days of exacerbation of HF, transmitted data reviewed by medical 
staff (including medical support) during office hours
Capomolla et al. 
200473
RCT, patients discharged from hospital (and received intervention) within 
28 days of exacerbation of HF, transmitted data reviewed by medical 
staff (including medical support) during office hours
Goldberg et al. 
2003 (WHARF)75
Goldberg et al. 2003 
(WHARF)75
RCT, patients discharged from hospital (and received intervention) within 
28 days of exacerbation of HF, transmitted data reviewed by medical 
staff (including medical support) 7 days a week but not 24/7
Kielblock et al. 
200776
Kielblock et al. 200776 RCT, patients discharged from hospital (and received intervention) within 
28 days of exacerbation of HF, medical support available 24/7 (note: 
classified as cohort study by Klersy et al.58)
Woodend et al. 
200883
Woodend et al. 200883 RCT, patients discharged from hospital (and received intervention) within 
28 days of exacerbation of HF, transmitted data reviewed by medical 
staff (including medical support) during office hours
Balk et al. 200894 RCT, stable HF patients, transmitted data reviewed by medical staff 
(including medical support) during office hours
Blum et al. 
2007 (MCCD) 
(Abstract)95,147
RCT, stable HF patients, transmitted data reviewed by medical staff 
(including medical support) during office hours
de Lusignan et al. 
200196
RCT, stable HF patients, transmitted data reviewed by medical staff 
(including medical support) during office hours; excluded by Klersy et 
al.58 because of the following reason: not pertinent 
Giordano et al. 
200997
RCT, stable HF patients, transmitted data reviewed by medical staff 
(including medical support) during office hours
Soran et al. 2008 
(HFHC)98
RCT, stable HF patients, transmitted data reviewed by medical staff 
(including medical support) 7 days a week but not 24/7
Villani et al. 
2007 (ICAROS) 
(Abstract)99
RCT, stable HF patients, transmitted data reviewed by medical staff 
(including medical support) during office hours; excluded by Klersy et 
al.58 because of the following reason: study protocol 
Zugck et al. 2008 
(HiTel) (Abstract)148
RCT, stable HF patients, transmitted data reviewed by medical staff 
(including medical support) during office hours
Cardiovascular implanted devices with monitoring vs cardiovascular implanted devices without monitoring 
(usual care)
Bourge et al. 2008105 RCT, stable HF patients
Other
Blue et al. 2001149 TM, RCT; excluded by Inglis et al.48 because of the following reason: 
intervention included home visits
Dunagan et al. 2005150 STS, RCT; excluded by Inglis et al.48 because of the following reason: 
intervention included home visits
Jerant et al. 2001151 TM, RCT; excluded by Inglis et al.48 because of the following reason: 
intervention included home visits
Kashem et al. 2008152 TM, RCT; excluded by Inglis et al.48 because of the following reason: 
web-based intervention
Kasper et al. 2002153 TM, RCT; excluded by Inglis et al.48 because of the following reason: 
intervention included home visits
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Author, year
Comment
Studies included 
by Inglis et al.48a
Studies included by 
Klersy et al.58b
Krumholz et al. 2002154 TM, RCT; excluded by Inglis et al.48 because of the following reason: 
frequent clinic and home visits
McDonald et al. 2002155 TM, RCT; excluded by Inglis et al.48 because of the following reason: 
frequent clinic visits with unstructured telephone follow-up
Schwarz et al. 2008156 TM, RCT; excluded by Inglis et al.48 because of the following reason: 
intervention involved caregivers as well as the patient with HF
Adamson et al. 2003157 Cardiovascular implanted monitoring devices, cohort study without 
contemporaneous control group
Gambetta et al. 2007158 TM, cohort study, stable HF patients
Hudson et al. 2005159 TM; excluded by Inglis et al.48 because of the following reason: not a RCT 
(before-and-after study)
Myers et al. 2006160 TM, cohort study, stable HF patients
Morguet et al. 2008161 TM; excluded by Inglis et al.48 because of the following reason: not a RCT 
(cohort study with stable HF patients)
Oeff et al. 2005162 TM; excluded by Inglis et al.48 because of the following reason: not a RCT 
(before-and-after study)
Roth et al. 2004163 TM, cohort study without contemporaneous control group
Scalvini et al. 2004164 TM; excluded by Inglis et al.48 because of the following reason: not a RCT 
(cohort study without contemporaneous control group)
Scalvini et al. 2005165 TM; excluded by Inglis et al.48 because of the following reason: not a RCT 
(cohort study with stable HF patients)
Scalvini et al. 2006166 TM; excluded by Inglis et al.48 because of the following reason: GP 
monitoring vs home-based monitoring (cohort study)
Scholfield et al. 2005167 TM, before-and-after study
CHAT, Chronic Heart-failure Assistance by Telephone; DIAL, Randomized Trial of Telephone Intervention in Chronic Heart 
Failure; GESICA, Grupo de Estudio de Sobrevida en la Insuficiencia Cardíaca en la Argentina; HFHC, Heart Failure Home 
Care; HHH, Home or Hospital in Heart Failure; HiTel, Heart In – sufficiency TELemonitoring Study; ICAROS, Integrated 
Care vs Conventional Intervention in Cardiac Failure Patients: Randomized Open Label Study; INH, Interdisciplinary 
Network for Heart Failure; MCCD, Medicare Coordinated Care Demonstration; PHARM, Pharmacist in Heart Failure 
Assessment Recommendation and Monitoring; REACT, Review of Education on ACE Inhibitors in Congestive Heart Failure 
Treatment; WHARF, Weight Monitoring in Heart Failure.
a The criteria for inclusion were as follows: population – patients (aged ≥ 18 years) with a definitive diagnosis of HF 
and recently discharged from an acute care setting to home (excluding nursing homes or convalescent homes) or 
recruited while managed in the community setting; interventions – STS or TM interventions initiated by a health-care 
professional and targeted towards the patient and not caregivers; delivered as the only HF disease management 
intervention, without home visits or intensified clinic follow-up; comparator – consisted of standard post-discharge 
care without intensified attendance at cardiology clinics or clinic-based HF disease management programme or home 
visits; outcomes – death (from any cause), hospitalisation (from any cause or HF related), length of stay, cost of the 
intervention or cost reductions, QoL, acceptability and adherence; study design – RCTs; other criteria – full peer-
reviewed journals published between January 2006 and November 2008 (this review updated a previously published 
review by the same authors that examined the period between 1966 and May 2006).
b The criteria for inclusion were as follows: population – patients with chronic HF; interventions – telephone monitoring 
approach including regularly scheduled structured telephone contact between patients and health-care providers 
(with or without home visits) and reporting of symptoms and/or physiological data; a technology-assisted monitoring 
approach relying on information communication technology, with transfer of physiological data collected via remote 
(at the patient’s home) external monitors or via cardiovascular implantable electronic devices; comparator – usual 
care approach, which referred to in-person visits at the doctor’s office, at a multidisciplinary outpatient clinic or at 
an emergency department without additional telephone calls to and from the patient; outcomes – death (from any 
cause), first hospitalisation (from any cause or HF related) and composite of individual outcomes; study design – RCTs 
and cohort studies; other criteria – full-text articles in peer-reviewed journals published between January 2000 and 
October 2008 and published in English, Spanish, German, French or Italian.
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Appendix 5 Methodological assessment tool for 
systematic reviews and meta-analysis66
Inglis et al.48 Klersy et al.58
1. Was an ‘a priori’ design provided?
The research question and inclusion criteria should be 
established before the conduct of the review
P Yes P Yes
No No
Can’t answer Can’t answer
Not applicable Not applicable
2.  Was there duplicate study selection and data 
extraction?
There should be at least two independent data 
extractors and a consensus procedure for disagreements 
should be in place
P Yes P Yes
No No
Can’t answer Can’t answer
Not applicable Not applicable
3. Was a comprehensive literature search performed?
At least two electronic sources should be searched. 
The report must include years and databases used 
[e.g. Cochrane Central Register of Controlled Trials 
(CENTRAL), EMBASE and MEDLINE]. Key words and/
or medical subject heading (MeSH) terms must be 
stated and where feasible the search strategy should 
be provided. All searches should be supplemented 
by consulting current contents, reviews, textbooks, 
specialised registers or experts in the particular field of 
study, and by reviewing the references in the studies 
found
P Yes Yes
No P No
Did not report consulting 
current contents, reviews, 
specialised registers or experts 
in field
Can’t answer Can’t answer
Not applicable Not applicable
4. Was the status of publication (i.e. grey literature) 
used as an inclusion criterion?
The authors should state that they searched for reports 
regardless of their publication type. The authors should 
state whether or not they excluded any reports (from 
the systematic review) based on their publication status, 
language, etc.
P Yes Yes
No P No
Authors searched for full-text 
peer-reviewed publications only
Can’t answer Can’t answer
Not applicable Not applicable
5. Was a list of studies (included and excluded) 
provided?
A list of included and excluded studies should be 
provided
P Yes P Yes
No No
Can’t answer Can’t answer
Not applicable Not applicable
6. Were the characteristics of the included studies 
provided?
Data from the original studies on the participants, 
interventions and outcomes should be provided in 
an aggregated form such as a table. The ranges of 
characteristics in all of the studies analysed, e.g. age, 
race, sex, relevant socioeconomic data, disease status, 
duration, severity or other diseases, should be reported
P Yes P Yes
No No
Can’t answer Can’t answer
Not applicable Not applicable
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Inglis et al.48 Klersy et al.58
7. Was the scientific quality of the included studies 
assessed and documented?
‘A priori’ methods of assessment should be provided 
[e.g. for effectiveness studies if the author(s) chose 
to include only randomised, double-blind, placebo-
controlled studies, or allocation concealment as 
inclusion criteria]; for other types of studies alternative 
items will be relevant
P Yes P Yes
No No
Can’t answer Can’t answer
Not applicable Not applicable
8. Was the scientific quality of the included studies 
used appropriately in formulating conclusions?
The results of the methodological rigour and scientific 
quality should be considered in the analysis and the 
conclusions of the review and explicitly stated in 
formulating recommendations
Yes Yes
P No
Authors did not consider 
recommendations in light of 
the quality of included trials
P No
Authors did not refer to 
study quality when discussing 
implications for practice
Can’t answer Can’t answer
Not applicable Not applicable
9. Were the methods used to combine the findings of 
studies appropriate?
For the pooled results a test should be carried out to 
ensure that the studies were combinable, to assess their 
homogeneity (i.e. chi-squared test for homogeneity, 
I²). If heterogeneity exists a random-effects model 
should be used and/or the clinical appropriateness of 
combining should be taken into consideration (i.e. is it 
sensible to combine?)
Yes P Yes
P No
‘Owing to differences 
in patient populations 
programme characteristics 
and length of follow-up, 
all meta-analyses were 
performed using a fixed-
effects model’ (p. 8)
No
Can’t answer Can’t answer
Not applicable Not applicable
10. Was the likelihood of publication bias assessed?
An assessment of publication bias should include a 
combination of graphical aids (e.g. funnel plot, other 
available tests) and/or statistical tests (e.g. Egger 
regression test)
P Yes P Yes
No No
Can’t answer Can’t answer
Not applicable Not applicable
11. Was the conflict of interest stated?
Potential sources of support should be clearly 
acknowledged in both the systematic review and the 
included studies
P Yes Yes
No P No
Authors listed their own sources 
of sponsorship but not those of 
the included trials
Can’t answer Can’t answer
Not applicable Not applicable
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Appendix 6 Clinical effectiveness review: table of 
excluded studies with rationale
Author, year Reason for exclusion
1. Anon 2009168 Foreign language (review article)
2. Abraham et al. 2011103 Patients discharged within the previous 12 months for HF but TM 
intervention performed < 28 days after being implanted with a 
cardiovascular monitoring device (CHAMPION)
3. Adamson et al. 2011169 Patients discharged within the previous 12 months for HF but TM 
intervention performed < 28 days after being implanted with a 
cardiovascular monitoring device (CHAMPION)
4. Adamson et al. 2011104 Patients discharged within the previous 12 months for HF but TM 
intervention performed < 28 days after being implanted with a 
cardiovascular monitoring device (REDUCEhf)
5. Adlbrecht et al. 2009170 Not TM or STS
6. Al-Khatib et al. 2010171 Not RM for HF – RM of device vs quarterly device interrogation
7. Anand et al. 2010172 Not TM or STS
8. Anand et al. 2011173 Not TM or STS
9. Antonicelli et al. 2010174 Not available
10. Arya et al. 2008175 Ongoing study (IN-TIME)
11. Bardy and McCullough 2008176 Editorial/comment
12. Bardy et al. 2008177 Not RM or STS
13. Bento et al. 2009178 Not RM or STS
14. Benvenuto et al. 2008179 Not RCT/cohort with concurrent control
15. Benvenuto et al. 2009180 Not RCT/cohort with concurrent control
16. Berkley et al. 2010181 Not RCT/cohort with concurrent control
17. Biddiss et al. 2009182 Not RCT/cohort with concurrent control
18. Bocchi et al. 2008183 Intervention included education and face-to-face (individual/group) support
19. Boehmer et al. 2009184 Not RCT/cohort with concurrent control
20. Boriani et al. 2009185 Editorial/comment
21. Boveda et al. 2009186 Not RM or STS
22. Bover et al. 2009187 Control group did not have usual care
23. Bowles and Horowitz 2008188 Intervention included home visits
24. Bowles et al. 2009189 Intervention included home visits
25. Boxer et al. 2010190 Insufficient information for inclusion (e.g. population, intervention, 
comparator, outcomes)
26. Boyne et al. 2009191 Discharge/intervention received > 28 days (TEHAF)  
27. Boyne et al. 2011135 Discharge/intervention received > 28 days (TEHAF)
28. Boyne et al. 2011192 Discharge/intervention received > 28 days (TEHAF)
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Author, year Reason for exclusion
29. Boyne et al. 2011193 Discharge/intervention received > 28 days (TEHAF)
30. Boyne et al. 2011100 Discharge/intervention received > 28 days (TEHAF)
31. Brandon et al. 2009194 Pre-test and post-test study design
32. Brandon et al. 2009195 Pre-test and post-test study design
33. Braunschweig et al. 2008196 Not RM for HF – paper states that there was no transfer of physiological 
data via technology (DOT-HF)
34. Broesch and Heywood 2009197 Not RCT/cohort with concurrent control
35. Brotons et al. 2009198 Foreign language
36. Burri et al. 2010199 Ongoing study (MORE-CARE)
37. Cardozo et al. 2010200 Intervention included home visits
38. Carson and Bella 2009201 Not RCT/cohort with concurrent control
39. Catanzariti et al. 2009202 Not TM or STS
40. Chen et al. 2010203 Not RCT/cohort with concurrent control
41. Clark et al. 200759 Systematic review and meta-analysis
42. Clark et al. 2010204 Systematic review and meta-analysis (abstract)
43. Cleland et al. 2011205 Discharge/intervention received > 28 days (TEHAF)
44. Conraads et al. 2011115 Discharge/intervention received > 28 days (cohort study) (SENSE-HF) 
45. Copeland et al. 2010206 Intervention included education and behaviour change
46. Cowie 2010207 Editorial/comment
47. Cowie et al. 2009208 Discharge/intervention received > 28 days (cohort study) (SENSE-HF) 
48. Crawford and Volkman 2010209 Not RCT/cohort with concurrent control
49. Crossley et al. 2008210 Not RM for HF – RM of arrhythmias (CONNECT)
50. Crossley et al. 2009211 Population not specific to HF (no useable data)
51. Crossley et al. 2011212 Not RM for HF – RM of arrhythmias (CONNECT)
52. Dansky et al. 2008213 Intervention included home visits
53. Dansky et al. 2008214 Not available
54. Dansky et al. 2009215 Intervention initiated after formal home care and not hospital discharge 
55. Dar et al. 2008216 Abstract (full text included) (Home-HF)
56. De Vries et al. 2010217 Ongoing study (IN TOUCH)
57. Delaney and Apostolidis 2010218 Pre-test and post-test study design
58. Desai et al. 2010219 Editorial/comment
59. Domingo et al. 2011220 Intervention included education (CARME)
60. Domingo et al. 2011221 Intervention included education (CARME)
61. Duffy et al. 2010222 Intervention included home visits
62. Ewald et al. 2009223 Not RCT/cohort with concurrent control
63. Ewald et al. 2009224 Not RCT/cohort with concurrent control
64. Fan et al. 2010225 Not available
65. Ferrante et al. 2010226 Discharge/intervention received > 28 days (extension study of the DIAL trial)
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Author, year Reason for exclusion
66. Finkelstein and Dennison 2010227 Not RCT/cohort with concurrent control
67. Finkelstein et al. 2010228 Not RCT/cohort with concurrent control
68. Fursse et al. 2008229 Not RCT/cohort with concurrent control
69. Germany et al. 2009230 Not RCT/cohort with concurrent control
70. Goernig et al. 2009231 Foreign language
71. Goernig et al. 2009232 Insufficient information on population, intervention, comparator or 
outcomes for inclusion
72. Gonzalez et al. 2010233 Intervention included education
73. Haddour 2008234 Foreign language (intervention included clinic and home visits)
74. Hannah et al. 2010235 Not RCT/cohort with concurrent control
75. HAYES Inc. 2008236 Not available
76. Holden et al. 2011237 Insufficient information on population, intervention, comparator or 
outcomes for inclusion
77. Houston-Feenstra et al. 2008238 Not TM or STS
78. Howlett et al. 2011239 Insufficient information on population, intervention, comparator or 
outcomes for inclusion
79. Inglis et al. 201048 Systematic review and meta-analysis
80. Jacobs 2011240 Not TM or STS
81. Kashem et al. 2008152 Web-based intervention
82. Katra et al. 2010241 Not RCT/cohort with concurrent control
83. Klersy et al. 200958 Systematic review and meta-analysis
84. Knotter et al. 2010242 Not RCT/cohort with concurrent control
85. Koehler et al. 2010243 Discharge > 28 days (TIM-HF)
86. Koehler et al. 201152 Discharge > 28 days (TIM-HF)
87. Konstam et al. 2011244 Intervention included home visits
88. Kraai et al. 2010245 Ongoing study (IN TOUCH)
89. Kriegeskorte 2008246 Foreign language (editorial/comment)
90. Kulshreshtha et al. 2008247 Abstract (full text included)
91. Kurtz et al. 2011248 Not RCT/cohort with concurrent control
92. LaFramboise et al. 2009249 Not RCT/cohort with concurrent control
93. Mainardi et al. 2010250 Foreign language
94. Margolis et al. 2010251 Population not specific to HF (no useable data)
95. Margolis et al. 2010252 Population not specific to HF (no useable data)
96. Maric et al. 2010253 Web-based intervention
97. Masella et al. 2008254 Not RCT/cohort with concurrent control
98. McEntee et al. 2010255 Not RCT/cohort with concurrent control
99. Melillo et al. 2009256 Review article
100. Merchant et al. 2010257 Review article
101. Meriggi et al. 2009258 Not RCT/cohort with concurrent control
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102. Metten et al. 2011259 Discharge/intervention received > 28 days (cohort study)
103. Morguet et al. 2008260 Population not specific to HF (no useable data)
104. Mullens et al. 2008261 Not RCT/cohort with concurrent control
105. Naccarella et al. 2008262 Editorial/comment
106. Nathani et al. 2010263 Insufficient information on population, intervention, comparator or 
outcomes for inclusion
107. Nikus et al. 2009264 Not RCT/cohort with concurrent control
108. Oliveira et al. 2009265 Not RCT/cohort with concurrent control
109. Paget et al. 2010266 Not RCT/cohort with concurrent control
110. Perl et al. 2011267 Insufficient information on population, intervention, comparator or 
outcomes for inclusion
111. Persson et al. 2011268 Insufficient information on population, intervention, comparator or 
outcomes for inclusion
112. Ramaekers et al. 2009269 Discharge/intervention received > 28 days (TEHAF)
113. Raval et al. 2011270 Patients discharged within the previous 12 months for HF but TM 
intervention performed < 28 days after being implanted with a 
cardiovascular monitoring device (CHAMPION)
114. Ricci et al. 2008271 Not RCT/cohort with concurrent control
115. Riley 2011272 Review article
116. Riley and Cowie 200915 Review article
117. Riley et al. 2008273 Abstract (full text included) (Home-HF)
118. Riley et al. 2009274 Abstract (full text included) (Home-HF)
119. Rosa 2008275 Review article
120. Rosati 2009276 Insufficient information on population, intervention, comparator or 
outcomes for inclusion
121. Santamore and Homko 2008277 Review article
122. Scalvini et al. 2010278 Not RCT/cohort with concurrent control
123. Schwarz et al. 2008156 Intervention involved caregivers as well as the patient with HF
124. Schweinzer 2009279 Not available
125. Seibert et al. 2008280 Not RCT/cohort with concurrent control
126. Seto et al. 2011281 Insufficient information on population, intervention, comparator or 
outcomes for inclusion
127. Smith et al. 2011282 Insufficient information on population, intervention, comparator or 
outcomes for inclusion
128. Sonntag et al. 2010283 Not RCT/cohort with concurrent control
129. Sprenger and Oeff 2009284 Not RCT/cohort with concurrent control
130. Stevenson 2010285 Editorial/comment
131. Stewart et al. 2010286 Not TM or STS
132. Stork et al. 2009287 Foreign language (review article)
133. Strobeck et al. 2008288 Review article
134. Takahashi et al. 2010289 Population not specific to HF (no useable data)
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Author, year Reason for exclusion
135. Talukder and Pray 2009290 Review article
136. Tang et al. 2010291 Ongoing study (OptiVol® Care Pathway study)
137. Tang et al. 2010292 Not TM or STS
138. Taylor 2008293 Not RCT/cohort with concurrent control
139. Thompson 2008294 Editorial/comment
140. Tompkins and Orwat 2010295 Intervention included education and intensive care management
141. Trembath et al. 2009296 Not RCT/cohort with concurrent control
142. van Veldhuisen et al. 2011297 Not RM for HF – paper states that there was no transfer of physiological 
data via technology (DOT-HF trial)
143. Vanderheyden et al. 2010298 Not RCT/cohort with concurrent control
144. Varma et al. 2011299 Not RM for HF – RM of arrhythmias (TRUST)
145. Varma et al. 2010300 Not RM for HF – RM of arrhythmias (TRUST)
146. Vercauteren et al. 2009301 Not RCT/cohort with concurrent control
147. Wade et al. 2011101 Discharge/intervention received > 28 days
148. Weintraub et al. 2010302 Intervention included home visits
149. Wexler 2010303 Editorial/comment
150. Whellan et al. 2010304 Not RCT/cohort with concurrent control
151. Wootton et al. 2009305 Intervention included education and face-to-face support
152. Zile et al. 2008306 Patients discharged within the previous 12 months for HF but TM 
intervention performed < 28 days after being implanted with a 
cardiovascular monitoring device (subgroup analysis of the COMPASS-HF 
trial)
153. Zucca et al. 2010307 Insufficient information on population, intervention, comparator or 
outcomes for inclusion
CARME, CAtalan Remote Management Evaluation; CHAMPION, CardioMEMS Heart Sensor Allows Monitoring of 
Pressure to Improve Outcomes in NYHA Class III Patients; COMPASS-HF, Chronicle Offers Management to Patients with 
Advanced Signs and Symptoms of Heart Failure; CONNECT, Clinical Evaluation of Remote Notification to Reduce Time to 
Clinical Decision; DIAL, Randomized Trial of Telephone Intervention in Chronic Heart Failure; DOT-HF, Diagnostic Outcome 
Trial in Heart Failure; IN-TIME, the INfluence of home monitoring on The clinIcal Management of heart failurE patients 
with impaired left ventricular function; IN TOUCH, INnovative ICT guided disease management and Telemonitoring in 
OUtpatient clinics for Chronic Heart failure patients; MORE-CARE, MOnitoring Resynchronization dEvices and CARdiac 
patiEnts; REDUCEhf, Reducing Decompensation Events Utilizing Intracardiac Pressures in Patients With Chronic Heart 
Failure; SENSE-HF, Sensitivity of the InSync Sentry OptiVol Feature for the Prediction of HF; TEHAF, Tailored Telemonitoring 
in Patients with Heart Failure; TRUST, Lumos-T Safely Reduces Routine Office Device Follow-up.
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Appendix 7 Summary of the trials included in 
the base-case network meta-analysis of recently 
discharged patients with heart failure
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Appendix 8 Additional analyses: summary of the 
design and patient characteristics of included studies 
of stable patients with heart failure
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Appendix 9 Summary of the trials included in 
the base-case network meta-analysis of patients with 
stable heart failure
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Appendix 10 MEDLINE search strategy for the 
cost-effectiveness review
1. exp Heart Failure/
2. ((heart or cardiac) adj failure).tw.
3. 1 or 2
4. exp Telecommunications/
5. Telemetry/
6. (telemetr$ or telemed$ or tele-med$ or telehealth$ or tele-health$ or telecare or tele-care or 
telecardiol$ or tele-cardiol$ or telehome or tele-home).tw.
7. (telemonitor$ or tele-monit$ or teleconsult$ or tele-consult$ or teleconferenc$ or tele-conferenc$ or 
telecommunicat$ or tele-communicat$).tw.
8. (telephon$ or phone$).tw.
9. Remote consultation/
10. (remote$ adj3 (consult$ or monitor$)).tw.
11. remote patient monitoring.tw.
12. Monitoring, Ambulatory/
13. ((implantable or wearable) and (monitor$ or system$ or sensor$)).tw.
14. Patient Care Planning/
15. Case Management/
16. disease management/
17. disease management.tw.
18. exp Comprehensive Health Care/
19. Home Care Services/
20. Home Care Services, Hospital-Based/
21. Clinical Protocols/
22. Nurse Clinicians/
23. Nurse Practitioners/
24. (nurse adj led).tw.
25. or/4-24
26. 3 and 25
27. exp “costs and cost analysis”/
28. economics/
29. exp economics, hospital/
30. exp economics, medical/
31. economics, nursing/
32. exp models, economic/
33. economics, pharmaceutical/
34. exp “fees and charges”/
35. exp budgets/
36. budget$.tw
37. ec.fs
38. cost$.ti
39. (cost$ adj2 (effective$ or utilit$ or benefit$ or minimi$)).ab
40. (economic$ or pharmacoeconomic$ or pharmaco-economic$).ti
41. (price$ or pricing$).tw
42. (financial or finance or finances or financed).tw
43. (fee or fees).tw
44. (value adj2 (money or monetary)).tw
45. quality-adjusted life years/
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46. (qaly or qalys).af.
47. (quality adjusted life year or quality adjusted life years).af.
48. or/27-48
49. 26 and 48
Quality-of-life filter in MEDLINE
1. “Quality of Life”/
2. (qol or (quality adj2 life)).ab,ti.
3. (value adj2 (money or monetary)).tw.
4. value of life/
5. quality adjusted life year/
6. quality adjusted life.tw.
7. (qaly$ or qald$ or qale$ or qtime$).tw.
8. disability adjusted life.tw.
9. daly$.tw.
10. health status indicators/
11. (sf36 or sf 36 or short form 36 or shortform 36 or sf thirtysix or sf thirty six or shorform thirtysix or 
shortform thirty six or short form thirtysix or short form thirty six).tw.
12. (sf 6 or sf6 or short form 6 or shortform 6 or sf six or sfsix or shortform six or short form six).tw.
13. (sf12 or sf 12 or short form 12 or shortform 12 or sf twelve or sftwelve or shortform twelve or short 
form twelve).tw.
14. (sf16 or sf 16 or short form 16 or shortform 16 or sf sixteen or sfsixteen or shortfrom sixteen or short 
form sixteen).tw.
15. (sf20 or sf 20 or short form 20 or shortform 20 or sf twenty or sftwenty or shortform twenty or short 
form twenty).tw.
16. (euroqol or euro qol or eq5d or eq 5d).tw.
17. (hql or hqol or h qol or hrqol or hr qol).tw.
18. (hye or hyes).tw.
19. health$ year$ equivalent$.tw.
20. health utilit$.tw.
21. (hui or hui1 or hui2 or hui3).tw.
22. disutilit$.tw.
23. rosser.tw.
24. (quality adj2 wellbeing).tw.
25. qwb.tw.
26. (willingness adj2 pay).tw.
27. standard gamble$.tw.
28. time trade off.tw.
29. time tradeoff.tw.
30. tto.tw.
31. letter.pt.
32. editorial.pt.
33. comment.pt.
34. 31 or 32 or 33
35. or/1-30
36. 35 not 34
37. 36 and 26 above
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Appendix 11 Table of excluded cost-effectiveness 
studies
Author, year Reason for exclusion
1. Almond et al. 2011308 Budget impact analysis, not a cost-effectiveness analysis
2. Barth 200172 Not a cost-effectiveness study
3. Benatar et al. 2003309 Trial-based analysis
4. Berg et al. 2004310 Trial-based cost analysis
5. Chan et al. 2008311 Not RM
6. Davalos et al. 2009312 Not a cost-effectiveness study
7. Eapen et al. 2011313 Not RM
8. Gregory et al. 2006314 Not RM
9. Herbert et al. 2008125 Cost evaluation
10. Perl et al. 2011267 Cost evaluation
11. Postmus et al. 2011315 Cost evaluation
12. Riegel et al. 200285 Commentary
13. Rojas et al. 2008316 Systematic review
14. Scalvini et al. 2004317 Cost evaluation
15. Scalvini et al. 2005165 Not a cost-effectiveness study
16. Seto 2008318 Not a cost-effectiveness study
17. Smith et al. 2008319 Cost evaluation
18. Soran et al. 2010320 Not a cost-effectiveness study
19. Stafylas et al. 2008321 Trial-based analysis
20. Stewart et al. 2002322 Not a cost-effectiveness study
21. Stone 2009323 Trial included home visit, trial-based cost-effectiveness analysis (not model based)
22. Van Montfort et al. 2006324 Not a cost-effectiveness study
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Appendix 12 Results for higher usual care cost 
scenarios
Economic analysis using base-case estimates 
Usual care STS HM STS HH
TM during 
office hours
Central estimates of HRs used as input 
Mortality HR 1.000 1.074 0.780 0.779
HF-related hospitalisation HR 1.000 1.045 0.778 0.966
All-cause hospitalisation HR 1.000 1.173 0.977 0.761
Treatment costs assumed per month (£) 99 119 179 175
Survival results (undiscounted)
1 year (%) 72.14 71.45 75.34 75.38
5 year (%) 33.75 33.43 35.25 35.27
Life expectancy over 30 years (years) 4.71 4.67 4.91 4.91 
Difference in life expectancy vs usual care (years) 0.00 –0.04 0.20 0.20 
Cost results (£)
Discounted cost of usual care 873 343 362 362
Discounted cost of treatment 0 632 978 957
Discounted cost of HF-related hospitalisations 4187 4169 4257 4348
Discounted cost of other hospitalisations 3800 3858 4007 3803
Total costs 8861 9001 9604 9470
Difference in costs from usual care (£)
Discounted cost of usual care 0 –530 –512 –511
Discounted cost of treatment 0 632 978 957
Discounted cost of HF-related hospitalisations 0 –19 70 161
Discounted cost of other hospitalisations 0 57 207 3
Total difference in costs 0 140 743 609
Overall cost rank (1 = lowest cost) 1 2 4 3
Discounted QALY results
QALYs with no hospitalisation decrement 2.5748 2.5509 2.6834 2.6848 
HF-related hospitalisation decrement –0.1611 –0.1604 –0.1638 –0.1673 
Total discounted QALYs 2.4137 2.3905 2.5196 2.5175 
Difference in QALYs from usual care
QALYs with no hospitalisation decrement 0.0000 –0.0239 0.1086 0.1100 
HF-related hospitalisation decrement 0.0000 0.0007 –0.0027 –0.0062 
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Usual care STS HM STS HH
TM during 
office hours
Total difference in discounted QALYs 0.0000 –0.0232 0.1059 0.1038 
Total discounted QALYs rank (1 = highest) 3 4 1 2
Probabilistic ICER vs usual care (£/QALY) Dominated 7015 5864
Probabilistic sequential ICER (£/QALY) Dominated 63,240a 5864
Uncertainty analyses using net benefit at £20,000 per QALY
Probability that strategy is most cost-effective (%) 1 18 36 44
Expected total costs from PSA (£) 8861 9001 9604 9470
Expected total QALYs from PSA 2.4137 2.3905 2.5196 2.5175
Expected net benefit from PSA (£) 39,413 38,809 40,788 40,880
Difference from usual care costs (£) 0 140 743 609
Difference from usual care QALYs 0.0000 –0.0232 0.1059 0.1038 
Difference from usual care net benefit (£) 0 –603.90 1375 1467
Net benefit rank (1 = highest) 3 4 2 1
Overall EVPI per patient at ICER of £20,000 per 
QALY (£)
820
Population EVPI (£) 44,918,530
a Last strategy in the cost-effectiveness frontier.
Economic analysis using data from predictive distributions 
Usual care STS HM STS HH
TM during 
office hours
Central estimates of HRs used as input 
Mortality HR 1.000 1.180 0.849 0.843
HF-related hospitalisation HR 1.000 1.063 0.790 0.982
All-cause hospitalisation HR 1.000 1.302 1.074 0.835
Treatment costs assumed per month (£) 99 119 179 175
Survival results (undiscounted)
1 year (%) 72.14 70.61 74.58 74.66
5 years (%) 33.75 33.04 34.89 34.93
Life expectancy over 30 years (years) 4.710 4.614 4.862 4.867 
Difference in life expectancy vs usual care (years) – –0.100 0.151 0.157 
Cost results (£)
Discounted cost of usual care 873 339 358 359
Discounted cost of treatment 0 627 972 951
Discounted cost of HF-related hospitalisations 4187 4130 4221 4316
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Usual care STS HM STS HH
TM during 
office hours
Discounted cost of other hospitalisations 3800 3869 4023 3811
Total costs 8861 8965 9574 9437
Difference in costs from usual care (£)
Discounted cost of usual care 0 –534 –515 –515
Discounted cost of treatment 0 627 972 951
Discounted cost of HF-related hospitalisations 0 –57 33 129
Discounted cost of other hospitalisations 0 69 223 11
Total difference in costs 0 104 713 576
Overall cost rank (1 = lowest cost) 1 2 4 3
Discounted QALY results
QALYs with no hospitalisation decrement 2.5748 2.5223 2.6575 2.6605 
HF-related hospitalisation decrement –0.1611 –0.1589 –0.1624 –0.1661 
Total discounted QALYs 2.4137 2.3633 2.4950 2.4944 
Difference in QALYs from usual care
QALYs with no hospitalisation decrement 0.0000 –0.0525 0.0827 0.0857 
HF-related hospitalisation decrement 0.0000 0.0022 –0.0013 –0.0050 
Total difference in discounted QALYs 0.0000 –0.0504 0.0814 0.0808 
Total discounted QALYs rank (1 = highest) 3 4 1 2
Probabilistic ICER vs usual care (£/QALY) Dominated 8768 7133
Probabilistic sequential ICER (£/QALY) Dominated 228,035a 7133
Uncertainty analyses using net benefit at 
£20,000 per QALY
Probability that strategy is most cost-effective (%) 4 19 35 41
Expected total costs from PSA (£) 8861 8965 9574 9437
Expected total QALYs from PSA 2.4137 2.3633 2.4950 2.4944
Expected net benefit from PSA (£) 39,413 38,301 40,327 40,452
Difference from usual care costs (£) 0 104 713 576
Difference from usual care QALYs 0.0000 –0.0504 0.0814 0.0808 
Difference from usual care net benefit (£) 0 –1111.22 914 1039
Net benefit rank (1 = highest) 3 4 2 1
Overall EVPI per patient at ICER of £20,000 per 
QALY (£)
1811
Population EVPI (£) 99,204,217
a Last strategy in the cost-effectiveness frontier.
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Economic analysis using data excluding the Home-HF study67 
Usual care STS HM STS HH
TM during 
office hours
Central estimates of HRs used as input 
Mortality HR 1.000 1.007 0.757 0.627
HF-related hospitalisation HR 1.000 1.042 0.766 0.872
All-cause hospitalisation HR 1.000 1.134 0.969 0.678
Treatment costs assumed per month (£) 99 119 179 175
Survival results (undiscounted)
1 year (%) 72.14 72.14 75.67 77.63
5 years (%) 33.75 33.75 35.40 36.32
Life expectancy over 30 years (years) 4.710 4.710 4.930 5.052 
Difference in life expectancy vs usual care (years) – –0.0003 0.2200 0.3420
Cost results (£)
Discounted cost of usual care 873 346 363 373
Discounted cost of treatment 0 635 981 972
Discounted cost of HF-related hospitalisations 4187 4206 4269 4426
Discounted cost of other hospitalisations 3800 3873 4021 3879
Total costs 8861 9060 9635 9650
Difference in costs from usual care (£)
Discounted cost of usual care 0 –527 –510 –501
Discounted cost of treatment 0 635 981 972
Discounted cost of HF-related hospitalisations 0 18 82 239
Discounted cost of other hospitalisations 0 73 221 79
Total difference in costs 0 199 774 789
Overall cost rank (1 = lowest cost) 1 2 3 4
Discounted QALY results
QALYs with no hospitalisation decrement 2.5748 2.5747 2.6949 2.7612 
HF-related hospitalisation decrement –0.1611 –0.1619 –0.1643 –0.1703 
Total discounted QALYs 2.4137 2.4128 2.5306 2.5908 
Difference in QALYs from usual care
QALYs with no hospitalisation decrement 0.0000 –0.0002 0.1200 0.1864 
HF-related hospitalisation decrement 0.0000 –0.0007 –0.0032 –0.0092 
Total difference in discounted QALYs 0.0000 –0.0009 0.1169 0.1772 
Total discounted QALYs rank (1 = highest) 3 4 2 1
Probabilistic ICER vs usual care (£/QALY) Dominated 6621 4455
Probabilistic sequential ICER (£/QALY) Dominated Extendedly 
dominated
4455a
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Usual care STS HM STS HH
TM during 
office hours
Uncertainty analyses using net benefit at £20,000 per QALY
Probability that strategy is most cost-effective (%) 0 5 12 83
Expected total costs from PSA (£) 8861 9060 9635 9650
Expected total QALYs from PSA 2.4137 2.4128 2.5306 2.5908
Expected net benefit from PSA (£) 39,413 39,196 40,976 42,167
Difference from usual care costs (£) 0 199 774 789
Difference from usual care QALYs 0.0000 –0.0009 0.1169 0.1772 
Difference from usual care net benefit (£) 0 –216.70 1564 2754
Net benefit rank (1 = highest) 3 4 2 1
Overall EVPI per patient at ICER of £20,000 per 
QALY (£)
133
Population EVPI (£) 7,285,566
a Last strategy in the cost-effectiveness frontier.
Economic analysis using data from predictive distributions 
excluding the Home-HF study67 
Usual care STS HM STS HH
TM during 
office hours
Central estimates of HRs used as input 
Mortality HR 1.000 1.032 0.776 0.642
HF-related hospitalisation HR 1.000 1.058 0.778 0.883
All-cause hospitalisation HR 1.000 1.235 1.048 0.731
Treatment costs assumed per month (£) 99 119 179 175
Survival results (undiscounted)
1 year (%) 72.14 71.89 75.44 77.44
5 years (%) 33.75 33.63 35.30 36.23
Life expectancy over 30 years (years) 4.71 4.69 4.92 5.04 
Difference in life expectancy vs usual care (years) 0.00 –0.02 0.21 0.33 
Cost results (£)
Discounted cost of usual care 873 345 362 372
Discounted cost of treatment 0 634 979 971
Discounted cost of HF-related hospitalisations 4187 4200 4262 4422
Discounted cost of other hospitalisations 3800 3909 4055 3901
Total costs 8861 9087 9658 9665
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Usual care STS HM STS HH
TM during 
office hours
Difference in costs from usual care (£)
Discounted cost of usual care 0 –528 –511 –502
Discounted cost of treatment 0 634 979 971
Discounted cost of HF-related hospitalisations 0 12 75 234
Discounted cost of other hospitalisations 0 108 255 101
Total difference in costs 0 226 797 804
Overall cost rank (1 = lowest cost) 1 2 3 4
Discounted QALY results
QALYs with no hospitalisation decrement 2.5748 2.5659 2.6870 2.7548 
HF-related hospitalisation decrement –0.1611 –0.1616 –0.1640 –0.1701 
Total discounted QALYs 2.4137 2.4043 2.5230 2.5847 
Difference in QALYs from usual care
QALYs with no hospitalisation decrement 0.0000 –0.0089 0.1122 0.1800 
HF-related hospitalisation decrement 0.0000 –0.0004 –0.0029 –0.0090 
Total difference in discounted QALYs 0.0000 –0.0093 0.1093 0.1710 
Total discounted QALYs rank (1 = highest) 3 4 2 1
Probabilistic ICER vs usual care (£/QALY) Dominated 7295 4703
Probabilistic sequential ICER (£/QALY) Dominated Extendedly 
dominated
4703a
Uncertainty analyses using net benefit at £20,000 per QALY
Probability that strategy is most cost-effective (%) 1 7 19 73
Expected total costs from PSA (£) 8861 9087 9658 9665
Expected total QALYs from PSA 2.4137 2.4043 2.5230 2.5847
Expected net benefit from PSA (£) 39,413 39,000 40,801 42,029
Difference from usual care costs (£) 0 226 797 804
Difference from usual care QALYs 0.0000 –0.0093 0.1093 0.1710 
Difference from usual care net benefit (£) 0 –412.88 1389 2616
Net benefit rank (1 = highest) 3 4 2 1
Overall EVPI per patient at ICER of £20,000 per 
QALY (£)
406
Population EVPI (£) 22,240,150
a Last strategy in the cost-effectiveness frontier.
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Appendix 13 Results for lower-cost 
telemonitoring during office hours scenarios
Economic analysis using base-case estimates
Usual care STS HM STS HH
TM during 
office hours
Central estimates of HRs used as input 
Mortality HR 1.000 1.074 0.780 0.779
HF-related hospitalisation HR 1.000 1.045 0.778 0.966
All-cause hospitalisation HR 1.000 1.173 0.977 0.761
Treatment costs assumed per month (£) 27 119 179 175
Survival results (undiscounted)
1 year (%) 72.14 71.45 75.34 75.38
5 years (%) 33.75 33.43 35.25 35.27
Life expectancy over 30 years (years) 4.71 4.67 4.91 4.91 
Difference in life expectancy vs usual care (years) 0.00 –0.04 0.20 0.20 
Cost results (£)
Discounted cost of usual care 491 343 362 362
Discounted cost of treatment 0 632 978 730
Discounted cost of HF-related hospitalisations 4187 4169 4257 4348
Discounted cost of other hospitalisations 3800 3858 4007 3803
Total costs 8478 9001 9604 9243
Difference in costs from usual care (£)
Discounted cost of usual care 0 –148 –129 –129
Discounted cost of treatment 0 632 978 730
Discounted cost of HF-related hospitalisations 0 –19 70 161
Discounted cost of other hospitalisations 0 57 207 3
Total difference in costs 0 523 1126 765
Overall cost rank (1 = lowest cost) 1 2 4 3
Discounted QALY results
QALYs with no hospitalisation decrement 2.5748 2.5509 2.6834 2.6848 
HF-related hospitalisation decrement –0.1611 –0.1604 –0.1638 –0.1673 
Total discounted QALYs 2.4137 2.3905 2.5196 2.5175 
Difference in QALYs from usual care
QALYs with no hospitalisation decrement 0.0000 –0.0239 0.1086 0.1100 
HF-related hospitalisation decrement 0.0000 0.0007 –0.0027 –0.0062 
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Usual care STS HM STS HH
TM during 
office hours
Total difference in discounted QALYs 0.0000 –0.0232 0.1059 0.1038 
Total discounted QALYs rank (1 = highest) 3 4 1 2
Probabilistic ICER vs usual care (£/QALY) Dominated 10,629 7367
Probabilistic sequential ICER (£/QALY) Dominated 170,629a 7367
Uncertainty analyses using net benefit at £20,000 per QALY
Probability that strategy is most cost-effective (%) 2 17 31 50
Expected total costs from PSA (£) 8478 9001 9604 9243
Expected total QALYs from PSA 2.4137 2.3905 2.5196 2.5175
Expected net benefit from PSA (£) 39,795 38,809 40,788 41,107
Difference from usual care costs (£) 0 523 1126 765
Difference from usual care QALYs 0.0000 –0.0232 0.1059 0.1038 
Difference from usual care net benefit (£) 0 –986.75 993 1311
Net benefit rank (1 = highest) 3 4 2 1
Overall EVPI per patient at ICER of £20,000 per 
QALY (£)
707
Population EVPI (£) 38,728,537
a Last strategy in the cost-effectiveness frontier.
Economic analysis using data from predictive distributions 
Usual care STS HM STS HH
TM during 
office hours
Central estimates of HRs used as input 
Mortality HR 1.000 1.180 0.849 0.843
HF-related hospitalisation HR 1.000 1.063 0.790 0.982
All-cause hospitalisation HR 1.000 1.302 1.074 0.835
Treatment costs assumed per month (£) 27 119 179 175
Survival results (undiscounted)
1 year (%) 72.14 70.61 74.58 74.66
5 years (%) 33.75 33.04 34.89 34.93
Life expectancy over 30 years (years) 4.710 4.614 4.862 4.867 
Difference in life expectancy vs usual care (years) – –0.100 0.151 0.157 
Cost results (£)
Discounted cost of usual care 491 339 358 359
Discounted cost of treatment 0 627 972 726
Discounted cost of HF-related hospitalisations 4187 4130 4221 4316
Discounted cost of other hospitalisations 3800 3869 4023 3811
Total costs 8478 8965 9574 9211
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Usual care STS HM STS HH
TM during 
office hours
Difference in costs from usual care (£)
Discounted cost of usual care 0 –152 –132 –132
Discounted cost of treatment 0 627 972 726
Discounted cost of HF-related hospitalisations 0 –57 33 129
Discounted cost of other hospitalisations 0 69 223 11
Total difference in costs 0 487 1096 733
Overall cost rank (1 = lowest cost) 1 2 4 3
Discounted QALY results
QALYs with no hospitalisation decrement 2.5748 2.5223 2.6575 2.6605 
HF-related hospitalisation decrement –0.1611 –0.1589 –0.1624 –0.1661 
Total discounted QALYs 2.4137 2.3633 2.4950 2.4944 
Difference in QALYs from usual care
QALYs with no hospitalisation decrement 0.0000 –0.0525 0.0827 0.0857 
HF-related hospitalisation decrement 0.0000 0.0022 –0.0013 –0.0050 
Total difference in discounted QALYs 0.0000 –0.0504 0.0814 0.0808 
Total discounted QALYs rank (1 = highest) 3 4 1 2
Probabilistic ICER vs usual care (£/QALY) Dominated 13,473 9080
Probabilistic sequential ICER (£/QALY) Dominated 605,112a 9080
Uncertainty analyses using net benefit at £20,000 per QALY
Probability that strategy is most cost-effective (%) 6 18 33 44
Expected total costs from PSA (£) 8478 8965 9574 9211
Expected total QALYs from PSA 2.4137 2.3633 2.4950 2.4944
Expected net benefit from PSA (£) 39,795 38,301 40,327 40,677
Difference from usual care costs (£) 0 487 1096 733
Difference from usual care QALYs 0.0000 –0.0504 0.0814 0.0808 
Difference from usual care net benefit (£) 0 –1494.07 531 882
Net benefit rank (1 = highest) 3 4 2 1
Overall EVPI per patient at ICER of £20,000 per 
QALY (£)
1702
Population EVPI (£) 93,233,339
a Last strategy in the cost-effectiveness frontier.
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Economic analysis using data excluding the Home-HF study67
Usual care STS HM STS HH
TM during 
office hours
Central estimates of HRs used as input 
Mortality HR 1.000 1.007 0.757 0.627
HF-related hospitalisation HR 1.000 1.042 0.766 0.872
All-cause hospitalisation HR 1.000 1.134 0.969 0.678
Treatment costs assumed per month (£) 27 119 179 175
Survival results (undiscounted)
1 year (%) 72.14 72.14 75.67 77.63
5 years (%) 33.75 33.75 35.40 36.32
Life expectancy over 30 years (years) 4.710 4.710 4.930 5.052 
Difference in life expectancy vs usual care (years) – –0.0003 0.2200 0.3420
Cost results (£)
Discounted cost of usual care 491 346 363 373
Discounted cost of treatment 0 635 981 742
Discounted cost of HF-related hospitalisations 4187 4206 4269 4426
Discounted cost of other hospitalisations 3800 3873 4021 3879
Total costs 8478 9060 9635 9420
Difference in costs from usual care (£)
Discounted cost of usual care 0 –144 –127 –118
Discounted cost of treatment 0 635 981 742
Discounted cost of HF-related hospitalisations 0 18 82 239
Discounted cost of other hospitalisations 0 73 221 79
Total difference in costs 0 582 1157 942
Overall cost rank (1 = lowest cost) 1 2 4 3
Discounted QALY results
QALYs with no hospitalisation decrement 2.5748 2.5747 2.6949 2.7612 
HF-related hospitalisation decrement –0.1611 –0.1619 –0.1643 –0.1703 
Total discounted QALYs 2.4137 2.4128 2.5306 2.5908 
Difference in QALYs from usual care
QALYs with no hospitalisation decrement 0.0000 –0.0002 0.1200 0.1864 
HF-related hospitalisation decrement 0.0000 –0.0007 –0.0032 –0.0092 
Total difference in discounted QALYs 0.0000 –0.0009 0.1169 0.1772 
Total discounted QALYs rank (1 = highest) 3 4 2 1
Probabilistic ICER vs usual care (£/QALY) Dominated 9897 5315
Probabilistic sequential ICER (£/QALY) Dominated Extendedly 
dominated
5315a
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Usual care STS HM STS HH
TM during 
office hours
Uncertainty analyses using net benefit at £20,000 per QALY
Probability that strategy is most cost-effective (%) 0 4 9 87
Expected total costs from PSA (£) 8478 9060 9635 9420
Expected total QALYs from PSA 2.4137 2.4128 2.5306 2.5908
Expected net benefit from PSA (£) 39,795 39,196 40,976 42,397
Difference from usual care costs (£) 0 582 1157 942
Difference from usual care QALYs 0.0000 –0.0009 0.1169 0.1772 
Difference from usual care net benefit (£) 0 –599.54 1181 2602
Net benefit rank (1 = highest) 3 4 2 1
Overall EVPI per patient at ICER of £20,000 per 
QALY (£)
100
Population EVPI (£) 5,477,869
a Last strategy in the cost-effectiveness frontier.
Economic analysis using data from predictive distributions 
excluding the Home-HF study67 
Usual care STS HM STS HH
TM during 
office hours
Central estimates of HRs used as input 
Mortality HR 1.000 1.032 0.776 0.642
HF-related hospitalisation HR 1.000 1.058 0.778 0.883
All-cause hospitalisation HR 1.000 1.235 1.048 0.731
Treatment costs assumed per month (£) 27 119 179 175
Survival results (undiscounted)
1 year (%) 72.14 71.89 75.44 77.44
5 years (%) 33.75 33.63 35.30 36.23
Life expectancy over 30 years (years) 4.71 4.69 4.92 5.04 
Difference in life expectancy vs usual care (years) 0.00 –0.02 0.21 0.33 
Cost results (£)
Discounted cost of usual care 491 345 362 372
Discounted cost of treatment 0 634 979 741
Discounted cost of HF-related hospitalisations 4187 4200 4262 4422
Discounted cost of other hospitalisations 3800 3909 4055 3901
Total costs 8478 9087 9658 9435
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Usual care STS HM STS HH
TM during 
office hours
Difference in costs from usual care (£)
Discounted cost of usual care 0 –145 –128 –119
Discounted cost of treatment 0 634 979 741
Discounted cost of HF-related hospitalisations 0 12 75 234
Discounted cost of other hospitalisations 0 108 255 101
Total difference in costs 0 609 1180 957
Overall cost rank (1 = lowest cost) 1 2 4 3
Discounted QALY results
QALYs with no hospitalisation decrement 2.5748 2.5659 2.6870 2.7548 
HF-related hospitalisation decrement –0.1611 –0.1616 –0.1640 –0.1701 
Total discounted QALYs 2.4137 2.4043 2.5230 2.5847 
Difference in QALYs from usual care
QALYs with no hospitalisation decrement 0.0000 –0.0089 0.1122 0.1800 
HF-related hospitalisation decrement 0.0000 –0.0004 –0.0029 –0.0090 
Total difference in discounted QALYs 0.0000 –0.0093 0.1093 0.1710 
Total discounted QALYs rank (1 = highest) 3 4 2 1
Probabilistic ICER vs usual care (£/QALY) Dominated 10,798 5595
Probabilistic sequential ICER (£/QALY) Dominated Extendedly 
dominated
5595a
Uncertainty analyses using net benefit at £20,000 per QALY
Probability that strategy is most cost-effective (%) 1 6 16 77
Expected total costs from PSA (£) 8478 9087 9658 9435
Expected total QALYs from PSA 2.4137 2.4043 2.5230 2.5847
Expected net benefit from PSA (£) 39,795 39,000 40,801 42,259
Difference from usual care costs (£) 0 609 1180 957
Difference from usual care QALYs 0.0000 –0.0093 0.1093 0.1710 
Difference from usual care net benefit (£) 0 –795.73 1006 2463
Net benefit rank (1 = highest) 3 4 2 1
Overall EVPI per patient at ICER of £20,000 per 
QALY (£)
353
Population EVPI (£) 19,336,879
a Last strategy in the cost-effectiveness frontier.
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Appendix 14 Results for higher-cost 
telemonitoring during office hours scenarios
Economic analysis using base-case estimates 
Usual care STS HM STS HH
TM during 
office hours
Central estimates of HRs used as input 
Mortality HR 1.000 1.074 0.780 0.779
HF-related hospitalisation HR 1.000 1.045 0.778 0.966
All-cause hospitalisation HR 1.000 1.173 0.977 0.761
Treatment costs assumed per month (£) 27 119 179 175
Survival results (undiscounted)
1 year (%) 72.14 71.45 75.34 75.38
5 years (%) 33.75 33.43 35.25 35.27
Life expectancy over 30 years (years) 4.71 4.67 4.91 4.91 
Difference in life expectancy vs usual care (years) 0.00 –0.04 0.20 0.20 
Cost results (£)
Discounted cost of usual care 491 343 362 362
Discounted cost of treatment 0 632 978 1173
Discounted cost of HF-related hospitalisations 4187 4169 4257 4348
Discounted cost of other hospitalisations 3800 3858 4007 3803
Total costs 8478 9001 9604 9686
Difference in costs from usual care (£)
Discounted cost of usual care 0 –148 –129 –129
Discounted cost of treatment 0 632 978 1173
Discounted cost of HF-related hospitalisations 0 –19 70 161
Discounted cost of other hospitalisations 0 57 207 3
Total difference in costs 0 523 1126 1207
Overall cost rank (1 = lowest cost) 1 2 3 4
Discounted QALY results
QALYs with no hospitalisation decrement 2.5748 2.5509 2.6834 2.6848 
HF-related hospitalisation decrement –0.1611 –0.1604 –0.1638 –0.1673 
Total discounted QALYs 2.4137 2.3905 2.5196 2.5175 
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Usual care STS HM STS HH
TM during 
office hours
Difference in QALYs from usual care
QALYs with no hospitalisation decrement 0.0000 –0.0239 0.1086 0.1100 
HF-related hospitalisation decrement 0.0000 0.0007 –0.0027 –0.0062 
Total difference in discounted QALYs 0.0000 –0.0232 0.1059 0.1038 
Total discounted QALYs rank (1 = highest) 3 4 1 2
Probabilistic ICER vs usual care (£/QALY) Dominated 10,629 11,633
Probabilistic sequential ICER (£/QALY) Dominated 10,629a Dominated
Uncertainty analyses using net benefit at £20,000 per QALY
Probability that strategy is most cost-effective (%) 3 19 40 38
Expected total costs from PSA (£) 8478 9001 9604 9686
Expected total QALYs from PSA 2.4137 2.3905 2.5196 2.5175
Expected net benefit from PSA (£) 39,795 38,809 40,788 40,664
Difference from usual care costs (£) 0 523 1126 1207
Difference from usual care QALYs 0.0000 –0.0232 0.1059 0.1038 
Difference from usual care net benefit (£) 0 –986.75 993 869
Net benefit rank (1 = highest) 3 4 1 2
Overall EVPI per patient at ICER of £20,000 per 
QALY (£)
829
Population EVPI (£) 45,411,538
a Last strategy in the cost-effectiveness frontier.
Economic analysis using data from predictive distributions 
Usual care STS HM STS HH
TM during 
office hours
Central estimates of HRs used as input 
Mortality HR 1.000 1.180 0.849 0.843
HF-related hospitalisation HR 1.000 1.063 0.790 0.982
All-cause hospitalisation HR 1.000 1.302 1.074 0.835
Treatment costs assumed per month (£) 27 119 179 175
Survival results (undiscounted)
1 year (%) 72.14 70.61 74.58 74.66
5 years (%) 33.75 33.04 34.89 34.93
Life expectancy over 30 years (years) 4.710 4.614 4.862 4.867 
Difference in life expectancy vs usual care (years) – –0.100 0.151 0.157 
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Usual care STS HM STS HH
TM during 
office hours
Cost results (£)
Discounted cost of usual care 491 339 358 359
Discounted cost of treatment 0 627 972 1166
Discounted cost of HF-related hospitalisations 4187 4130 4221 4316
Discounted cost of other hospitalisations 3800 3869 4023 3811
Total costs 8478 8965 9574 9652
Difference in costs from usual care (£)
Discounted cost of usual care 0 –152 –132 –132
Discounted cost of treatment 0 627 972 1166
Discounted cost of HF-related hospitalisations 0 –57 33 129
Discounted cost of other hospitalisations 0 69 223 11
Total difference in costs 0 487 1096 1174
Overall cost rank (1 = lowest cost) 1 2 3 4
Discounted QALY results
QALYs with no hospitalisation decrement 2.5748 2.5223 2.6575 2.6605 
HF-related hospitalisation decrement –0.1611 –0.1589 –0.1624 –0.1661 
Total discounted QALYs 2.4137 2.3633 2.4950 2.4944 
Difference in QALYs from usual care
QALYs with no hospitalisation decrement 0.0000 –0.0525 0.0827 0.0857 
HF-related hospitalisation decrement 0.0000 0.0022 –0.0013 –0.0050 
Total difference in discounted QALYs 0.0000 –0.0504 0.0814 0.0808 
Total discounted QALYs rank (1 = highest) 3 4 1 2
Probabilistic ICER vs usual care (£/QALY) Dominated 13,473 14,532
Probabilistic sequential ICER (£/QALY) Dominated 13,473a Dominated
Uncertainty analyses using net benefit at £20,000 per QALY
Probability that strategy is most cost-effective (%) 7 20 37 37
Expected total costs from PSA (£) 8478 8965 9574 9652
Expected total QALYs from PSA 2.4137 2.3633 2.4950 2.4944
Expected net benefit from PSA (£) 39,795 38,301 40,327 40,237
Difference from usual care costs (£) 0 487 1096 1174
Difference from usual care QALYs 0.0000 –0.0504 0.0814 0.0808 
Difference from usual care net benefit (£) 0 –1494.07 531 442
Net benefit rank (1 = highest) 3 4 1 2
Overall EVPI per patient at ICER of £20,000 per 
QALY (£)
1871
Population EVPI (£) 102,490,939
a Last strategy in the cost-effectiveness frontier.
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Economic analysis using data excluding the Home-HF study67 
Usual care STS HM STS HH
TM during 
office hours
Central estimates of HRs used as input 
Mortality HR 1.000 1.007 0.757 0.627
HF-related hospitalisation HR 1.000 1.042 0.766 0.872
All-cause hospitalisation HR 1.000 1.134 0.969 0.678
Treatment costs assumed per month (£) 27 119 179 175
Survival results (undiscounted)
1 year (%) 72.14 72.14 75.67 77.63
5 years (%) 33.75 33.75 35.40 36.32
Life expectancy over 30 years (years) 4.710 4.710 4.930 5.052 
Difference in life expectancy vs usual care (years) – –0.0003 0.2200 0.3420
Cost results (£)
Discounted cost of usual care 491 346 363 373
Discounted cost of treatment 0 635 981 1191
Discounted cost of HF-related hospitalisations 4187 4206 4269 4426
Discounted cost of other hospitalisations 3800 3873 4021 3879
Total costs 8478 9060 9635 9870
Difference in costs from usual care (£)
Discounted cost of usual care 0 –144 –127 –118
Discounted cost of treatment 0 635 981 1191
Discounted cost of HF-related hospitalisations 0 18 82 239
Discounted cost of other hospitalisations 0 73 221 79
Total difference in costs 0 582 1157 1392
Overall cost rank (1 = lowest cost) 1 2 3 4
Discounted QALY results
QALYs with no hospitalisation decrement 2.5748 2.5747 2.6949 2.7612 
HF-related hospitalisation decrement –0.1611 –0.1619 –0.1643 –0.1703 
Total discounted QALYs 2.4137 2.4128 2.5306 2.5908 
Difference in QALYs from usual care
QALYs with no hospitalisation decrement 0.0000 –0.0002 0.1200 0.1864 
HF-related hospitalisation decrement 0.0000 –0.0007 –0.0032 –0.0092 
Total difference in discounted QALYs 0.0000 –0.0009 0.1169 0.1772 
Total discounted QALYs rank (1 = highest) 3 4 2 1
Probabilistic ICER vs usual care (£/QALY) Dominated 9897 7854
Probabilistic sequential ICER (£/QALY) Dominated Extendedly 
dominated
7854a
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Usual care STS HM STS HH
TM during 
office hours
Uncertainty analyses using net benefit at £20,000 per QALY
Probability that strategy is most cost-effective (%) 0 6 16 78
Expected total costs from PSA (£) 8478 9060 9635 9870
Expected total QALYs from PSA 2.4137 2.4128 2.5306 2.5908
Expected net benefit from PSA (£) 39,795 39,196 40,976 41,947
Difference from usual care costs (£) 0 582 1157 1392
Difference from usual care QALYs 0.0000 –0.0009 0.1169 0.1772 
Difference from usual care net benefit (£) 0 –599.54 1181 2152
Net benefit rank (1 = highest) 3 4 2 1
Overall EVPI per patient at ICER of £20,000 per 
QALY (£)
175
Population EVPI (£) 9,586,271
a Last strategy in the cost-effectiveness frontier.
Economic analysis using data from predictive distributions 
excluding the Home-HF study67 
Usual care STS HM STS HH
TM during 
office hours
Central estimates of HRs used as input 
Mortality HR 1.000 1.032 0.776 0.642
HF-related hospitalisation HR 1.000 1.058 0.778 0.883
All-cause hospitalisation HR 1.000 1.235 1.048 0.731
Treatment costs assumed per month (£) 27 119 179 175
Survival results (undiscounted)
1 year (%) 72.14 71.89 75.44 77.44
5 years (%) 33.75 33.63 35.30 36.23
Life expectancy over 30 years (years) 4.71 4.69 4.92 5.04 
Difference in life expectancy vs usual care (years) 0.00 –0.02 0.21 0.33 
Cost results (£)
Discounted cost of usual care 491 345 362 372
Discounted cost of treatment 0 634 979 1190
Discounted cost of HF-related hospitalisations 4187 4200 4262 4422
Discounted cost of other hospitalisations 3800 3909 4055 3901
Total costs 8478 9087 9658 9884
Difference in costs from usual care (£)
Discounted cost of usual care 0 –145 –128 –119
Discounted cost of treatment 0 634 979 1190
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Usual care STS HM STS HH
TM during 
office hours
Discounted cost of HF-related hospitalisations 0 12 75 234
Discounted cost of other hospitalisations 0 108 255 101
Total difference in costs 0 609 1180 1406
Overall cost rank (1 = lowest cost) 1 2 3 4
Discounted QALY results
QALYs with no hospitalisation decrement 2.5748 2.5659 2.6870 2.7548 
HF-related hospitalisation decrement –0.1611 –0.1616 –0.1640 –0.1701 
Total discounted QALYs 2.4137 2.4043 2.5230 2.5847 
Difference in QALYs from usual care
QALYs with no hospitalisation decrement 0.0000 –0.0089 0.1122 0.1800 
HF-related hospitalisation decrement 0.0000 –0.0004 –0.0029 –0.0090 
Total difference in discounted QALYs 0.0000 –0.0093 0.1093 0.1710 
Total discounted QALYs rank (1 = highest) 3 4 2 1
Probabilistic ICER vs usual care (£/QALY) Dominated 10,798 8223
Probabilistic sequential ICER (£/QALY) Dominated Extendedly 
dominated
8223a
Uncertainty analyses using net benefit at £20,000 per QALY
Probability that strategy is most cost-effective (%) 1 8 23 68
Expected total costs from PSA (£) 8478 9087 9658 9884
Expected total QALYs from PSA 2.4137 2.4043 2.5230 2.5847
Expected net benefit from PSA (£) 39,795 39,000 40,801 41,809
Difference from usual care costs (£) 0 609 1180 1406
Difference from usual care QALYs 0.0000 –0.0093 0.1093 0.1710 
Difference from usual care net benefit (£) 0 –795.73 1006 2014
Net benefit rank (1 = highest) 3 4 2 1
Overall EVPI per patient at ICER of £20,000 per 
QALY (£)
473
Population EVPI (£) 25,910,322
a Last strategy in the cost-effectiveness frontier.
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Appendix 15 Results for higher-cost structured 
telephone support human-to-human contact cost 
scenarios
Economic analysis using base-case estimates 
Usual care STS HM STS HH
TM during 
office hours
Central estimates of HRs used as input 
Mortality HR 1.000 1.074 0.780 0.779
HF-related hospitalisation HR 1.000 1.045 0.778 0.966
All-cause hospitalisation HR 1.000 1.173 0.977 0.761
Treatment costs assumed per month (£) 27 119 179 175
Survival results (undiscounted)
1 year (%) 72.14 71.45 75.34 75.38
5 years (%) 33.75 33.43 35.25 35.27
Life expectancy over 30 years (years) 4.71 4.67 4.91 4.91 
Difference in life expectancy vs usual care (years) 0.00 –0.04 0.20 0.20 
Cost results (£)
Discounted cost of usual care 491 343 362 362
Discounted cost of treatment 0 632 1049 957
Discounted cost of HF-related hospitalisations 4187 4169 4257 4348
Discounted cost of other hospitalisations 3800 3858 4007 3803
Total costs 8478 9001 9675 9470
Difference in costs from usual care (£)
Discounted cost of usual care 0 –148 –129 –129
Discounted cost of treatment 0 632 1049 957
Discounted cost of HF-related hospitalisations 0 –19 70 161
Discounted cost of other hospitalisations 0 57 207 3
Total difference in costs 0 523 1197 992
Overall cost rank (1 = lowest cost) 1 2 4 3
Discounted QALY results
QALYs with no hospitalisation decrement 2.5748 2.5509 2.6834 2.6848 
HF-related hospitalisation decrement –0.1611 –0.1604 –0.1638 –0.1673 
Total discounted QALYs 2.4137 2.3905 2.5196 2.5175 
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Usual care STS HM STS HH
TM during 
office hours
Difference in QALYs from usual care
QALYs with no hospitalisation decrement 0.0000 –0.0239 0.1086 0.1100 
HF-related hospitalisation decrement 0.0000 0.0007 –0.0027 –0.0062 
Total difference in discounted QALYs 0.0000 –0.0232 0.1059 0.1038 
Total discounted QALYs rank (1 = highest) 3 4 1 2
Probabilistic ICER vs usual care (£/QALY) Dominated 11,300 9552
Probabilistic sequential ICER (£/QALY) Dominated 97,300a 9552
Uncertainty analyses using net benefit at £20,000 per QALY
Probability that strategy is most cost-effective (%) 2 19 34 46
Expected total costs from PSA (£) 8478 9001 9675 9470
Expected total QALYs from PSA 2.4137 2.3905 2.5196 2.5175
Expected net benefit from PSA (£) 39,795 38,809 40,717 40,880
Difference from usual care costs (£) 0 523 1197 992
Difference from usual care QALYs 0.0000 –0.0232 0.1059 0.1038 
Difference from usual care net benefit (£) 0 –986.75 922 1084
Net benefit rank (1 = highest) 3 4 2 1
Overall EVPI per patient at ICER of £20,000 per 
QALY (£)
801
Population EVPI (£) 43,877,735
a Last strategy in the cost-effectiveness frontier.
Economic analysis using data from predictive distributions 
Usual care STS HM STS HH
TM during 
office hours
Central estimates of HRs used as input 
Mortality HR 1.000 1.180 0.849 0.843
HF-related hospitalisation HR 1.000 1.063 0.790 0.982
All-cause hospitalisation HR 1.000 1.302 1.074 0.835
Treatment costs assumed per month (£) 27 119 179 175
Survival results (undiscounted)
1 year (%) 72.14 70.61 74.58 74.66
5 years (%) 33.75 33.04 34.89 34.93
Life expectancy over 30 years (years) 4.710 4.614 4.862 4.867 
Difference in life expectancy vs usual care (years) – –0.10 0.151 0.157 
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Usual care STS HM STS HH
TM during 
office hours
Cost results (£)
Discounted cost of usual care 491 339 358 359
Discounted cost of treatment 0 627 1043 951
Discounted cost of HF-related hospitalisations 4187 4130 4221 4316
Discounted cost of other hospitalisations 3800 3869 4023 3811
Total costs 8478 8965 9645 9437
Difference in costs from usual care (£)
Discounted cost of usual care 0 –152 –132 –132
Discounted cost of treatment 0 627 1043 951
Discounted cost of HF-related hospitalisations 0 –57 33 129
Discounted cost of other hospitalisations 0 69 223 11
Total difference in costs 0 487 1167 959
Overall cost rank (1 = lowest cost) 1 2 4 3
Discounted QALY results
QALYs with no hospitalisation decrement 2.5748 2.5223 2.6575 2.6605 
HF-related hospitalisation decrement –0.1611 –0.1589 –0.1624 –0.1661 
Total discounted QALYs 2.4137 2.3633 2.4950 2.4944 
Difference in QALYs from usual care
QALYs with no hospitalisation decrement 0.0000 –0.0525 0.0827 0.0857 
HF-related hospitalisation decrement 0.0000 0.0022 –0.0013 –0.0050 
Total difference in discounted QALYs 0.0000 –0.0504 0.0814 0.0808 
Total discounted QALYs rank (1 = highest) 3 4 1 2
Probabilistic ICER vs usual care (£/QALY) Dominated 14,341 11,873
Probabilistic sequential ICER (£/QALY) Dominated 346,341a 11,873
Uncertainty analyses using net benefit at £20,000 per QALY
Probability that strategy is most cost-effective (%) 6 19 34 41
Expected total costs from PSA (£) 8478 8965 9645 9437
Expected total QALYs from PSA 2.4137 2.3633 2.4950 2.4944
Expected net benefit from PSA (£) 39,795 38,301 40,256 40,452
Difference from usual care costs (£) 0 487 1167 959
Difference from usual care QALYs 0.0000 –0.0504 0.0814 0.0808 
Difference from usual care net benefit (£) 0 –1494.07 460 656
Net benefit rank (1 = highest) 3 4 2 1
Overall EVPI per patient at ICER of £20,000 per 
QALY (£)
1806
Population EVPI (£) 98,930,324
a Last strategy in the cost-effectiveness frontier.
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Economic analysis using data excluding the Home-HF study67
Usual care STS HM STS HH
TM during 
office hours
Central estimates of HRs used as input 
Mortality HR 1.000 1.007 0.757 0.627
HF-related hospitalisation HR 1.000 1.042 0.766 0.872
All-cause hospitalisation HR 1.000 1.134 0.969 0.678
Treatment costs assumed per month (£) 27 119 179 175
Survival results (undiscounted)
1 year (%) 72.14 72.14 75.67 77.63
5 years (%) 33.75 33.75 35.40 36.32
Life expectancy over 30 years (years) 4.710 4.710 4.930 5.052 
Difference in life expectancy vs usual care (years) – –0.0003 0.2200 0.3420
Cost results (£)
Discounted cost of usual care 491 346 363 373
Discounted cost of treatment 0 635 1052 972
Discounted cost of HF-related hospitalisations 4187 4206 4269 4426
Discounted cost of other hospitalisations 3800 3873 4021 3879
Total costs 8478 9060 9706 9650
Difference in costs from usual care (£)
Discounted cost of usual care 0 –144 –127 –118
Discounted cost of treatment 0 635 1052 972
Discounted cost of HF-related hospitalisations 0 18 82 239
Discounted cost of other hospitalisations 0 73 221 79
Total difference in costs 0 582 1228 1172
Overall cost rank (1 = lowest cost) 1 2 4 3
Discounted QALY results
QALYs with no hospitalisation decrement 2.5748 2.5747 2.6949 2.7612 
HF-related hospitalisation decrement –0.1611 –0.1619 –0.1643 –0.1703 
Total discounted QALYs 2.4137 2.4128 2.5306 2.5908 
Difference in QALYs from usual care
QALYs with no hospitalisation decrement 0.0000 –0.0002 0.1200 0.1864 
HF-related hospitalisation decrement 0.0000 –0.0007 –0.0032 –0.0092 
Total difference in discounted QALYs 0.0000 –0.0009 0.1169 0.1772 
Total discounted QALYs rank (1 = highest) 3 4 2 1
Probabilistic ICER vs usual care (£/QALY) Dominated 10,506 6616
Probabilistic sequential ICER (£/QALY) Dominated Extendedly 
dominated
6616a
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Usual care STS HM STS HH
TM during 
office hours
Uncertainty analyses using net benefit at £20,000 per QALY
Probability that strategy is most cost-effective (%) 0 5 11 84
Expected total costs from PSA (£) 8478 9060 9706 9650
Expected total QALYs from PSA 2.4137 2.4128 2.5306 2.5908
Expected net benefit from PSA (£) 39,795 39,196 40,905 42,167
Difference from usual care costs (£) 0 582 1228 1172
Difference from usual care QALYs 0.0000 –0.0009 0.1169 0.1772 
Difference from usual care net benefit (£) 0 –599.54 1110 2371
Net benefit rank (1 = highest) 3 4 2 1
Overall EVPI per patient at ICER of £20,000 per 
QALY (£)
125
Population EVPI (£) 6,847,336
a Last strategy in the cost-effectiveness frontier.
Economic analysis using data from predictive distributions 
excluding the Home-HF study67 
Usual care STS HM STS HH
TM during 
office hours
Central estimates of HRs used as input 
Mortality HR 1.000 1.032 0.776 0.642
HF-related hospitalisation HR 1.000 1.058 0.778 0.883
All-cause hospitalisation HR 1.000 1.235 1.048 0.731
Treatment costs assumed per month (£) 27 119 179 175
Survival results (undiscounted)
1 year (%) 72.14 71.89 75.44 77.44
5 years (%) 33.75 33.63 35.30 36.23
Life expectancy over 30 years (years) 4.71 4.69 4.92 5.04 
Difference in life expectancy vs usual care (years) 0.00 –0.02 0.21 0.33 
Cost results (£)
Discounted cost of usual care 491 345 362 372
Discounted cost of treatment 0 634 1050 971
Discounted cost of HF-related hospitalisations 4187 4200 4262 4422
Discounted cost of other hospitalisations 3800 3909 4055 3901
Total costs 8478 9087 9729 9665
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Usual care STS HM STS HH
TM during 
office hours
Difference in costs from usual care (£)
Discounted cost of usual care 0 –145 –128 –119
Discounted cost of treatment 0 634 1050 971
Discounted cost of HF-related hospitalisations 0 12 75 234
Discounted cost of other hospitalisations 0 108 255 101
Total difference in costs 0 609 1251 1187
Overall cost rank (1 = lowest cost) 1 2 4 3
Discounted QALY results
QALYs with no hospitalisation decrement 2.5748 2.5659 2.6870 2.7548 
HF-related hospitalisation decrement –0.1611 –0.1616 –0.1640 –0.1701 
Total discounted QALYs 2.4137 2.4043 2.5230 2.5847 
Difference in QALYs from usual care
QALYs with no hospitalisation decrement 0.0000 –0.0089 0.1122 0.1800 
HF-related hospitalisation decrement 0.0000 –0.0004 –0.0029 –0.0090 
Total difference in discounted QALYs 0.0000 –0.0093 0.1093 0.1710 
Total discounted QALYs rank (1 = highest) 3 4 2 1
Probabilistic ICER vs usual care (£/QALY) Dominated 11,449 6942
Probabilistic sequential ICER (£/QALY) Dominated Extendedly 
dominated
6942a
Uncertainty analyses using net benefit at £20,000 per QALY
Probability that strategy is most cost-effective (%) 1 7 18 74
Expected total costs from PSA (£) 8478 9087 9729 9665
Expected total QALYs from PSA 2.4137 2.4043 2.5230 2.5847
Expected net benefit from PSA (£) 39,795 39,000 40,730 42,029
Difference from usual care costs (£) 0 609 1251 1187
Difference from usual care QALYs 0.0000 –0.0093 0.1093 0.1710 
Difference from usual care net benefit (£) 0 –795.73 935 2233
Net benefit rank (1 = highest) 3 4 2 1
Overall EVPI per patient at ICER of £20,000 per 
QALY (£)
396
Population EVPI (£) 21,692,363
a Last strategy in the cost-effectiveness frontier.
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Appendix 16 Results for lower-cost structured 
telephone support human-to-human contact cost 
scenarios
Economic analysis using base-case estimates 
Usual care STS HM STS HH
TM during 
office hours
Central estimates of HRs used as input 
Mortality HR 1.000 1.074 0.780 0.779
HF-related hospitalisation HR 1.000 1.045 0.778 0.966
All-cause hospitalisation HR 1.000 1.173 0.977 0.761
Treatment costs assumed per month (£) 27 119 179 175
Survival results (undiscounted)
1 year (%) 72.14 71.45 75.34 75.38
5 years (%) 33.75 33.43 35.25 35.27
Life expectancy over 30 years (years) 4.71 4.67 4.91 4.91 
Difference in life expectancy vs usual care (years) 0.00 –0.04 0.20 0.20 
Cost results (£)
Discounted cost of usual care 491 343 362 362
Discounted cost of treatment 0 632 956 957
Discounted cost of HF-related hospitalisations 4187 4169 4257 4348
Discounted cost of other hospitalisations 3800 3858 4007 3803
Total costs 8478 9001 9582 9470
Difference in costs from usual care (£)
Discounted cost of usual care 0 –148 –129 –129
Discounted cost of treatment 0 632 956 957
Discounted cost of HF-related hospitalisations 0 –19 70 161
Discounted cost of other hospitalisations 0 57 207 3
Total difference in costs 0 523 1104 992
Overall cost rank (1 = lowest cost) 1 2 4 3
Discounted QALY results
QALYs with no hospitalisation decrement 2.5748 2.5509 2.6834 2.6848 
HF-related hospitalisation decrement –0.1611 –0.1604 –0.1638 –0.1673 
Total discounted QALYs 2.4137 2.3905 2.5196 2.5175 
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Usual care STS HM STS HH
TM during 
office hours
Difference in QALYs from usual care
QALYs with no hospitalisation decrement 0.0000 –0.0239 0.1086 0.1100 
HF-related hospitalisation decrement 0.0000 0.0007 –0.0027 –0.0062 
Total difference in discounted QALYs 0.0000 –0.0232 0.1059 0.1038 
Total discounted QALYs rank (1 = highest) 3 4 1 2
Probabilistic ICER vs usual care (£/QALY) Dominated 10,423 9552
Probabilistic sequential ICER (£/QALY) Dominated 52,951a 9552
Uncertainty analyses using net benefit at £20,000 per QALY
Probability that strategy is most cost-effective (%) 2 18 36 43
Expected total costs from PSA (£) 8478 9001 9582 9470
Expected total QALYs from PSA 2.4137 2.3905 2.5196 2.5175
Expected net benefit from PSA (£) 39,795 38,809 40,810 40,880
Difference from usual care costs (£) 0 523 1104 992
Difference from usual care QALYs 0.0000 –0.0232 0.1059 0.1038 
Difference from usual care net benefit (£) 0 –986.75 1014 1084
Net benefit rank (1 = highest) 3 4 2 1
Overall EVPI per patient at ICER of £20,000 per 
QALY (£)
834
Population EVPI (£) 45,685,432
a Last strategy in the cost-effectiveness frontier.
Economic analysis using data from predictive distributions 
Usual care STS HM STS HH
TM during 
office hours
Central estimates of HRs used as input
Mortality HR 1.000 1.180 0.849 0.843
HF-related hospitalisation HR 1.000 1.063 0.790 0.982
All-cause hospitalisation HR 1.000 1.302 1.074 0.835
Treatment costs assumed per month (£) 7 119 179 175
Survival results (undiscounted)
1 year (%) 72.14 70.61 74.58 74.66
5 years (%) 33.75 33.04 34.89 34.93
Life expectancy over 30 years (years) 4.710 4.614 4.862 4.867 
Difference in life expectancy vs usual care (years) – –0.100 0.151 0.157 
© Queen’s Printer and Controller of HMSO 2013. This work was produced by Pandor et al. under the terms of a commissioning contract issued by the Secretary of State for 
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals 
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be 
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science 
Park, Southampton SO16 7NS, UK.
DOI: 10.3310/hta17320 HealtH tecHnOlOgy assessment 2013 VOl. 17 nO. 32
185
Usual care STS HM STS HH
TM during 
office hours
Cost results (£)
Discounted cost of usual care 491 339 358 359
Discounted cost of treatment 0 627 951 951
Discounted cost of HF-related hospitalisations 4187 4130 4221 4316
Discounted cost of other hospitalisations 3800 3869 4023 3811
Total costs 8478 8965 9553 9437
Difference in costs from usual care (£)
Discounted cost of usual care 0 –152 –132 –132
Discounted cost of treatment 0 627 951 951
Discounted cost of HF-related hospitalisations 0 –57 33 129
Discounted cost of other hospitalisations 0 69 223 11
Total difference in costs 0 487 1075 959
Overall cost rank (1 = lowest cost) 1 2 4 3
Discounted QALY results
QALYs with no hospitalisation decrement 2.5748 2.5223 2.6575 2.6605 
HF-related hospitalisation decrement –0.1611 –0.1589 –0.1624 –0.1661 
Total discounted QALYs 2.4137 2.3633 2.4950 2.4944 
Difference in QALYs from usual care
QALYs with no hospitalisation decrement 0.0000 –0.0525 0.0827 0.0857 
HF-related hospitalisation decrement 0.0000 0.0022 –0.0013 –0.0050 
Total difference in discounted QALYs 0.0000 –0.0504 0.0814 0.0808 
Total discounted QALYs rank (1 = highest) 3 4 1 2
Probabilistic ICER vs usual care (£/QALY) Dominated 13,206 11,873
Probabilistic sequential ICER (£/QALY) Dominated 193,206a 11,873
Uncertainty analyses using net benefit at £20,000 per QALY
Probability that strategy is most cost-effective (%) 6 19 35 40
Expected total costs from PSA (£) 8478 8965 9553 9437
Expected total QALYs from PSA 2.4137 2.3633 2.4950 2.4944
Expected net benefit from PSA (£) 39,795 38,301 40,348 40,452
Difference from usual care costs (£) 0 487 1075 959
Difference from usual care QALYs 0.0000 –0.0504 0.0814 0.0808 
Difference from usual care net benefit (£) 0 –1494.07 553 656
Net benefit rank (1 = highest) 3 4 2 1
Overall EVPI per patient at ICER of £20,000 per 
QALY (£)
1839
Population EVPI (£) 100,738,020
a Last strategy in the cost-effectiveness frontier.
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Economic analysis using data excluding the Home-HF study67
Usual care STS HM STS HH
TM during 
office hours
Central estimates of HRs used as input 
Mortality HR 1.000 1.007 0.757 0.627
HF-related hospitalisation HR 1.000 1.042 0.766 0.872
All-cause hospitalisation HR 1.000 1.134 0.969 0.678
Treatment costs assumed per month (£) 27 119 179 175
Survival results (undiscounted)
1 year (%) 72.14 72.14 75.67 77.63
5 years (%) 33.75 33.75 35.40 36.32
Life expectancy over 30 years (years) 4.710 4.710 4.930 5.052 
Difference in life expectancy vs usual care (years) – –0.0003 0.2200 0.3420
Cost results (£)
Discounted cost of usual care 491 346 363 373
Discounted cost of treatment 0 635 959 972
Discounted cost of HF-related hospitalisations 4187 4206 4269 4426
Discounted cost of other hospitalisations 3800 3873 4021 3879
Total costs 8478 9060 9613 9650
Difference in costs from usual care (£)
Discounted cost of usual care 0 –144 –127 –118
Discounted cost of treatment 0 635 959 972
Discounted cost of HF-related hospitalisations 0 18 82 239
Discounted cost of other hospitalisations 0 73 221 79
Total difference in costs 0 582 1135 1172
Overall cost rank (1 = lowest cost) 1 2 3 4
Discounted QALY results
QALYs with no hospitalisation decrement 2.5748 2.5747 2.6949 2.7612 
HF-related hospitalisation decrement –0.1611 –0.1619 –0.1643 –0.1703 
Total discounted QALYs 2.4137 2.4128 2.5306 2.5908 
Difference in QALYs from usual care
QALYs with no hospitalisation decrement 0.0000 –0.0002 0.1200 0.1864 
HF-related hospitalisation decrement 0.0000 –0.0007 –0.0032 –0.0092 
Total difference in discounted QALYs 0.0000 –0.0009 0.1169 0.1772 
Total discounted QALYs rank (1 = highest) 3 4 2 1
Probabilistic ICER vs usual care (£/QALY) Dominated 9709 6616
Probabilistic sequential ICER (£/QALY) Dominated Extendedly 
dominated
6616a
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Usual care STS HM STS HH
TM during 
office hours
Uncertainty analyses using net benefit at £20,000 per QALY
Probability that strategy is most cost-effective (%) 0 5 12 83
Expected total costs from PSA (£) 8478 9060 9613 9650
Expected total QALYs from PSA 2.4137 2.4128 2.5306 2.5908
Expected net benefit from PSA (£) 39,795 39,196 40,998 42,167
Difference from usual care costs (£) 0 582 1135 1172
Difference from usual care QALYs 0.0000 –0.0009 0.1169 0.1772 
Difference from usual care net benefit (£) 0 –599.54 1203 2371
Net benefit rank (1 = highest) 3 4 2 1
Overall EVPI per patient at ICER of £20,000 per 
QALY (£)
136
Population EVPI (£) 7,449,902
a Last strategy in the cost-effectiveness frontier.
Economic analysis using data from predictive distributions 
excluding the Home-HF study67 
Usual care STS HM STS HH
TM during 
office hours
Central estimates of HRs used as input 
Mortality HR 1.000 1.032 0.776 0.642
HF-related hospitalisation HR 1.000 1.058 0.778 0.883
All-cause hospitalisation HR 1.000 1.235 1.048 0.731
Treatment costs assumed per month (£) 27 119 179 175
Survival results (undiscounted)
1 year (%) 72.14 71.89 75.44 77.44
5 years (%) 33.75 33.63 35.30 36.23
Life expectancy over 30 years (years) 4.71 4.69 4.92 5.04 
Difference in life expectancy vs usual care (years) 0.00 –0.02 0.21 0.33 
Cost results (£)
Discounted cost of usual care 491 345 362 372
Discounted cost of treatment 0 634 957 971
Discounted cost of HF-related hospitalisations 4187 4200 4262 4422
Discounted cost of other hospitalisations 3800 3909 4055 3901
Total costs 8478 9087 9636 9665
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Usual care STS HM STS HH
TM during 
office hours
Difference in costs from usual care (£)
Discounted cost of usual care 0 –145 –128 –119
Discounted cost of treatment 0 634 957 971
Discounted cost of HF-related hospitalisations 0 12 75 234
Discounted cost of other hospitalisations 0 108 255 101
Total difference in costs 0 609 1158 1187
Overall cost rank (1 = lowest cost) 1 2 3 4
Discounted QALY results
QALYs with no hospitalisation decrement 2.5748 2.5659 2.6870 2.7548 
HF-related hospitalisation decrement –0.1611 –0.1616 –0.1640 –0.1701 
Total discounted QALYs 2.4137 2.4043 2.5230 2.5847 
Difference in QALYs from usual care
QALYs with no hospitalisation decrement 0.0000 –0.0089 0.1122 0.1800 
HF-related hospitalisation decrement 0.0000 –0.0004 –0.0029 –0.0090 
Total difference in discounted QALYs 0.0000 –0.0093 0.1093 0.1710 
Total discounted QALYs rank (1 = highest) 3 4 2 1
Probabilistic ICER vs usual care (£/QALY) Dominated 10,598 6942
Probabilistic sequential ICER (£/QALY) Dominated Extendedly 
dominated
6942a
Uncertainty analyses using net benefit at £20,000 per QALY
Probability that strategy is most cost-effective (%) 1 7 19 72
Expected total costs from PSA (£) 8478 9087 9636 9665
Expected total QALYs from PSA 2.4137 2.4043 2.5230 2.5847
Expected net benefit from PSA (£) 39,795 39,000 40,823 42,029
Difference from usual care costs (£) 0 609 1158 1187
Difference from usual care QALYs 0.0000 –0.0093 0.1093 0.1710 
Difference from usual care net benefit (£) 0 –795.73 1028 2233
Net benefit rank (1 = highest) 3 4 2 1
Overall EVPI per patient at ICER of £20,000 per 
QALY (£)
414
Population EVPI (£) 22,678,379
a Last strategy in the cost-effectiveness frontier.
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Appendix 17 Results for 12-month treatment 
duration scenario
Economic analysis using base-case estimates 
Usual care STS HM STS HH
TM during 
office hours
Central estimates of HRs used as input 
Mortality HR 1.000 1.074 0.780 0.779
HF-related hospitalisation HR 1.000 1.045 0.778 0.966
All-cause hospitalisation HR 1.000 1.173 0.977 0.761
Treatment costs assumed per month (£) 27 119 179 175
Survival results (undiscounted)
1 year (%) 72.14 71.31 77.58 77.67
5 years (%) 33.75 33.36 36.39 36.44
Life expectancy over 30 years (years) 4.71 4.66 5.05 5.05
Difference in life expectancy vs usual care (years) 0.00 –0.05 0.34 0.34
Cost results (£)
Discounted cost of usual care 575 306 334 334
Discounted cost of treatment 0 1158 1828 1788
Discounted cost of HF-related hospitalisations 4187 4178 4285 4456
Discounted cost of other hospitalisations 3800 3928 4156 3775
Total costs 8562 9571 10,603 10,353
Difference in costs from usual care (£)
Discounted cost of usual care 0 –269 –241 –240
Discounted cost of treatment 0 1158 1828 1788
Discounted cost of HF-related hospitalisations 0 –9 97 268
Discounted cost of other hospitalisations 0 128 356 –25
Total difference in costs 0 1009 2040 1791
Overall cost rank (1 = lowest cost) 1 2 4 3
Discounted QALY results
QALYs with no hospitalisation decrement 2.5748 2.5465 2.7583 2.7613 
HF-related hospitalisation decrement –0.1611 –0.1608 –0.1649 –0.1715 
Total discounted QALYs 2.4137 2.3857 2.5935 2.5898 
Difference in QALYs from usual care
QALYs with no hospitalisation decrement 0.0000 –0.0283 0.1835 0.1865 
HF-related hospitalisation decrement 0.0000 0.0003 –0.0037 –0.0103 
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Usual care STS HM STS HH
TM during 
office hours
Total difference in discounted QALYs 0.0000 –0.0280 0.1798 0.1761 
Total discounted QALYs rank (1 = highest) 3 4 1 2
Probabilistic ICER vs usual care (£/QALY) Dominated 11,349 10,167
Probabilistic sequential ICER (£/QALY) Dominated 68,189a 10,167
Uncertainty analyses using net benefit at £20,000 per QALY
Probability that strategy is most cost-effective (%) 2 18 35 44
Expected total costs from PSA (£) 8562 9571 10,603 10,353
Expected total QALYs from PSA 2.4137 2.3857 2.5935 2.5898
Expected net benefit from PSA (£) 39,711 38,143 41,267 41,443
Difference from usual care costs (£) 0 1009 2040 1791
Difference from usual care QALYs 0.0000 –0.0280 0.1798 0.1761 
Difference from usual care net benefit (£) 0 –1568.71 1555 1732
Net benefit rank (1 = highest) 3 4 2 1
Overall EVPI per patient at ICER of £20,000 per 
QALY (£)
1401
Population EVPI (£) 76,745,379
a Last strategy in the cost-effectiveness frontier.
Economic analysis using data from predictive distributions 
Usual care STS HM STS HH
TM during 
office hours
Central estimates of HRs used as input
Mortality HR 1.000 1.180 0.849 0.843
HF-related hospitalisation HR 1.000 1.063 0.790 0.982
All-cause hospitalisation HR 1.000 1.302 1.074 0.835
Treatment costs assumed per month (£) 27 119 179 175
Survival results (undiscounted)
1 year (%) 72.14 70.31 76.50 76.66
5 years (%) 33.75 32.89 35.88 35.96
Life expectancy over 30 years (years) 4.710 4.596 4.980 4.991
Difference in life expectancy vs usual care (years) – –0.110 0.270 0.281
Cost results (£)
Discounted cost of usual care 575 302 329 330
Discounted cost of treatment 0 1147 1812 1773
Discounted cost of HF-related hospitalisations 4187 4138 4237 4414
© Queen’s Printer and Controller of HMSO 2013. This work was produced by Pandor et al. under the terms of a commissioning contract issued by the Secretary of State for 
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals 
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be 
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science 
Park, Southampton SO16 7NS, UK.
DOI: 10.3310/hta17320 HealtH tecHnOlOgy assessment 2013 VOl. 17 nO. 32
191
Usual care STS HM STS HH
TM during 
office hours
Discounted cost of other hospitalisations 3800 3977 4204 3809
Total costs 8562 9564 10,582 10,326
Difference in costs from usual care (£)
Discounted cost of usual care 0 –273 –246 –245
Discounted cost of treatment 0 1147 1812 1773
Discounted cost of HF-related hospitalisations 0 –49 50 227
Discounted cost of other hospitalisations 0 177 404 9
Total difference in costs 0 1002 2019 1764
Overall cost rank (1 = lowest cost) 1 2 4 3
Discounted QALY results
QALYs with no hospitalisation decrement 2.5748 2.5129 2.7219 2.7275 
HF-related hospitalisation decrement –0.1611 –0.1593 –0.1631 –0.1699 
Total discounted QALYs 2.4137 2.3536 2.5589 2.5576 
Difference in QALYs from usual care
QALYs with no hospitalisation decrement 0.0000 –0.0619 0.1471 0.1527 
HF-related hospitalisation decrement 0.0000 0.0019 –0.0019 –0.0087 
Total difference in discounted QALYs 0.0000 –0.0601 0.1452 0.1439 
Total discounted QALYs rank (1 = highest) 3 4 1 2
Probabilistic ICER vs usual care (£/QALY) Dominated 13,911 12,257
Probabilistic sequential ICER (£/QALY) Dominated 205,182a 12,257
Uncertainty analyses using net benefit at £20,000 per QALY
Probability that strategy is most cost-effective (%) 7 19 34 40
Expected total costs from PSA (£) 8562 9564 10,582 10,326
Expected total QALYs from PSA 2.4137 2.3536 2.5589 2.5576
Expected net benefit from PSA (£) 39,711 37,509 40,596 40,826
Difference from usual care costs (£) 0 1002 2019 1764
Difference from usual care QALYs 0.0000 –0.0601 0.1452 0.1439 
Difference from usual care net benefit (£) 0 –2202.89 884 1114
Net benefit rank (1 = highest) 3 4 2 1
Overall EVPI per patient at ICER of £20,000 per 
QALY (£)
3034
Population EVPI (£) 166,199,486
a Last strategy in the cost-effectiveness frontier.
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Economic analysis using data excluding the Home-HF study67
Usual care STS HM STS HH
TM during 
office hours
Central estimates of HRs used as input 
Mortality HR 1.000 1.007 0.757 0.627
HF-related hospitalisation HR 1.000 1.042 0.766 0.872
All-cause hospitalisation HR 1.000 1.134 0.969 0.678
Treatment costs assumed per month (£) 27 119 179 175
Survival results (undiscounted)
1 year (%) 72.14 72.25 78.14 81.54
5 years (%) 33.75 33.81 36.67 38.32
Life expectancy over 30 years (years) 4.710 4.716 5.082 5.293
Difference in life expectancy vs usual care (years) – 0.0062 0.3720 0.5830
Cost results (£)
Discounted cost of usual care 575 310 336 352
Discounted cost of treatment 0 1168 1835 1837
Discounted cost of HF-related hospitalisations 4187 4227 4303 4580
Discounted cost of other hospitalisations 3800 3939 4180 3895
Total costs 8562 9645 10,655 10,663
Difference in costs from usual care (£)
Discounted cost of usual care 0 –265 –238 –223
Discounted cost of treatment 0 1168 1835 1837
Discounted cost of HF-related hospitalisations 0 40 116 392
Discounted cost of other hospitalisations 0 139 380 95
Total difference in costs 0 1082 2093 2101
Overall cost rank (1 = lowest cost) 1 2 3 4
Discounted QALY results
QALYs with no hospitalisation decrement 2.5748 2.5782 2.7773 2.8921 
HF-related hospitalisation decrement –0.1611 –0.1627 –0.1656 –0.1762 
Total discounted QALYs 2.4137 2.4155 2.6117 2.7159 
Difference in QALYs from usual care
QALYs with no hospitalisation decrement 0.0000 0.0034 0.2025 0.3173 
HF-related hospitalisation decrement 0.0000 –0.0015 –0.0045 –0.0151 
Total difference in discounted QALYs 0.0000 0.0019 0.1980 0.3022 
Total discounted QALYs rank (1 = highest) 4 3 2 1
Probabilistic ICER vs usual care (£/QALY) 584,066 10,567 6953
Probabilistic sequential ICER (£/QALY) Dominated Extendedly 
dominated
6953a
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Usual care STS HM STS HH
TM during 
office hours
Uncertainty analyses using net benefit at £20,000 per QALY
Probability that strategy is most cost-effective (%) 0 5 12 83
Expected total costs from PSA (£) 8562 9645 10,655 10,663
Expected total QALYs from PSA 2.4137 2.4155 2.6117 2.7159
Expected net benefit from PSA (£) 39,711 38,666 41,580 43,654
Difference from usual care costs (£) 0 1082 2093 2101
Difference from usual care QALYs 0.0000 0.0019 0.1980 0.3022 
Difference from usual care net benefit (£) 0 –1045.41 1868 3942
Net benefit rank (1 = highest) 3 4 2 1
Overall EVPI per patient at ICER of £20,000 per 
QALY (£)
225
Population EVPI (£) 12,325,275
a Last strategy in the cost-effectiveness frontier.
Economic analysis using data from predictive distributions 
excluding the Home-HF study67 
Usual care STS HM STS HH
TM during 
office hours
Central estimates of HRs used as input 
Mortality HR 1.000 1.032 0.776 0.642
HF-related hospitalisation HR 1.000 1.058 0.778 0.883
All-cause hospitalisation HR 1.000 1.235 1.048 0.731
Treatment costs assumed per month (£) 27 119 179 175
Survival results (undiscounted)
1 year (%) 72.14 71.91 77.80 81.26
5 years (%) 33.75 33.65 36.50 38.19
Life expectancy over 30 years (years) 4.71 4.70 5.06 5.28
Difference in life expectancy vs usual care (years) 0.00 –0.01 0.35 0.57
Cost results (£)
Discounted cost of usual care 575 309 335 350
Discounted cost of treatment 0 1165 1830 1833
Discounted cost of HF-related hospitalisations 4187 4223 4295 4575
Discounted cost of other hospitalisations 3800 4012 4247 3940
Total costs 8562 9708 10,707 10,698
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Usual care STS HM STS HH
TM during 
office hours
Difference in costs from usual care (£)
Discounted cost of usual care 0 –266 –240 –224
Discounted cost of treatment 0 1165 1830 1833
Discounted cost of HF-related hospitalisations 0 36 108 387
Discounted cost of other hospitalisations 0 212 447 140
Total difference in costs 0 1146 2145 2136
Overall cost rank (1 = lowest cost) 1 2 4 3
Discounted QALY results
QALYs with no hospitalisation decrement 2.5748 2.5669 2.7657 2.8825 
HF-related hospitalisation decrement –0.1611 –0.1625 –0.1653 –0.1760 
Total discounted QALYs 2.4137 2.4044 2.6005 2.7065 
Difference in QALYs from usual care
QALYs with no hospitalisation decrement 0.0000 –0.0079 0.1909 0.3077 
HF-related hospitalisation decrement 0.0000 –0.0013 –0.0042 –0.0149 
Total difference in discounted QALYs 0.0000 –0.0093 0.1868 0.2928 
Total discounted QALYs rank (1 = highest) 3 4 2 1
Probabilistic ICER vs usual care (£/QALY) Dominated 11,486 7296
Probabilistic sequential ICER (£/QALY) Dominated Extendedly 
dominated
7296a
Uncertainty analyses using net benefit at £20,000 per QALY
Probability that strategy is most cost-effective (%) 1 7 19 73
Expected total costs from PSA (£) 8562 9708 10,707 10,698
Expected total QALYs from PSA 2.4137 2.4044 2.6005 2.7065
Expected net benefit from PSA (£) 39,711 38,380 41,302 43,431
Difference from usual care costs (£) 0 1146 2145 2136
Difference from usual care QALYs 0.0000 –0.0093 0.1868 0.2928 
Difference from usual care net benefit (£) 0 –1331.28 1590 3720
Net benefit rank (1 = highest) 3 4 2 1
Overall EVPI per patient at ICER of £20,000 per 
QALY (£)
693
Population EVPI (£) 37,961,847
a Last strategy in the cost-effectiveness frontier.
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Appendix 18 Protocol
HTA Reference No. 09/107
1. Title of the project:
Home telemonitoring or structured telephone support programmes for patients with heart failure
2. Name of TAR team and project ‘lead’
School of Health and Related Research (ScHARR), Technology Assessment Group, The University 
of Sheffield
Project lead:
Abdullah Pandor, Research Fellow
ScHARR Technology Assessment Group (ScHARR-TAG), University of Sheffield, Regent Court, 30 Regent 
Street, Sheffield S1 4DA
Direct line: 0114 222 0778
Fax: 0114 272 4095
E-mail: a.pandor@sheffield.ac.uk
3. Plain English Summary
Heart failure is a complex clinical syndrome that can result from any structural abnormality or cardiac 
dysfunction that impairs the ability of the heart to fill with, or eject, a sufficient amount of blood 
throughout the body.1 It is characterised by symptoms (such as shortness of breath or fatigue, either at 
rest or during exertion), and signs of fluid retention (such as pulmonary congestion or ankle swelling) 
and objective evidence of a structural or functional abnormality of the heart at rest.2 The severity of heart 
failure, based on symptoms and physical activity from the New York Heart Association (NYHA) functional 
classification, is highly variable (there is no definitive progression of NYHA status – a patient’s condition 
can improve as well as deteriorate), and can change unevenly over time.3 Heart failure is associated with 
significant morbidity, mortality and reduced quality of life, particularly in those aged over 60 years.4 It also 
exerts a significant burden on healthcare systems, with the majority of its economic burden attributable 
to repeated and lengthy admissions to hospital.5 Multidisciplinary chronic heart failure (CHF) disease 
management programmes that include structured follow-up with patient education, optimisation 
of medical treatment, psychosocial care and access to care have shown promise with decreased 
hospitalisation rates and improved clinical outcomes.6,7,8,9,10 However, access to these programmes is 
limited, as a result of barriers related to funding or inaccessibility by some patients due to geographic 
location.11,12
Remote monitoring using structured telephone support between patients and health care providers or 
patient initiated electronic monitoring (transfer of physiological data such as weight, blood pressure 
and electrocardiographic details via a telephone or digital cable from home to healthcare provider) 
or cardiovascular implanted monitoring devices, may help provide wider access to CHF management 
programmes to a larger number of patients including those constrained by geography, transport 
or infirmity.13,14 Previous systematic reviews and meta-analysis have shown that CHF management 
programmes that include remote monitoring have a beneficial effect on clinical outcomes in patients with 
CHF compared with usual care.15,16,14,9,17 Since the last systematic reviews by Clark et al.14 (search date 
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from January 2002 to May 2006) and Klersy et al.16 (search date from January 2000 and October 2008) 
several studies of remote monitoring have become available.18,19,20,21,22,23,24 Despite the benefits, remote 
monitoring may generate false alerts leading to inappropriate hospitalisation25 and it may not be feasible 
for healthcare providers to telephone all patients on a regular basis and or provide specialised equipment 
to all patients who may benefit.
The aim of this review is to update earlier systematic reviews16,14 and evaluate the potential cost-
effectiveness of home telemonitoring or structured telephone support strategies compared with usual care 
for adult patients who have been discharged from an acute care setting after a recent exacerbation of 
heart failure. A specific focus will be taken in assessing the need for primary research in this area.
4. Decision problem
Purpose of the decision to be made
The assessment will address the question: what is the clinical and cost-effectiveness of home 
telemonitoring, or structured telephone support programmes for adults who have been discharged from 
an acute care setting after a recent exacerbation of heart failure (including subgroups such as those with 
transiently or persistently severe and CHF).
Clear definition of the intervention
Telemonitoring, defined as the use of information and communications technologies to monitor and 
transmit items related to patient health status between geographically separated individuals,26 permits 
home monitoring of patients (living at home, or in nursing or residential care homes) using external 
electronic devices in conjunction with a telecommunication system (land line or mobile telephone, cable 
network or broadband technology). Telemonitoring allows frequent or continuous assessment of heart 
failure signs and symptoms measured by patients, family, or caregivers at home, while allowing patients to 
remain under close supervision.2,14 Symptoms reported by patients can be remotely reviewed by a health 
care professional and appropriate action can be initiated. Telephone support is another form of remote 
management that can be provided through structured telephone contact between patients and healthcare 
providers (with or without home visits) and reporting of symptoms and or physiological data.16,14 
Cardiovascular implanted monitoring devices such as modern pacemakers, implantable cardioverter 
defibrillators or cardiac resynchronisation devices are also capable of delivering remote physiological 
monitoring often without the need for a patient to trigger the transmission of data.27
The highest risk period for rehospitalisation is in the first few weeks after discharge from hospital.13 
Structured telephone support and or home telemonitoring interventions should be performed at least 
once within the first 28 days following discharge from hospital and must be targeted towards patients and 
intended to address the patients´ concerns and problems not those of caregivers.14
Place of the intervention in the treatment pathway(s)
The review will focus on the use of home telemonitoring or structured telephone support programmes for 
patients who have been discharged from an acute care setting after a recent exacerbation of heart failure.
International guidelines for heart failure care generally recommend early face to face follow-up of patients 
following hospitalisation, education to facilitate self care, and ongoing support from a multidisciplinary 
team that is responsive to the patient´s need.13,2 Similar guidelines have been adopted in the UK;3,28,29,30 
however, the content and structure of heart failure management programmes vary widely between 
countries and healthcare settings, and are tailored to meet local needs.31
Although specific guidelines for the use of telemonitoring in heart failure have not been developed, 
the highest risk period for rehospitalisation is in the first few weeks after discharge from hospital.32 
The optimum time period for telemonitoring is unclear; however, it is likely that services will provide 
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telemonitoring or structured telephone support for at least 4 to 6 months following discharge from 
hospital with its usefulness evaluated at 30 day intervals thereafter.13
Relevant comparators
The relevant comparator is considered as usual care. This involves standard post discharge multidisciplinary 
care without regular follow-up and may include 1) in person follow-up visits to a primary care physician 2) 
attendance at a clinic based CHF disease management programme 3) any visits at home by a specialised 
CHF health care professional (referred to as enhanced conventional care).16,14
Population and relevant sub-groups
The population will include any adults (defined as ≥ 18 years of age) of either sex or ethnic group with a 
diagnosis of heart failure and discharged from an acute care setting (including emergency departments 
and one-day stay procedures) to home (including relatives home or to nursing or residential care homes). 
The identification of subgroups of patients for whom home telemonitoring or structured telephone 
support programmes are particularly appropriate or inappropriate will be governed by the available 
evidence. However, on a priori grounds, information will be sought for people with transiently or 
persistently severe and CHF.
Outcomes
The outcomes of the review are mortality (all cause), all cause admission to hospital, CHF related admission 
to hospital, length of stay (days in hospital), health-related quality of life (HRQoL) and acceptability 
of interventions to patients. If the evidence allows, additional outcomes of interest may be include 
medicine usage, patient satisfaction and functional capacity (e.g. exercise tolerance, and left ventricular 
ejection fraction).
Key factors to be addressed
The review will aim to evaluate the following objectives:
1. Update two existing systematic reviews16,14 of telemonitoring or structured telephone support 
programmes for patients with heart failure within the scope of the current review
2. Evaluate the effectiveness and cost-effectiveness of home telemonitoring and or structured telephone 
support packages compared with usual post-discharge care
3. Identify key areas for primary research
5. Report methods for synthesis of evidence of clinical effectiveness
A review of the evidence for clinical effectiveness will be undertaken systematically following the general 
principles recommended in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) statement (http://www.prisma-statement.org/). The review will assess the clinical and cost-
effectiveness of home telemonitoring or structured telephone support strategies compared with usual care 
for adults who have been discharged from an acute care setting after a recent exacerbation of heart failure 
(including subgroups such as those with transiently or persistently severe and CHF).
Inclusion/Exclusion criteria:
Population
The population will comprise adults (defined as ≥ 18 years of age) with a diagnosis of heart failure and 
discharged from an acute care setting to home (including relatives home or to nursing or residential 
care homes).
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Interventions
The following interventions will be included: 1) Remote home-telemonitoring using patient initiated 
external electronic devices or cardiovascular implanted monitoring devices, with transfer of physiological 
data from the patient to the health care provider via land line or mobile telephone, cable network or 
broadband technology, 2) Structured telephone support including regularly scheduled telephone contact 
between patients and healthcare providers and reporting of symptoms and or physiological data. In 
addition, structured telephone support and or home telemonitoring interventions were required to 
be performed at least once within the first 28 days following discharge from hospital and be targeted 
towards patients and intended to address the patients´ concerns and problems not those of caregivers.
Comparators
Usual care (defined as standard post discharge multidisciplinary care without regular follow-up or 
enhanced conventional care with home visits by a specialised CHF health care professional)
Outcomes
The outcomes of the review will include mortality (all cause), all cause admission to hospital, CHF 
related admission to hospital, length of stay (days in hospital), health-related quality of life (HRQoL) and 
acceptability of interventions to patients. If the evidence allows, additional outcomes of interest may 
be include medicine usage, patient satisfaction and functional capacity (e.g. exercise tolerance, and left 
ventricular ejection fraction).
Search strategy
The search strategy will update the two existing systematic reviews16,14 and comprise the following 
main elements:
 z Searching of electronic databases
 z Contact with experts in the field
 z Scrutiny of bibliographies of all retrieved papers
The following electronic databases will be searched: MEDLINE; MEDLINE in-Process and Other Non-indexed 
Citations; EMBASE; all databases in the Cochrane Library including the Cochrane Database of Systematic 
Reviews, the Cochrane Central Register of Controlled Trials and NHS EED; AMED; CINAHL; PsycINFO; and 
the ISI Web of Science Citation Index. The search strategy will be adapted across the databases. The clinical 
effectiveness searches will be limited by date from 2006 (the search strategies from the existing systematic 
reviews appear to be of good quality [and clearly reported] and as a result all studies prior to 2006 should 
have been identified) to present and all economic literature searches will be undertaken from inception to 
present (searches for economic studies was not undertaken in the previous reviews). None of the searches 
will be restricted by language. An example of the MEDLINE search strategy is shown in Appendix 1.
For ongoing, completed and unpublished randomised controlled trials, searches will be carried out in the 
National Research Register Archive and the ClinicalTrials.gov trials registry. Conference proceedings will 
be identified through searches in the ISI Conference Proceedings Index, the IEEE/IET Electronic Library 
and ZETOC.
Additional searches on the outcomes to inform the decision-analytic model where required in the course 
of the project, will be carried out through consultation between the information specialists and the 
TAR team.
Inclusion criteria
All randomised controlled trials or observational cohort studies with a contemporaneous control group 
published from 2006 to present (as well as those identified by the existing systematic reviews) that 
evaluate home telemonitoring, or structured telephone support programmes with usual post discharge 
multidisciplinary care for adults who have been discharged from an acute care setting to home (including 
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relatives home or nursing or residential care homes) after a recent exacerbation of heart failure will be 
included. Before and after studies without a concurrent control group will be excluded because the 
absence of a control group to record concurrent changes over time means that changes due to the 
intervention or due to temporal trends, concurrent changes or a Hawthorne effect would be conflated. 
Such trials therefore represent very weak evidence of effectiveness. The inclusion of potentially relevant 
articles will be undertaken using a two-step process. First all titles will be examined for inclusion by 
one reviewer (any citations that clearly do not meet the inclusion criteria i.e. non-human, unrelated to 
telemonitoring and or heart failure will be excluded). Second, all abstracts and full text articles will be 
examined independently by two reviewers. Any disagreements in the selection process will be resolved 
through discussion.
Exclusion criteria
Reviews of primary studies will not be included in the analysis, but will be retained for discussion and 
identification of additional studies. Moreover, the following publication types will be excluded from the 
review: animal models; preclinical and biological studies; narrative reviews, editorials, opinions; non-English 
language papers and reports published as meeting abstracts only, where insufficient methodological 
details are reported to allow critical appraisal of study quality. Details of all full text excluded papers 
(including non-English language citations) will also be provided in the review.
Data extraction strategy
Data will be extracted independently by one reviewer using a standardised data extraction form and 
independently checked for accuracy by a second. Uncertainties will be resolved by discussion. Where 
multiple publications of the same study are identified, data will be extracted and reported as a single 
study. Moreover, as this is an update of two existing reviews,16,14 all relevant data will be extracted from the 
reviews in the first instance, but will be cross checked for accuracy with the original papers. If necessary, 
additional data will be extracted from the original papers.
Quality assessment strategy
The methodological quality of each included study will be assessed according to (adapted) criteria 
based on those proposed by Verhagen et al.33 for randomised controlled trials and by Wells et al.34 for 
observational studies.
Consideration of study quality to assess randomised controlled trials will include the following factors: 
method of randomisation, allocation concealment, blinding of outcome assessors and data-analysts 
(it is not considered plausible that patients could be blinded to these types of interventions), numbers 
of participants randomised, baseline comparability between groups, specification of eligibility criteria, 
whether or not intent to treat analysis is performed, completeness of follow up and whether or not study 
power calculations are performed and reported.
Consideration of study quality to assess observational studies will include the following factors: 
representativeness of the exposed cohort, selection of the non exposed cohort, comparability of cohorts on 
the basis of the design or analysis, assessment of outcome, was follow-up long enough for outcomes to 
occur and adequacy of follow up of cohorts.
Methods of analysis/synthesis
Data will be tabulated and discussed in a narrative review. Where appropriate (i.e. populations, 
interventions and outcomes are comparable), meta-analysis will be employed to estimate a summary 
measure of effect on relevant outcomes based on intention to treat analyses. It is expected that this will 
incorporate previously identified primary studies from existing reviews and new studies identified by the 
updated searches.
Meta-analysis will be conducted; however, the choice of methods will depend on the type and magnitude 
of uncertainty in the data. First, analyses will be conducted using a fixed- or random-effects model, using 
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the Cochrane Collaboration Review Manager Software (version 5.0).35 Heterogeneity will be evaluated 
through consideration of the study populations, methods and interventions, by visualisation of results 
and, in statistical terms, by the χ2 test for homogeneity and the I2 statistic. Second, meta-regression 
will be employed if the source of heterogeneity is identified and quantifiable (e.g, variability arising due 
to different health systems, heterogeneous populations, country-specific differences or different care 
situations). Third, if necessary, Bayesian meta-analysis techniques will be considered.
6. Report methods for synthesising evidence of cost-
effectiveness
Methods for estimating quality of life
The time horizon of our analysis will be a patient’s lifetime in order to reflect the chronic nature of the 
disease and potential mortality differences between the intervention strategies. The perspective will be 
that of the National Health Services and Personal Social Services. Both cost and quality adjusted life years 
(QALYs) will be discounted at 3.5%.36
Identifying and systematically reviewing published cost-effectiveness studies
The review detailed in section 5 will be used to identify studies of cost-effectiveness of home 
telemonitoring or structured telephone support programmes compared with usual care (standard care 
or enhanced conventional care) for adult patients who have been discharged from an acute care setting 
after a recent exacerbation of heart failure. An economic search filter will be incorporated into the 
search strategy to identify relevant studies (as shown in Appendix 1). Identified economic literature will 
be critically appraised and quality assessed using the critical appraisal checklist for economic evaluations 
proposed by Drummond and colleagues.37 Existing cost-effectiveness analyses will also be used to identify 
sources of evidence to inform structural modelling assumptions and parameter values for the de novo 
economic model.
Evaluation of costs and cost-effectiveness, which may include 
development of a de novo economic model
A new economic evaluation of the cost-effectiveness of home telemonitoring or structured telephone 
support programmes for adult patients who have been discharged from an acute care setting after a 
recent exacerbation of heart failure will be developed and the identification of subgroups of patients will 
be governed by the available evidence.
The ScHARR modelling team have published papers using different modelling techniques (such as 
discrete event simulation,38,39,40 transition state modelling41 and meta-modelling).42 The model structure 
and software used to construct the model will be determined following data collection in order that the 
most appropriate technique is used for this particular assessment. Clinical experts will be consulted at the 
conceptual stage to ensure that the structure of the model is appropriate to clinical practice.
Ideally, health related quality-of-life evidence will be available directly from the review literature. In the 
absence of such evidence, the mathematical model may use indirect evidence on quality of life from 
alternative sources. Quality-of-life data will be reviewed and used to generate the quality adjustment 
weights required for the model. In addition to the reviewed literature, national sources (e.g. NHS reference 
costs,43 national unit costs,44 and the British National Formulary (http://bnf.org)) will be used to estimate 
unit costs for use in the economic model.
It is anticipated that there may be limited evidence for some of the parameters that will be included in 
the economic model. Therefore, the uncertainty around the parameter estimates will be modelled to take 
this into account. The uncertainty in the central value for each required parameter will be represented by 
a distribution, enabling probabilistic sensitivity analysis to be undertaken. This will allow an assessment of 
the uncertainty to be made.
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Value of information techniques will be undertaken within the work. The expected value of perfect 
information (EVPI)45 will be explicitly calculated. EVPI is defined as the maximum investment a decision 
maker would be willing to pay to eliminate all uncertainty from the decision problem. It is initially 
calculated in terms of a defined unit (typically per patient) and then multiplied by the number of people 
expected to benefit from eliminating all uncertainty to form an estimate of total EVPI. EVPI per person is 
relatively high where there is large uncertainty in the adoption decision; conversely where there is only 
a small probability of error and the impact of an incorrect decision is small the EVPI per person will be 
relatively low.
Depending upon the resources required more complex methodologies (the expected value of partial 
perfect information (EVPPI)45 and the expected value of sample information (EVSI)46 may be undertaken. 
EVPPI differs from EVPI as it evaluates the maximum value of removing all uncertainty in one, or a 
subset of parameters, but it is more computationally expensive as it requires two nested Monte Carlo 
sampling levels.47
EVSI is a more advanced methodology for determining the value of information, which explicitly takes 
into account that uncertainty will not be removed even with large sample sizes. The EVSI methodology 
simulates the results from the proposed research and synthesises the simulated data with prior knowledge 
to form a posterior distribution: the larger the trial size the more the posterior distribution resembles 
the simulated data which is then used in probabilistic sensitivity analyses. The optimal trial size from the 
options evaluated can then be estimated based on the costs of conducting the trial and the expected net 
benefit of the sampled information. The application of EVSI is becoming more widespread and case studies 
employing this methodology have been published.39,40
7. Expertise in this TAR team
TAR Centre
The ScHARR Technology Assessment Group (ScHARR-TAG) undertakes reviews of the effectiveness and 
cost-effectiveness of healthcare interventions for the NHS R&D Health Technology Assessment Programme 
on behalf of a range of policy makers in a short timescale, including the National Institute for Health and 
Clinical Excellence. A list of our publications can be found at: http://www.sheffield.ac.uk/scharr/sections/
heds/collaborations/scharr-tag/reports. Much of this work, together with our reviews for the international 
Cochrane Collaboration, underpins excellence in healthcare worldwide.
Team members’ contributions
Abdullah Pandor, Research Fellow: has extensive experience in systematic reviews of health technologies. 
AP will lead the project and undertake the systematic reviewing. AP will co-ordinate review process, 
protocol development, abstract assessment for eligibility, quality assessment of studies, data extraction, 
data entry, data analysis and review development of background information and clinical effectiveness.
Patrick Fitzgerald, Research Fellow: has extensive experience in quantitative data analysis and health 
economic modelling. PF will be involved in the protocol development, data analysis (including the use of 
Bayesian meta-analysis techniques) and development of the cost-effectiveness model.
Matt Stevenson, Reader in Health Technology Assessment: has extensive experience in mathematical 
modelling, undertaking health technology assessments and is a National Institute for Health and Clinical 
Excellence committee member. MS will act as project advisor for all aspects of the work and is one of the 
guarantors of the research.
Ruth Wong, Systematic Reviews Information Officer: has extensive experience of undertaking literature 
searches for the ScHARR Technology Assessment Group systematic reviews and other external projects. RW 
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will be involved in the protocol development and she will develop the search strategy and undertake the 
electronic literature searches.
Gill Rooney, Project Administrator:
Retrieval of papers and help in preparing and formatting the report.
Professor John Cleland, Professor of Cardiology, Head of Academic Unit of Cardiology, University of Hull, 
MRTDS Building, Castle Hill Hospital, Castle Road, Cottingham, Kingston-upon-Hull, HU16 5JQ.
Protocol development (advisor), help interpret data, provide a methodological, policy and clinical 
perspective on data and review development of background information and clinical effectiveness.
Dr Abdallah Al-Mohammad, Consultant Cardiologist, Northern General Hospital, Herries Road, Sheffield 
S5 7AU.
Protocol development (advisor), help interpret data, provide a methodological, policy and clinical 
perspective on data and review development of background information and clinical effectiveness.
Professor Mark Hawley, Professor of Health Services Research, ScHARR, University of Sheffield. Regent 
Court, 30 Regent Street, Sheffield S1 4DA.
Protocol development (advisor), help interpret data, provide a methodological, policy and clinical 
perspective on data and review development of background information and clinical effectiveness.
Hazel Marsh, Research Nurse, Barnsley Hospital NHS Foundation Trust, Gawber Rd, Barnsley S75 2EP
Protocol development (advisor), help interpret data, provide a methodological, policy and clinical 
perspective on data and review development of background information and clinical effectiveness.
Dr Rachel O’Hara, Lecturer in Public Health, ScHARR, University of Sheffield. Regent Court, 30 Regent 
Street, Sheffield S1 4DA.
Protocol development (advisor), help interpret data, provide a methodological, policy and clinical 
perspective on data and review development of background information and clinical effectiveness.
8. Competing interests of authors
None of the authors, except Professor Cleland, have financial interest in the companies who manufacture 
external electronic devices or cardiovascular implanted monitoring devices for home telemonitoring 
systems included in this review.
Professor Cleland is Chief Medical Officer on an EU/FP7 grant that includes Philips and Medtronic, 
providers of telemonitoring equipment. Professor Cleland is also in receipt of research support from Philips 
and has consulted and received research funding from Bosch and General Electric who have interests in 
this area.
9. Timetable/milestones
Milestone
Draft protocol 30 April 2010
Final protocol 5 July 2010
Progress report 28 February 2011
Assessment report 31 March 2011
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10. Appendices
Appendix 1: Draft search strategy (Ovid MEDLINE)
Clinical effectiveness search strategy
1. exp Heart Failure/
2. ((heart or cardiac) adj failure).tw.
3. 1 or 2
4. exp Telecommunications/
5. Telemetry/
6. (telemetr$ or telemed$ or tele-med$ or telehealth$ or tele-health$ or telecare or tele-care or 
telecardiol$ or tele-cardiol$ or telehome or tele-home).tw.
7. (telemonitor$ or tele-monit$ or teleconsult$ or tele-consult$ or teleconferenc$ or tele-conferenc$ or 
telecommunicat$ or tele-communicat$).tw.
8. (telephon$ or phone$).tw.
9. Remote consultation/
10. (remote$ adj (consult$ or monitor$)).tw.
11. (remote adj patient adj monitoring).tw.
12. Monitoring, Ambulatory/
13. ((implantable or wearable) and monitor$).tw.
14. Patient Care Planning/
15. Case Management/
16. disease management/
17. disease management.tw.
18. exp Comprehensive Health Care/
19. Home Care Services/
20. Home Care Services, Hospital-Based/
21. Clinical Protocols/
22. Nurse Clinicians/
23. Nurse Practitioners/
24. (nurse adj led).tw.
25. or/4-24
26. 3 and 25
27. limit 26 to yr=”2007 -Current”
Cost-effectiveness search strategy
For the cost-effectiveness searches, an economic filter will be integrated with the search strategy above.
28. exp “costs and cost analysis”/
29. economics/
30. exp economics, hospital/
31. exp economics, medical/
32. economics, nursing/
33. exp models, economic/
34. economics, pharmaceutical/
35. exp “fees and charges”/
36. exp budgets/
37. budget$.tw
38. ec.fs
39. cost$.ti
40. (cost$ adj2 (effective$ or utilit$ or benefit$ or minimi$)).ab
41. (economic$ or pharmacoeconomic$ or pharmaco-economic$).ti
42. (price$ or pricing$).tw
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43. (financial or finance or finances or financed).tw
44. (fee or fees).tw
45. (value adj2 (money or monetary)).tw
46. quality-adjusted life years/
47. (qaly or qalys).af.
48. (quality adjusted life year or quality adjusted life years).af.
49. or/27-48
50. 48 and 26 above
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